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Herpesviruses have mainly co-evolved with their hosts for millions 
of years. Consequently, different related host species may have been 
infected by various genetically related herpesviruses. Illustrating this 
concept, several ruminant alphaherpesviruses have been shown to form a 
cluster of viruses closely related to bovine herpesvirus 1 (BoHV-1): namely 
bovine herpesvirus 5, bubaline herpesvirus 1, caprine herpesvirus 1, cervid 
herpesviruses 1 and 2 and elk herpesvirus 1. These viruses share common 
antigenic properties and the serological relationships between them can be 
considered as a threat to BoHV-1 eradication programmes. BoHV-1 is a 
herpesvirus responsible for infectious bovine rhinotracheitis, which is a 
disease of major economic concern. In this article, the genetic properties of 
these ruminant alphaherpesviruses are reviewed on a comparative basis 
and the issue of interspecific recombination is assessed. The pathogenesis 
of these infections is described with emphasis on the host range and 
crossing of the host species barrier. Indeed, the non bovine ruminant 
species susceptible to these ruminant alphaherpesviruses may be potential 
BoHV-1 reservoirs. The differential diagnosis of these related infections is 
also discussed. In addition, epidemiological data available are used to 
assess the potential of cross-infection in ruminant populations. A better 
knowledge of these ruminant alphaherpesvirus infections is essential to 
successful control of infectious bovine rhinotracheitis. 
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Introduction 
 
Members of the family Herpesviridae are DNA viruses showing a spectacular evolutionary 
success. The name, derived from the Greek ερpiειν (herpein), “to creep”, refers to the characteristic 
lesions caused by two common human herpesviruses: fever blisters caused by herpes simplex virus 
(HSV), as well as varicella and shingles induced by varicella zoster virus (VZV). This virus family 
includes nearly two hundred viruses isolated from hosts as diverse as molluscs, fishes, amphibians, 
reptiles, birds and mammals (Roizman and Pellett, 2001). In nature, most herpesviruses are 
closely associated with a single host species, and almost all the animal hosts investigated to date 
support infections by at least one herpesvirus species. Host susceptibility to herpesviruses indicates 
that the viruses have mainly co-evolved with their hosts, leading to a close adaptation (Davison, 
2002). 
 
The family Herpesviridae is divided into three subfamilies, called Alpha-, Beta- and 
Gammaherpesvirinae. The Alphaherpesvirinae subfamily contains four genera: Simplexvirus, 
Varicellovirus, Mardiviruses and Iltoviruses (ICTV, 2002). This subfamily includes viruses 
characterised by a large host range, a short replication cycle and a capacity to induce latent 
infection mainly, but not exclusively, in neurons (Roizman and Pellett, 2001). Among 
alphaherpesviruses infecting ruminants, the prototype is bovine herpesvirus 1 (BoHV-1), a 
pathogen of cattle associated with two major syndromes, called infectious bovine rhinotracheitis 
(IBR) and infectious pustular vulvovaginitis (IPV), and a variety of clinical signs, such as 
conjunctivitis, encephalitis and abortions (Pastoret et al., 1982). IBR is a disease of major 
economic concern in many parts of the world and especially in Europe, both in countries where this 
infection has been eradicated and in those where the control of IBR is currently or will be 
undertaken (Thiry et al., 1999). 
 
Seroepidemiological surveys have been performed in other species of domestic or wild 
ruminants in order to investigate whether these animals could be potential BoHV-1 reservoirs. 
Antibodies against BoHV-1 have been detected in many ruminant species (Thiry and Lemaire, 
2001). In addition, several ruminant alphaherpesviruses related to BoHV-1 have been isolated and 
characterised. Bovine herpesvirus 5 (BoHV-5) is responsible for meningo-encephalitis in calves 
(Johnston et al., 1962). Caprine herpesvirus 1 (CpHV-1) causes systemic disease in young kids and 
abortion in adult goats (Saito et al., 1974). Cervid herpesvirus 1 (CvHV-1) has been isolated from 
ocular disease in red deer (Cervus elaphus) in Scotland (Inglis et al., 1983). Cervid herpesvirus 2 
(CvHV-2) has been isolated from reindeer (Rangifer tarandus) in Finland (Ek-Kommonen et al., 
1986), and serological evidence of infection with a virus related to BoHV-1 has been reported in 
caribou (Rangifer tarandus caribou) in Canada (El Azhary et al., 1979). Elk herpesvirus 1 (ElkHV-1) 
has been isolated from elk (Cervus elaphus) in North America (Deregt et al., 2000) and bubaline 
herpesvirus 1 (BuHV-1) infection has been reported in water buffalo (Bubalus bubalis) in Australia 
(St George and Philpott, 1972) (Table 1). 
 
Successful control of IBR depends on the use of efficient, sensitive and specific diagnostic 
tests. However, since most of the diagnostic tests are based on the detection of antibody in 
polyclonal sera, their specificity is compromised by the existence of a serological cross-reactivity 
between BoHV-1 and these other closely related ruminant alphaherpesviruses. This can be 
illustrated by the original situation observed in Finland. In 1982, 23% of reindeer of this country 
had antibodies against BoHV-1, while all cattle were seronegative (Ek-Kommonen et al., 1982). A 
superficial analysis of these data suggested a BoHV-1 infection of reindeer with an absence of 
transmission to cattle due to an apparent lack of contact between the two ruminant species. 
However, this simple hypothesis was rapidly rejected. Indeed, from a BoHV-1 seropositive 
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reindeer, a new virus was isolated and further characterised as CvHV-2. This infection provided a 
likely explanation for the presence of anti-CvHV-2 antibodies cross-reacting with BoHV-1 in 
reindeer (Ek-Kommonen et al., 1986). In spite of this epidemiological situation in reindeer, the 
Finnish cattle population maintained an IBR free status. This example reveals the importance of 
clarifying the cause of potential serological cross-relationships with BoHV-1. 
 
Table 1 – Ruminant alphaherpesviruses related to BoHV-1. 
virus natural host disease geographic distribution 
BoHV-1 bovine 
infectious bovine rhinotracheitis 
infectious pustular vulvovaginitis 
Europe, America, Asia, Australia 
BoHV-5 bovine bovine encephalitis Europe, America, Australia 
BuHV-1 water buffalo subclinical genital infection Europe, Australia 
CpHV-1 goat 
vulvovaginitis, abortion, neonatal 
systemic infection 
Europe, America, Australia 
CvHV-1 red deer ocular syndrome Europe 
CvHV-2 reindeer subclinical genital infection Europe 
ElkHV-1 elk subclinical genital infection North America 
 
This review focuses on ruminant alphaherpesviruses related to BoHV-1, with particular 
emphasis on molecular virology, pathogenesis, host range, diagnosis and prevention. Indeed, it is 
of major interest to obtain greater knowledge about the risks of acute and latent infections of cattle 
with other ruminant herpesviruses and about the potential presence of BoHV-1 reservoirs among 
ruminant species other than cattle. 
 
 
Molecular virology 
 
Morphology and genomic organisation 
 
The inner part of the herpesvirus virion consists of a core containing the viral genome, 
protected by an icosahedral nucleocapsid of 100 to 110 nm diameter made up of 150 hexamers 
and 12 pentamers. This structure is surrounded by a proteinaceous layer, defined as the tegument. 
The latter is surrounded by a lipid bilayer, the envelope, containing a large number of viral 
glycoproteins, among which glycoproteins gB, gC and gD are the most abundant. The mature virion 
particle ranges from 120 to 300 nm in diameter (Roizman and Pellet, 2001) (Figure 1). 
 
 
 
 
 
 
 
 
Figure 1 – Morphology of ruminant alphaherpesviruses. 
 
The genome of ruminant alphaherpesviruses consists of a double-stranded linear DNA. 
Like the other alphaherpesviruses belonging to the Varicellovirus genus, it contains an arrangement 
of one long unique unit (UL) and one short unique unit (US) flanked by two inverted repeat 
sequences, named internal repeat (IR) and terminal repeat (TR) (Schwyzer and Ackermann, 1996) 
(Figure 2). These characteristics allow its classification in class D of herpesvirus genomes (Roizman 
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and Knipe, 2001). In this genomic class, the UL segment is predominantly fixed in only one 
orientation, called the prototype orientation, so that equimolar amounts of the two isomers can be 
predicted in virion DNA due to the inversion of the US segment (Roizman and Pellett, 2001). 
However, low levels (5%) of genomes having the UL segment in an inverted orientation have been 
detected in BoHV-1 virion DNA (Schynts et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Genomic organisation of ruminant alphaherpesviruses. The genome consists of a 
double-stranded linear DNA. It contains an arrangement of one long unique unit (UL) and one short 
unique unit (US) flanked by two inverted repeat sequences, named internal repeat (IR) and terminal 
repeat (TR). The genome includes ten genes encoding glycoproteins: six are located in the UL segment 
and four in the US segment. The US segment can have two possible orientations (depicted by the 
arrows). The UL segment is predominantly present in one orientation. The broken arrow illustrates that 
about 5% of the encapsidated genomes show the UL segment in this inverted orientation. 
 
Alphaherpesvirus genes are expressed in a cascade-like fashion. The first step occurs 
immediately after release of the virion genome from the capsid to produce immediate-early 
proteins. The second step occurs after the synthesis of immediate-early proteins, leading to the 
production of early proteins. The third step, in which late proteins are produced, is delayed until 
after the synthesis of virion DNA. Finally, early-late protein expression starts before viral DNA 
replication but does not decrease during late protein expression (Roizman and Knipe, 2001). 
 
Genomic comparison between ruminant alphaherpesviruses 
 
The genomes of BoHV-1 and BoHV-5 have been sequenced (Delhon et al., 2003; Meyer et 
al., 1997; Schwyzer and Ackermann, 1996). The BoHV-5 genome is 138,390 bp long (72% G+C 
content), with 2 518 bp more than BoHV-1 (75% G+C content). It includes 72 genes, of which 68 
are present as single copies within the unique regions and two are completely located within the 
repeat region (BICP4 and BICP22) (Delhon et al., 2003). The BoHV-1 genome comprises 67 unique 
genes and two genes, both duplicated, in the inverted repeats (Schwyzer and Ackermann, 1996). 
The highest BoHV-5 similarity to BoHV-1 products (≥ 95% amino acid identity) is found in proteins 
involved in viral DNA replication and processing (UL5, UL15, UL29 and UL39) and in virion proteins 
(UL14, UL19, UL48 and US6). Among the least conserved (≤75%) are the homologues of 
immediate-early proteins BICP0, BICP4 and BICP22, these proteins being longer in BoHV-5 than in 
BoHV-1 (Delhon et al., 2003). It can be hypothesised that the same range of homology is shared 
by the other related ruminant alphaherpesviruses. 
 
The comparison between other ruminant alphaherpesviruses is based on limited sequence 
data. The genome sizes are estimated to be 137 kbp for CpHV-1, 141 kbp for CvHV-1 and 145 kbp 
for CvHV-2 (Engels et al., 1987; Vanderplasschen et al., 1993). Based on the complete gB gene 
sequence, which is the most conserved between herpesviruses (Griffin, 1991), the percentages of 
nucleotide sequence identity with BoHV-1 gB are 78.5% for CpHV-1, 84% for CvHV-2, 85.8% for 
CvHV-1, 87.4% for BoHV-5 and 87.7% for BuHV-1 (Ros and Belak, 2002). The gC and gD genes 
sequences are fully known for each ruminant alphaherpesviruses, except for BuHV-1 (Delhon et al., 
2003; Deregt et al., 2005; Keuser et al., 2006; Schwyzer and Ackermann, 1996; Tempesta et al., 
IR TR
UL
gK gC gB gH gM gL
gG gD gI gE
UL49.5
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2004b). On this basis, the percentages of amino acid sequence identity between BoHV-1 and 
ElkHV-1 are 71.7% (gC) or 72.9% (gD) (Deregt et al., 2005). The G+C contents of the gC (or gD) 
genes are 79.4% (77.2%) for CvHV-1, 79.2% (76%) for CvHV-2 and 78.7% (78.5%) for ElKHV-1 
(Deregt et al., 2005). Comparison of the coding sequence of the CvHV-2 gC region with other 
ruminant alphaherpesviruses has revealed a conserved central part of the gC gene, while the N-
terminal is highly variable with large deletions and insertions (Ros and Belak, 1999; Ros et al., 
1999). These results have allowed the classification of these viruses into a consistent group, where 
BoHV-5 and BuHV-1 are most closely related to BoHV-1, followed by ElkHV-1, CvHV-1, CvHV-2 
and, more distantly, by CpHV-1 (Deregt et al., 2005; Ros and Belak, 2002) (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Phylogenetic relationship between ruminant alphaherpesviruses. Phylogenetic tree 
inferred by amino acid sequences from the gB regions of ruminant alphaherpesviruses (reproduced from 
Ros and Belak (2002), with permission of Kluwer Academic Publishers). Based on the gC and gD 
sequences, ElkHV-1 clusters with CvHV-1 (Deregt et al., 2005). 
 
Viral glycoproteins 
 
Viral glycoproteins of herpesviruses play an important role in the interactions between 
these viruses and their host-cells. They are involved at several steps of the viral cycle, such as the 
attachment, penetration, maturation and egress of the virus. Therefore, they constitute an 
important target for the host immune response. Some glycoproteins also have immunogenic 
properties, allowing their use as a component of vaccines or diagnostic tests.  
 
Most of the BoHV-1 glycoproteins have already been characterised (Tikoo et al., 1995). 
The UL segment includes genes coding for glycoproteins gB (UL27), gC (UL44), gH (UL22), gL 
(UL1), gK (UL53) and gM (UL10), while four genes corresponding to gG (US4), gD (US6), gI (US6) 
and gE (US8) are grouped in a tandem organisation in the US segment (Schwyzer and Ackermann, 
1996) (Figure 1). Several constructions of mutant viruses have shown that gC, gI, gE, gG and gM 
are non essential glycoproteins (Baranowski et al., 1996; Konig et al., 2002). On the other hand, 
the deletion of the gene encoding either gB or gD or gH reduces the capacity of in vitro replication 
(Fehler et al., 1992; Meyer et al., 1998). Glycoproteins L and K are essential in HSV-1 and this is 
very likely to be the case in the other alphaherpesviruses (Hutchinson et al., 1992; Roop et al., 
1993). In the pseudorabies virus, an additional glycoprotein, designated gN (UL49.5), is a 
glycosylated 10 kDa transmembrane protein and is identified as an immune evasion molecule 
inhibiting the transporter associated with antigen processing (TAP) driven peptide import into the 
endoplasmic reticulum. The UL49.5 homologue encoded by BoHV-1 has the same immune evasion 
function, but is not classified as glycoprotein N (Koppers-Lalic et al., 2005). 
 
Considering the lack of data on glycoproteins, we hypothesise by analogy that the main 
0
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elements of structure and function of BoHV-1 glycoproteins are shared by the other ruminant 
alphaherpesviruses. Monoclonal antibody analysis allows the identification of antigenic differences 
between BoHV-1 and BoHV-5 (Collins et al., 1993; Egyed et al., 1992; Friedli and Metzler, 1987; 
Metzler et al., 1986). Glycoprotein C shows more divergence between BoHV-1 and BoHV-5 than gB 
and gD (Collins et al., 1993; Friedli and Metzler, 1987). BoHV-5 gC, although not essential, 
regulates neurotropism in some areas of the olfactory pathway and is important for BoHV-5 
neurovirulence in rabbits (Chowdhury et al., 2000b). This glycoprotein is also able to transfer the 
heparin binding phenotype of BoHV-5 to a recombinant BoHV-1 (Liman et al., 2000). The BoHV-5 
gE is involved in neural spread and neurovirulence within the central nervous system and cannot 
be substituted by BoHV-1 gE. However, BoHV-5 gE is not essential for the initial entry into the 
olfactory pathway (Chowdhury et al., 2000a). Glycoprotein I is not required for the neurovirulence 
of gE in BoHV-5 (Al-Mubarak and Chowdhury, 2004), but a glycine-rich BoHV-5 gE-specific epitope 
is essential for expression of the full virulence potential of BoHV-5 (Al-Mubarak et al., 2004). 
Generally, gE and gI seem to be important for BoHV-5 neuropathogenicity and its ability to 
reactivate from latency (Hubner et al., 2005). Glycoprotein H is one of the most conserved 
glycoproteins in herpesviruses (Gompels et al., 1988). BoHV-1 and BoHV-5 gH are both expressed 
as early-late proteins. Glycoprotein H is essential for both penetration and cell-to-cell spread 
(Baranowski et al., 1995; Meyer et al., 1998; Meyer et al., 1999). In CpHV-1, gD shows a 
relatively high homology to BoHV-1 gD amino acid sequences (similarity of 68.8%) and has a 
molecular mass similar to BoHV-1 gD. CpHV-1 gD contains complex N-linked oligosaccharides, but 
the presence of O-glycosylation has not been demonstrated. In contrast with BoHV-1 gD, CpHV-1 
gD is seemingly expressed as a late protein (Keuser et al., 2006). 
 
Recombination between ruminant alphaherpesviruses 
 
Recombination is thought to be an important source of genetic variation in herpesviruses. 
Several studies, performed in vitro and in vivo, have detected recombinant viruses after the co-
inoculation of two distinguishable strains of the same herpesvirus species (Thiry et al., 2005; Thiry 
et al., 2006). After experimental co-inoculation of calves with two parental BoHV-1 mutants, 
recombination has been identified as a frequent event in vivo. Recombinant viruses have been 
detected both during primary infection and after reactivation from latency (Schynts et al., 2003). 
The mechanism involved is mainly homologous recombination. Its role in creating viral diversity 
needs to be evaluated in BoHV-1 control and eradication programmes. In order to assess the risk 
of recombination between BoHV-1 gE negative marker vaccine and field strains, different factors 
influencing the onset of recombinant viruses have been investigated. In natural conditions, 
superinfection is a more likely event than co-infection. Superinfection with a time interval of 2 to 8 
h between two successive infections allows the establishment of a barrier to prevent recombination 
between BoHV-1 strains (Meurens et al., 2004a). Therefore, only co-infection or delayed infection 
over a very short interval of time might lead to the production of recombinant viruses. 
 
The efficiency of interspecific recombination has been assessed between ruminant 
alphaherpesviruses. Indeed, successful homologous recombination requires two closely related 
parental viruses. Two recombinants between BoHV-1 and BoHV-5 have been isolated, but no 
recombinant has been detected between BoHV-1 and the less closely related CpHV-1 and CvHV-2 
(Meurens et al., 2004b). Nevertheless, even in the absence of mature recombinant viruses, these 
results do not exclude a recombination process occurring in the cell, because mixed concatemers 
between BoHV-1 and CvHV-2, and between CvHV-1 and CvHV-2, have been identified in co-
infected cells (Meurens, 2004). The close genetic relatedness between ruminant 
alphaherpesviruses suggests a theoretical risk of recombination between these virus species. This 
risk must also be evaluated by considering the sites of alphaherpesvirus replication: two 
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alphaherpesviruses are unlikely to recombine if they replicate in two distant sites, such as the 
genital and the respiratory mucosae. 
 
 
Pathogenesis and clinical signs 
 
The pathogenesis of BoHV-1 infection is well described (Engels and Ackermann, 1996; 
Jones, 2003; Pastoret et al., 1982). After infection and virus replication in mucosa, BoHV-1 spreads 
both in the extracellular space and also from cell-to-cell. By this latter mechanism, it may enter 
axons of local nerve cells. Then, by intra-axonal transport, the viruses reach the sensitive neuronal 
bodies in the regional nervous ganglia, where latency can be established. This pathogenic 
mechanism is shared by the other ruminant alphaherpesviruses. Although infection can lead to 
lethal or systemic disease, especially in newborn animals, clinical signs are usually mild, but may 
vary according to the animal species and the virus species and strain concerned. 
Alphaherpesviruses, like other herpesviruses, are able to interfere with the host’s innate and 
adaptative immune responses. A growing list of immune evasion mechanisms is described (Vossen 
et al., 2002), such as, for example, inhibition of TAP proteins (Koppers-Lalic et al., 2005) or Fc 
receptor activity of viral glycoproteins (Favoreel et al., 2003). 
 
Bovine herpesvirus 5 
 
The pathogenesis of bovine herpesvirus encephalitis is not yet completely elucidated. 
Comparative experiments of inoculation with BoHV-1 and BoHV-5 have been carried out in cattle 
(Bagust, 1972; Bagust and Clark, 1972; Belknap et al., 1994; Hall et al., 1966; Meyer et al., 2001; 
Schudel et al., 1986). After primary infection by intranasal inoculation, BoHV-1 and BoHV-5 
replicate at the portal of entry in the respiratory mucosa (Bagust and Clark, 1972). Experimentally 
infected calves show similar profiles for the length of excretion (ten to sixteen days) and for the 
amount of excreted viruses. The rate of virus excretion is high, with a peak between the fourth and 
sixth days post infection (Belknap et al., 1994; Meyer et al., 2001; Thiry et al., 1999). After 
primary infection, BoHV-5 induces a transient viremia and virus is recovered in secondary organs 
(Belknap et al., 1994). 
 
The dissemination of BoHV-5 infection probably follows the same three routes as BoHV-1: 
blood, nervous system and cell-to-cell spread (Bagust and Clark, 1972; Belknap et al., 1994; Hall 
et al., 1966; Meyer et al., 2000; Pastoret et al., 1982). BoHV-5 induces a replication cycle in cells 
of the respiratory epithelium and reaches the nervous system by a mechanism strongly associated 
with intra-axonal transport. Neurons of the peripheral nervous system are infected first of all, 
especially cells of the trigeminal ganglia and olfactory cells of nasal mucosa. The virus invades all 
areas of the central nervous system by neuron-to-neuron spread, using the olfactory and 
trigeminal pathways (Meyer et al., 2000). In a rabbit model of infection, the olfactory pathway was 
indeed shown to be the main route of infection of the central nervous system (Lee et al., 1999). 
Cell-to-cell transmission without extracellular phase and in the absence of specific antibodies has 
been demonstrated for BoHV-1. It can be postulated that the same mechanism drives the local 
transfer of BoHV-5 to the central nervous system (Meyer et al., 2000). 
 
In calves, BoHV-5 has been shown to produce fatal meningo-encephalitis after intranasal 
inoculation or a meningitis-like disease after intravaginal infection because the virus involves the 
central nervous system (Meyer et al., 2001). Inoculation of conjunctival, nasal and vaginal 
mucosae provokes conjunctivitis, rhinitis and vulvovaginitis, respectively. Clinical signs of BoHV-5 
are characterised by serous nasal discharge and sneezing; apathy and anorexia are also observed. 
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Neurological signs start with severe depression with anorexia, jaw champing and hypersalivation. 
In the next phase, calves are affected by muscle trembling, circling to one side, pushing their head 
against a wall and ataxia, followed by seizure-like episodes and opisthotonos (Meyer et al., 2001). 
Histological lesions in the brain consist of meningitis, mononuclear perivascular cuffing, 
neurophagia, satellitosis, gliosis, haemorrhage, necrosis and oedema (Perez et al., 2002). 
 
After primary infection, BoHV-5 latency is established in surviving calves. The classical 
latency sites are the trigeminal ganglia, but BoHV-5 DNA could also be present throughout the 
central nervous system during latent infection and probably in nasal and tracheal mucosae, where 
viral DNA has been detected by PCR (Meyer et al., 2001). Virus reactivation may result in the 
establishment of latent infection in additional sites of the brain (Vogel et al., 2003). The 
establishment of latent infection has also been demonstrated in the rabbit model (Caron et al., 
2002). Reactivation of BoHV-5 can be provoked by the same glucocorticoid treatment as for BoHV-
1: 0.1 mg of dexamethasone per kg body weight for five consecutive days (Meyer et al., 2001). 
 
Caprine herpesvirus 1 
 
The pathogenesis of CpHV-1 infection in goats and BoHV-1 infection in calves is very 
similar (Engels and Thiry, 2000). Local respiratory or genital infection is followed by a mononuclear 
cell-associated viremia, which can lead to systemic infection and abortion. The main sources of 
infection are acutely and latently infected animals. During acute infection, the virus is excreted via 
ocular, nasal and genital routes. The genital route is thought to be the main entry site of the virus 
and is thought to be responsible for the maintenance of infection in a herd (Tempesta et al., 2000).  
 
In kids, CpHV-1 causes a systemic disease characterised by high morbidity and mortality 
rates. Ulcerative and necrotic lesions are distributed throughout the enteric tract (Mettler et al., 
1979). In adult goats, the infection leads to vulvovaginitis or balanoposthitis. Abortions associated 
with CpHV-1 occur during the second half of pregnancy and can be experimentally reproduced after 
intranasal or intravenous inoculation of pregnant goats (Tempesta et al., 2004; Uzal et al., 2004; 
Williams et al., 1997). The viral DNA is identified in both the placenta and several inner organs of 
the aborted foetus (Keuser et al., 2002; Tempesta et al., 2004; Waldvogel et al., 1981). 
 
Natural reactivation from latent CpHV-1 infection can be induced by a physiological stress 
during the mating season. The hormonal status at oestrus could play a role in the induction of 
reactivation. Under experimental and natural conditions, the reactivation of a latent virus is difficult 
(Buonavoglia et al., 1996; Keuser et al., 2004b; Tempesta et al., 2000). Experimental reactivation 
requires the use of high doses of dexamethasone: six consecutive daily injections at a dose rate of 
4.4 mg per kg bodyweight (Buonavoglia et al., 1996). Re-excretion after reactivation is observed in 
goats with relatively low antibody titres (Tempesta et al., 1998). Viruses are isolated from nasal, 
genital, rectal and ocular swabs, suggesting several potential latency sites (Buonavoglia et al., 
1996; Plebani et al., 1983), such as sacral ganglia where latent CpHV-1 has been detected by PCR 
(Tempesta et al., 1999a). The site supporting CpHV-1 re-excretion may depend on the route of 
primary infection. After reactivation of a virus previously inoculated intranasally, the virus is shed 
from the nose and vagina (Tempesta et al., 1999b). In contrast, after a genital primary infection, 
reactivated CpHV-1 is only re-excreted from the vagina (Tempesta et al., 2000). 
 
Cervid herpesvirus 1 
 
Primary sites of CvHV-1 infection are the anterior respiratory and ocular mucosae (Keuser 
et al., 2000). Viruses can be recovered from between two and six days post-infection in nasal and 
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ocular swabs (Reid et al., 1986). However, a genital transmission cannot be excluded because 
CvHV-1 has been isolated from red deer sperm (Tisdall and Rowe, 2001). CvHV-1 is responsible for 
an ocular syndrome in red deer (Inglis et al., 1983). This syndrome is characterised by 
conjunctivitis and purulent ocular discharge, hypopyon, uniform corneal opacity without ulceration, 
mucopurulent nasal discharge and photophobia. Moderate swelling of the periorbital tissues and 
marked oedema of the upper eyelids are also observed (Inglis et al., 1983).  
 
Experimental infection induces hyperthermia, nasal ulceration and conjunctivitis. These 
clinical signs are mild in comparison with natural infection. CvHV-1 can be also isolated after 
intramuscular injection with 50 mg of a synthetic glucocorticoid for twelve consecutive days. This 
result suggests that this virus is able to establish a persistent infection and be reactivated 
(Ronsholt et al., 1987). 
 
Cervid herpesvirus 2 
 
Reindeer infection by CvHV-2 is asymptomatic (Nettleton et al., 1988a). The first virus 
isolation was performed on vaginal swabs from reindeer identified as seropositive for BoHV-1. 
Reindeer were injected intramuscularly on four consecutive days with dexamethasone at a dose 
rate of 0.1 mg per kg bodyweight (Ek-Kommonen et al., 1986). Therefore, CvHV-2 most likely 
establishes a latent infection and can be re-excreted in genital secretions. A serological 
investigation showing a high prevalence in adult reindeer suggests a genital transmission 
(Nettleton et al., 1988b). 
 
Bubaline and elk herpesviruses 1 
 
Recently, a field strain of BuHV-1 was isolated after a reactivation treatment. Water 
buffaloes were injected intramuscularly daily for five consecutive days with dexamethasone at a 
dosage of 4 mg per kg bodyweight. Only slight diarrhoea and serous nasal discharge were 
observed (De Carlo et al., 2004). Concerning ElkHV-1 infection, pathogenesis and clinical signs 
remain to be investigated. 
 
 
Cross-species infection 
 
Cross-infection studies have been performed in order to gain greater knowledge about 
risks of acute and latent infections in cattle with other ruminant alphaherpesviruses and about 
potential BoHV-1 reservoirs among ruminant species other than cattle. The results of experimental 
infections of calves with BoHV-5, CpHV-1, CvHV-1, CvHV-2 and ElkHV-1, and infection of goats, 
sheep, red deer and reindeer with BoHV-1 are summarised in Tables 2 and 3 (Thiry et al., 2001). 
 
Bovine herpesvirus 1 infection of goats and sheep 
 
Experimental infection of goats with BoHV-1 has clearly shown that this virus is able to 
infect the heterologous host. This infection leads to mild clinical signs, high levels of BoHV-1 
excretion for several days during primary infection and a serological response. BoHV-1 is able to 
establish a latent infection in the trigeminal ganglia of goats and sheep (Ackermann et al., 1986; 
Engels et al., 1992; Lehmkuhl et al., 1985; Pirak et al., 1983; Six et al., 2001; Wafula et al., 
1985). Reactivation of latent BoHV-1 is obtained by a daily dexamethasone treatment on five 
consecutive days of 2.5 mg per kg bodyweight in goats (Six et al., 2001) and 0.1 mg per kg 
bodyweight in sheep (Banks et al., personal communication). Field cases of BoHV-1 latent 
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infections have also been recorded in goats (Tolari et al., 1990). Although they are usually 
subclinical in sheep, acute BoHV-1 infections can sometimes be associated with clinical signs, such 
as acute, fatal pneumonia, or with aborted foetuses (Whetstone and Evermann, 1988). However, 
sheep do not play a major role in BoHV-1 transmission to calves (Hage et al., 1997). 
 
Bovine herpesvirus 1 infection of red deer and reindeer 
 
Red deer could become infected following a profound BoHV-1 challenge, but titres of 
excreted virus are very low and almost certainly would not represent a source of contagious 
spread. Furthermore, there is no evidence that BoHV-1 establishes a latent infection in red deer. 
Seroconversions to BoHV-1 in red deer do not occur and are most likely the result of a CvHV-1 
rather than BoHV-1 infection (Nettleton et al., 1988a; Reid et al., 1986). Another deer species, 
mule deer (Odocoileus hemionus) exhibits a greater susceptibility to BoHV-1 because it actively 
excretes BoHV-1 and shows seroconversion after experimental inoculation (Nettleton et al., 
1988b).  
 
In reindeer, experimental BoHV-1 infection is asymptomatic and does not usually give rise 
to neutralising antibodies. The titres of nasally excreted viruses are very low and the virus cannot 
be reactivated experimentally (Thiry et al., 2001). 
 
Bovine herpesvirus 5 infection of sheep 
 
Sheep are susceptible to acute and latent infection with BoHV-5. Experimental inoculation 
of BoHV-5 shows that this virus is able to infect the heterologous host by invading the central 
nervous system. Resulting clinical signs are similar to those observed in cattle (Belak et al., 1999). 
A dexamethasone treatment of 2 mg daily for five consecutive days results in reactivation of the 
latent infection and virus shedding in lambs (Silva et al., 1999). No BoHV-5 natural infection has 
yet been reported in sheep. 
 
Caprine herpesvirus 1 infection of calves and sheep 
 
Bovine calves intranasally infected with CpHV-1 have been shown to excrete the virus. 
CpHV-1 is able to establish a latent infection in trigeminal ganglia. However, reactivation of latent 
CpHV-1 from calves has not been successfully achieved (Six et al., 2001). In the same way, lambs 
are susceptible to CpHV-1 infection, but no virus has been isolated after clinical reactivation 
(Papanastasopoulou et al., 1991). In natural conditions, CpHV-1 virulence is restricted to the 
natural host (Engels et al., 1992). 
 
Cervid herpesvirus 1 infection of calves 
 
Bovine calves are almost refractory to infection with CvHV-1 by intranasal challenge: 
neither clinical signs nor virus excretion are observed. Furthermore, when calves are challenged 
with BoHV-1 after a CvHV-1 infection, they develop pyrexia and the virus is recovered in nasal and 
ocular swabs, thereby showing that a prior infection with CvHV-1 does not induce any protective 
immune response (Nettleton et al., 1988a; Reid et al., 1986). In addition, no infection has been 
noticed in cattle housed in close contact with infected deer (Ronsholt et al., 1987). 
 
Cervid herpesvirus 2 infection of calves 
 
In experimental conditions, cattle can be successfully infected intranasally with CvHV-2 
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and mild rhinitis is observed. The virus is isolated for six to nine days from nasal and genital swabs 
(Nettleton et al., 1988b). Therefore, CvHV-2 replication can occur experimentally in bovines, but 
cattle housed in close contact with infected reindeer are not infected (Ek-Kommonen et al., 1986). 
These results suggest that the risk of transmission between reindeer and cattle is low in natural 
conditions. 
 
Elk herpesvirus 1 infection of cattle 
 
Experimentally, cattle are susceptible to infection with ElkHV-1, but do not show any 
clinical signs. A cow inoculated intranasally has been shown to develop neutralising antibodies, 
while a genital inoculation failed to induce any serological response in another cow (Deregt et al., 
2000). More recently, reactivation from latency was serologically demonstrated in cattle 
experimentally infected with ElkHV-1 after a daily dexamethasone treatment for five consecutive 
days of 0.1 mg per kg bodyweight (Deregt et al., 2005). Natural cross-infection has not yet been 
recorded. 
 
 
 
 
Epidemiology 
 
Bovine herpesvirus 5 
 
Since 1962, several outbreaks of herpesvirus encephalitis have been described and were 
later on attributed to BoHV-5. In Australia and South America, this infection occurs in cattle not 
immunised against BoHV-1 and is inducing a major economic problem, mainly in central and 
southern Brazil and Argentina. Indeed, the morbidity rate may vary between 15 and 50% and the 
lethal rate is close to 100% (Carillo et al., 1983; Johnston et al., 1962; Perez et al., 2003; 
Salvador et al., 1998; Weiblen et al., 1989). In USA, BoHV-5 has been associated with field cases 
of bovine encephalitis (D’Offay et al., 1993). In Europe, BoHV-5 has been isolated only once in 
Hungary (Bartha et al., 1969), but BoHV-5 infection is probably also present in Germany and 
eastern European countries (Meyer et al., 2000). 
 
Caprine herpesvirus 1 
 
CpHV-1 was initially isolated in 1975 in California from the tissues of newborn kids 
Table 2 – Consequences of infection of calves                                          
with ruminant alphaherpesviruses related to bovine herpesvirus 1. 
virus 
primary                 
infection 
serological             
response 
latency 
reactivation and 
reexcretion 
BoHV-5 + + + + 
CpHV-1 + + + - 
CvHV-1 - - - - 
CvHV-2 + + - - 
Table 3 – Consequences of infection of ruminant species with bovine herpesvirus 1. 
host 
primary                 
infection 
serological             
response 
latency 
reactivation and 
reexcretion 
goat + + + + 
sheep + + + + 
red deer + - - - 
reindeer + - - - 
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affected with mild to severe enteritis (Saito et al., 1974). In 1979, it was isolated from kids in a 
herd in the Bregaglia valley of Switzerland (Mettler et al., 1979). Distribution of CpHV-1 infection 
has not been systematically studied in goats but the virus has been identified in several countries 
in Europe including Greece, Italy, Spain and Switzerland, as well as in Australia, Canada, New 
Zealand and the USA (Chenier et al., 2004; Grewal and Wells, 1986; Horner et al., 1982; Keuser et 
al., 2004b; Koptopoulos et al., 1988; Mettler et al., 1979; Muluneh and Liebermann, 1990; Plebani 
et al., 1983; Roperto et al., 2000; Saito et al., 1974). The apparent prevalences are variable. In 
many countries where goats play an economical role, a high seroprevalence is observed: between 
30 and 40% in southern Italy and more than 50% in Greece (Guercio et al., 1998; Koptopoulos et 
al., 1988; Tempesta et al., 1994). CpHV-1 infection has not been identified in Belgium, France 
(Keuser and Thiry, unpublished results) or the United Kingdom. 
 
Cervid herpesvirus 1 
 
CvHV-1 was initially isolated in 1983 in farmed red deer. The outbreak occurred in a 
group of 80 red deer in the north of Scotland and 50 to 60 animals exhibited clinical signs (Inglis et 
al., 1983). More recently, CvHV-1 was identified in New Zealand where the virus was isolated 
during routine export examination of semen collected from red deer stags (Tisdall and Rowe, 
2001). CvHV-1 infection is widespread in Great Britain. Indeed, 35% of animals older than one 
year are seropositive for CvHV-1 (Nettleton et al., 1986). Moreover, a Czech investigation showed 
that 71% of red deer imported from Scotland were seropositive (Pospisil et al., 1996). The 
apparent prevalence of seropositive free ranging deer has been shown to be 11% in Belgium and 
1% in France (Thiry et al., 1988). More recently, a further Belgian investigation has shown a 
seroprevalence of 30% in free ranging adults and 1.4% in calves (Gregoire and Linden, 
unpublished results). In 1988, 43% of deer in a Belgian farm were shown to be seropositive to 
CvHV-1 (Thiry, unpublished results). Although the serological analyses were performed with tests 
detecting anti-BoHV-1 antibodies, they are most suggestive of CvHV-1 infection in wild populations 
of red deer. 
 
Cervid herpesvirus 2 
 
Serological evidence of exposure of reindeer to a virus related to BoHV-1 has formerly 
been reported in Canada (El Azhary et al., 1979) and in the USA (Dietrich, 1981). More recently, 
evidence of alphaherpesvirus infection has been reported in isolated populations of woodland 
caribou in western Canada (Jordan et al., 2003). In 1982, a prevalence of 23% reindeer 
seropositive to BoHV-1 was observed in Finnish Lapland (Ek-Kommonen et al., 1982). In Finland, 
64% of adult reindeer and 1% of calves have been shown to be seropositive to CvHV-2 (Nettleton 
et al., 1988b). A Norwegian investigation showed similar results: 60% of reindeer and 15% of 
calves were shown to be seropositive (Hyllseth et al., 1993). In Norway, during the period 1993-
2000, antibodies against BoHV-1 related alphaherpesviruses were found in 28.5% of reindeer 
(Lillehaug et al., 2003). These results indicate that alphaherpesvirus infections are endemic in 
reindeer and that CvHV-2 is most likely the herpesvirus responsible for the observed prevalences. 
 
Bubaline and elk herpesviruses 1 
 
BuHV-1 was isolated in 1971 from prepuces of water buffaloes (St George and Philpott, 
1972). More recently, a field strain of BuHV-1 has been isolated from buffaloes in Italy (De Carlo et 
al., 2004). To date, only one case of ElkHV-1 infection has been reported. The virus was isolated 
from the semen of a North American elk (Deregt et al., 2000). 
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Diagnosis 
 
The capacity of these related alphaherpesviruses to spread in ruminant populations is a threat 
to BoHV-1 eradication programmes. Indeed, infection with related viruses could lead to false positive 
diagnosis of BoHV-1. Moreover, heterologous ruminant species could serve as BoHV-1 reservoirs. 
Consequently, diagnostic tools able to distinguish between ruminant alphaherpesviruses related to BoHV-1 
and BoHV-1 itself are of great interest. 
 
Virological diagnosis 
 
The use of tests based on virus isolation or viral DNA detection can avoid misinterpretation due 
to these cross-reactions. Restriction endonuclease analysis (REA) performed on viral isolates allows the 
identification and distinguishing of the related viruses (Brake and Studdert, 1985; Bulach and Studdert, 
1990; Buonavoglia et al., 1996; D’Arce et al., 2002; Engels et al., 1981, 1983, 1986, 1987; Pidone et 
al., 1999; Pratelli et al., 2000; Rimstad et al., 1992; Ronsholt et al., 1987; Vanderplasschen et al., 1993; 
Williams et al., 1997) and could be used to detect interspecific recombinants (Meurens et al., 
2004b). However, this procedure is not convenient for general use in a diagnostic laboratory. Highly 
specific methods using viral DNA amplification have therefore been developed. Differential PCR assays 
use pairs of consensus primers selected for the detection of bovine, caprine and cervid herpesviruses, 
and discrimination is achieved by subsequent REA of PCR products (Lyaku et al., 1996; Ros and Belak, 
1999) (Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – PCR amplification of ruminant alphaherpesvirus DNA. A mimic molecule is used for 
control. The final identification of the amplicon is performed by restriction enzyme analysis (reproduced 
from Ros and Belak (1999), with permission of the American Society for Microbiology).  
 
Another PCR system, using four primer pairs, specifically amplifies a part of the gC gene of 
each alphaherpesvirus (Ros et al., 1999). A multiplex PCR is available for differentiation between 
BoHV-1 and BoHV-5 (Alegre et al., 2001). A quantitative real time PCR is available for the detection 
and quantitation of CpHV-1 DNA in goats (Tempesta et al., 2005). 
 
There also exist monoclonal antibodies that can distinguish between BoHV-1 and BoHV-5 by 
immunofluorescence, immunoprecipitation or western blot (Friedli and Metzler, 1987; Metzler et al., 
1986; Oldoni et al., 2004). More recently, an immunofluorescence assay able to differentiate the five 
related herpesviruses has been developed. This method is based on the use of four monoclonal 
antibodies directed against gC, and one against gD, of these related viruses (Keuser et al., 2004a) 
(Figure 5). 
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Figure 5 – Indirect immunofluorescence staining of cells infected with ruminant 
alphaherpesviruses. The primary monoclonal antibodies directed against BoHV-1, BoHV-5, CpHV-1, 
CvHV-2 and CvHV-1 were detected by FITC-conjugated rabbit immunoglobulin anti-mouse IgG 
(reproduced from Keuser et al. (2004b), with permission of the American Society for Microbiology). 
 
Serological diagnosis 
 
Serological analysis is very difficult due to the antigenic similarity of ruminant 
alphaherpesviruses related to BoHV-1. Indeed, these viruses cross-react in ELISA and 
seroneutralisation tests (Lyaku et al., 1992; Martin et al., 1990; Nixon et al., 1988). The current 
available serological tests are almost unable to discriminate the related alphaherpesviruses. 
 
A method combining two blocking ELISAs allows a distinction to be made between anti-BoHV-1 
and anti-BoHV-5 antibodies in cattle. A serum positive to BoHV-1 in a blocking ELISA based on the 
recognition of BoHV-1 glycoprotein B is further analysed by a BoHV-1 gE blocking ELISA. Provided there 
is no vaccination of cattle with a gE negative BoHV-1 vaccine, a negative result in this second test will 
indicate an infection with BoHV-5. However, the sensitivity and the specificity of this test have been 
tested only on a very limited number of experimental sera (Wellenberg et al., 2001). 
 
An early study demonstrated a full agreement between seroneutralisation and indirect ELISA 
for the detection of anti-CpHV-1 antibodies in goats (Plebani et al., 1983). Commercially available 
BoHV-1 gB blocking ELISA has been tried in other animal species, namely goats and red deer. 
Compared to CpHV-1 seroneutralisation, this test, applied to the detection of anti-CpHV-1 
antibodies in goats, exhibits a relative sensitivity of 95.8% ± 2.4% for experimental sera and 
98.7% ± 2.5% for field sera, as well as a relative specificity of 96.9% ± 2.5% for experimental sera 
and 91.4% ± 9.2% for field sera (Keuser et al., 2003). These good relative intrinsic values are 
enough to recommend their use at herd level but not on an individual basis. It must be emphasised 
that this test cannot differentiate between anti-BoHV-1 and anti-CpHV-1 antibodies. The same 
BoHV-1 gB blocking ELISA has been successfully tested on deer sera to detect antibodies to CvHV-
1 by cross-reaction with the same inability to distinguish between anti-BoHV-1 and anti-CvHV-1 
antibodies (Reid, personal communication). Any further attempt to develop specific ELISAs has 
failed to date. The challenge is therefore to develop a differentiating serological test that could be 
free from high antigenic cross-reactions. 
 
Neutralising antibodies are raised after each alphaherpesvirus infection: for example, 
 
BoHV-1 BoHV-5 CpHV-1 CvHV-1 CvHV-2
MAb anti-BoHV-1 gC
MAb anti-BoHV-5 gC
MAb anti-CpHV-1 gC
MAb anti-CvHV-2 gC
MAb anti-CvHV-1 gD
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bovine field or experimental sera (Meyer et al., 2000), sera from hyperimmunised rabbits 
(Bratanich et al., 1991) and monoclonal antibodies raised against gB, gC or gD (Collins et al., 
1993; Friedli and Metzler, 1987) exhibit neutralising properties against BoHV-5. 
  
In several combinations, cross-neutralisation assays can differentiate antibodies between 
the related alphaherpesviruses. A one way cross-neutralisation can be demonstrated for each 
combination of BoHV-1 and related alphaherpesviruses. Therefore, BoHV-1 specific antiserum 
neutralises the heterologous virus to a greater extent than anti-sera specific to related 
alphaherpesviruses have been shown to neutralise BoHV-1 (Deregt et al., 2005; Engels et al., 
1983; Meyer et al., 2001; Nettleton et al., 1988a). 
 
 
Prevention 
 
Although there is no commercially available vaccine against BoHV-5, it is possible to take 
advantage of a previous immunisation against BoHV-1. Indeed, a primary infection with BoHV-1 
affords a cross-protection that protects cattle clinically against a BoHV-5 superinfection (Bratanich 
et al., 1991; Cascio et al., 1999). This feature can explain the epidemiology of BoHV-5 infection in 
several continents. Indeed, BoHV-5 can induce outbreaks of meningo-encephalitis in calves not 
vaccinated against BoHV-1. In North America, IBR vaccination is widely used and sporadic cases of 
BoHV-5 have only been seen to emerge in calves badly or not immunised against BoHV-1 (D’offay 
et al., 1993). A recombinant gE negative BoHV-1 vaccine has been shown to be unable to confer 
full protection against the challenge of BoHV-5 (Spilki et al., 2004). Therefore, the efficacy of the 
cross-protection afforded by commercial BoHV-1 vaccines needs to be evaluated. 
 
A classical inactivated vaccine confers protection against CpHV-1 infection in goats. This 
vaccine shows a high immunogenicity and good clinical protection (Tempesta et al., 2001). 
However, this vaccine has very little chance of being marketed because the veterinary 
pharmaceutical industry has only a poor interest in the development of vaccines for minor species 
like goats. As goats are susceptible to BoHV-1, both live and inactivated BoHV-1 vaccines might be 
tested in goats for their efficacy in the face of a CpHV-1 infection. In this way, a recent preliminary 
experiment showed that a commercially available live attenuated gE negative BoHV-1 vaccine 
afforded only a partial protection to intranasally challenged goats (Thiry et al., 2006).  
 
No vaccines are available to protect animals against CvHV-1, CvHV-2, ElkHV-1 or BuHV-1 
infections. The main reasons are the low virulence of these viruses and the lack of interest by the 
industry in these animal species, which are seemingly of minor importance. Currently, no data 
indicate whether BoHV-1 vaccine is able to protect ruminants infected by their own herpesviruses. 
However, the close antigenic relationship between these viruses may suggest a cross-protection, 
but this must, however, be evidenced in challenge experiments. 
 
In the absence of commercialised vaccines, the control of these infections relies on 
hygienic prophylactic measures: isolation of infected animals and disinfection of farms. Serological 
diagnosis by a fast and inexpensive method, such as ELISA, is essential to control herds and to 
give and maintain virus-free status. The removal of seropositive animals considered to be latent 
carriers, can lead to the forming of seronegative herds, which are likely to be free of virus 
infection. Such control measures are especially important in deer farming, which is becoming 
widespread in many countries.  
 
In free-ranging ruminants, control of alphaherpesvirus infection seems extremely difficult 
Ruminant alphaherpesviruses related to BoHV-1 
 - 17 - 
to achieve. The only possibility of doing this relies upon the prevention of extensive contact 
between animals in order to reduce virus spread. 
 
 
Conclusion 
 
BoHV-1 is antigenically and genetically related to several ruminant alphaherpesviruses. 
The existence of antigenic cross-reactions between these viruses and their ability to cross, at least 
in some instances, the species barrier raise theoretical problems for differential diagnosis. 
Therefore, it is advisable carefully to evaluate the existence of any other alphaherpesvirus 
reservoir, both in regions and countries where BoHV-1 infection has been eradicated and in those 
where the control of IBR is currently or will be undertaken. There must be a requirement to verify 
that BoHV-1 seropositive ruminants are not infected with BoHV-1 but are infected with their own 
specific virus. In order to avoid such misdiagnosis, new diagnostic tools are currently being 
developed. PCR and immunofluorescence tests, using monoclonal antibodies, allow unambiguous 
discrimination of each ruminant alphaherpesvirus related to BoHV-1. These advances in diagnostic 
methods must be completed by a better knowledge of the pathogenesis of ruminant 
alphaherpesvirus infections. The successful control of IBR depends on the parallel surveillance of 
putative reservoirs of BoHV-1. 
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Ruminant alphaherpesviruses related to bovine herpesvirus 1 (BoHV-1) are a cluster of 
viruses antigenically and genetically closely related (Thiry et al., 2006b). The prototype of this 
cluster, BoHV-1, is a major pathogen of cattle associated with various clinical manifestations 
including infectious bovine rhinotracheitis (IBR) and infectious pustular vulvovaginitis (IPV) 
(Muylkens et al., 2007). IBR is a disease of major economic concern in many parts of the world and 
especially in Europe, both in countries where this infection has been eradicated and in those where 
the control of IBR is currently or will be undertaken (Thiry et al., 1999). The massive use of 
vaccination allowed a significant reduction of the number of IBR clinical cases. However, the 
existence of closely related viruses to BoHV-1 is a threat for IBR eradication programmes. 
Consequently, the main objective of the present work is dedicated to afford a better knowledge of 
the interaction between alphaherpesviruses and their ruminant hosts in order to contribute to 
improve the control of IBR. 
 
To meet the objective, two approaches have been developed: the study of the viral 
diversity aiming to extend both epidemiological and virological data about ruminant 
alphaherpesviruses related to BoHV-1 and the study of the heterologous protection aiming to 
protect minor ruminant species by the concept of the “cascade” vaccination. 
 
Illustrating the problematic of the cluster of ruminant alphaherpesviruses related to 
BoHV-1, an original situation has been described recently in Belgium. During 2001 and 2002 
hunting seasons, 28.9% of red deer were detected seropositive to BoHV-1 (Grégoire and Linden, 
unpublished data). Due to an apparent lack of contact between cattle and red deer, it was 
suggested that a BoHV-1 related virus was spreading in the Belgian red deer population. Thus, the 
first isolation of cervid herpesvirus 1 (CvHV-1) in wild fauna is reported, which brings the 
opportunity to deeper analyse the antigenic, genomic and genetic relationship between BoHV-1 and 
its related ruminant alphaherpesviruses. 
 
This isolation demonstrates that a ruminant can be strongly identified as BoHV-1 positive 
while in actual fact it is infected with a related but distinct alphaherpesvirus and this ruminant will 
be declared as false positive. The problem is even greater when these viruses become latent 
allowing their possible reactivation and persistence for a very long time in their ecological niches 
(Thiry et al., 2006b). It is necessary to have tests which can differentiate related 
alphaherpesviruses that infect different ruminant species. The control of IBR relies on the use of 
BoHV-1 gB and gE blocking enzyme linked immunosorbent assays (ELISA) in order to differentiate 
infected and gE-negative vaccinated animals (European Food Safety Authority, 2005). Knowing 
that CpHV-1 is the most distant virus from BoHV-1, it can be hypothesised that a BoHV-1 gB 
blocking ELISA detects CpHV-1 but that CpHV-1 infection could be discriminated by a BoHV-1 gE 
blocking ELISA. CpHV-1 being mainly distributed in the Mediterranean part of Europe as Greece, 
Spain and Italy, the analysis was performed with field serums collected in France with the aim to 
update the epidemiological situation of the infection in Europe.     
 
Besides BoHV-1, CpHV-1 is the most relevant infection in Europe but is sadly neglected. 
The first reason is that economic losses are restricted to a herd level in contrast with IBR that 
brings an economical impact at a country level. The second reason is that goat is considered as a 
minor species. In this context, the problem is still not big enough for commercial interest towards 
vaccine development. The European Union has recently pointed out the problem of minor uses and 
minor species and allowed off label use of veterinary medicinal products or the use of a product 
licensed for a major species when an authorised veterinary medicinal product is not available 
(“cascade” principle). Goat being a minor species and CpHV-1 sharing close antigenic and genetic 
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properties with BoHV-1, a live attenuated gE-negative BoHV-1 vaccine has been assessed in goats 
to protect against either a nasal or a genital CpHV-1 infection. 
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The subfamily of alphaherpesviruses includes a cluster of viruses 
antigenically and genetically closely related to bovine herpesvirus 1 (BoHV-
1): namely bovine herpesvirus 5 (BoHV-5), bubaline herpesvirus 1 (BuHV-
1), caprine herpesvirus 1 (CpHV-1), cervid herpesviruses 1 (CvHV-1) and 2 
(CvHV-2) and elk herpesvirus 1 (ElkHV-1). Taking into account the 
serological relationship between these ruminant alphaherpesviruses, 
several serological surveys demonstrated BoHV-1 related virus infection in 
ruminant species by using BoHV-1 serological tools. In this way, a recent 
investigation indicated a high increase of the prevalence in the free-ranging 
red deer population in Belgium. The current study reports the isolation of a 
virus closely related to BoHV-1 in a free-ranging red deer. The isolate was 
antigenically, genomically and genetically characterised by comparison with 
each BoHV-1 related ruminant alphaherpesvirus. Immunofluorescence 
assays revealed the isolate was antigenically distinct from bovine and 
caprine alphaherpesviruses. BamHI and BstEII restriction analyses 
demonstrated the genomic difference between the isolate and the other 
BoHV-1 related ruminant alphaherpesviruses. The sequencing of selected 
parts of UL27 and US8 genes showed a high degree of homologies between 
each BoHV-1 related ruminant alphaherpesvirus and the isolate. Besides a 
close relationship between all ruminant alphaherpesviruses, the 
phylogenetic analysis revealed that the isolate clustered with CvHV-1. 
Taken together, the obtained data show that a strain of CvHV-1 circulates 
in wild red deer in continental Europe. 
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Introduction 
 
The family Herpesviridae includes nearly two hundred viruses isolated from various hosts 
including molluscs, fishes, amphibians, reptiles, birds, mammals and at least one invertebrate. 
Based on biological and molecular properties, the family has been divided into three subfamilies of 
viruses, Alpha-, Beta- and Gammaherpesvirinae, which have co-evolved with different host species. 
Illustrating the concept, several ruminant alphaherpesviruses form a cluster of antigenically and 
genetically related viruses (Thiry et al., 2006a) Seven alphaherpesviruses belong to this cluster 
where bovine herpesvirus 1 (BoHV-1), responsible for infectious bovine rhinotracheitis (IBR), a 
cattle disease of major economic concern in Europe, is the prototype (Muylkens et al., 2007): 
bovine herpesvirus 5 (BoHV-5) causing meningo-encephalitis in calves (Johnston et al., 1962), 
bubaline herpesvirus 1 (BuHV-1) responsible for subclinical infections in water buffaloes (St George 
and Philpott, 1972), caprine herpesvirus 1 (CpHV-1) inducing systemic disease in kids and abortion 
in adults (Saito et al., 1974), cervid herpesvirus 1 (CvHV-1) responsible for conjunctivitis in red 
deer (Inglis et al., 1983), cervid herpesvirus 2 (CvHV-2) and elk herpesvirus 1 (ElkHV-1) causing 
subclinical genital infections in reindeer and elk respectively (Deregt et al., 2000; Ek-Kommonen et 
al., 1982). Phylogenetic studies of conserved herpesvirus sequences showed that BoHV-5 and 
BuHV-1 were most closely related to BoHV-1, followed by ElkHV-1, CvHV-1, CvHV-2 and CpHV-1 
(Deregt et al., 2000; 2005b; Ros and Belák, 1999). However, BoHV-1 related ruminant 
alphaherpesvirus are not always restricted to their natural host species. Indeed, buffalo, goat, 
sheep, red deer and reindeer were successfully infected with BoHV-1 under experimental 
conditions. Similarly, cattle were shown to be susceptible to BuHV-1, CpHV-1, CvHV-1, CvHV-2 and 
ElkHV-1 (Thiry et al., 2006a). The cross-serological relationship between these viruses and BoHV-1 
was also demonstrated by seroneutralisation and enzyme linked immunosorbent assays (ELISA) 
(Wellenberg et al., 2001; Lyaku et al., 1992; Martin et al., 1990; Nixon et al., 1988). 
Consequently, the properties shared by BoHV-1 related alphaherpesviruses can lead to 
misdiagnosis of BoHV-1 infection which can be considered as a threat to infectious bovine 
rhinotracheitis eradication programmes (Thiry et al., 2006a).  
 
CvHV-1 was firstly isolated in 1983 from a farmed red deer suffering of ocular lesions. 
The disease, showing a contagious character, emerged at the end of 1982 in a red deer stag in 
northern Scotland. Fifty to sixty animals out of 80 exhibited clinical signs at various degrees. A 
seroneutralisation assay demonstrated the serological relationship of the virus with BoHV-1 (Inglis 
et al., 1983). Since this isolation, no epidemic of the ocular disease in red deer stags and no severe 
epidemic in free-ranging animals have been reported. More recently, CvHV-1 was identified in New-
Zealand during routine export examination of semen collected from red deer stags (Tisdall and 
Rowe, 2001). CvHV-1 is responsible for the herpetic conjunctivitis of red deer commonly named 
ocular syndrome. The disease is characterised by purulent ocular discharge, hypopyon, uniform 
corneal opacity without ulceration, mucopurulent nasal discharge and photophobia. Moderate 
swelling of the periorbital tissues and marked oedema of the upper eyelids are also observed 
(Inglis et al., 1983). The reactivation of CvHV-1 was successfully performed suggesting the 
persistence of the infection in a latent state (Ronsholt et al., 1987).        
 
Since it was demonstrated that red deer is infected by a herpesvirus, several studies have 
been initiated to evaluate the percentage of animals seropositive to BoHV-1 and CvHV-1 (Nettleton 
et al., 1988a; 1988b). The first serological survey revealed that CvHV-1 infection was widespread 
in Scotland with prevalences of 40% in hill deer and 33% in farmed deer (Nettleton et al., 1986). 
English farmed deer were also tested for CvHV-1 antibody and presented a prevalence of 14% 
(Nettleton et al., 1986). In Germany, 12.8% of red deer hunted between 1984 and 1986 were 
seropositive to BoHV-1 (Kokles et al., 1988) and the serological evidence of a CvHV-1 infection was 
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reported one year later (Liebermann et al., 1989). More recently, antibodies against BoHV-1 were 
found in 5.4% red deer from the German region Brandenburg (Muller et al., 1997). In Czech 
republic, 68% and 71% of red deer were seropositive to BoHV-1 and CvHV-1 respectively (Pospisil 
et al., 1996) and 0.5% of free-ranging red deer in Norway (Lillehaug et al., 2003). Outside of 
Europe, CvHV-1 infection was identified in New Zealand (Tisdall and Rowe, 2001; Motha and 
Jenner, 2001) and 55% of red deer living in United States National Parks were seropositive to 
BoHV-1 (Aguirre et al., 1995). However, these results only suggest a red deer CvHV-1 infection 
since the selected tests were not specific to CvHV-1 but to BoHV-1 (Thiry et al., 2006a ; Mollema 
et al., 2005). 
 
In Belgium, two serological investigations aiming to detect antibodies against BoHV-1 
were performed. The first one indicated that 11% of Belgian red deer were seropositive to BoHV-1 
or another related herpesvirus (Thiry et al., 1988). In 2001 and 2002, a higher prevalence was 
noticed with 28.9% of red deer positive to BoHV-1 (Grégoire and Linden, unpublished data). 
However, since experimental quantification of BoHV-1 transmission in red deer demonstrated that 
BoHV-1 would probably not survive more than a few decades in red deer populations (Mollema et 
al., 2005), it is most likely that BoHV-1 antibodies prevalence was due to CvHV-1 and not a BoHV-
1 cross-species infection. Regarding these data, it was decided to investigate the presence of an 
alphaherpesvirus spreading in the Belgian free-ranging red deer population. 
 
 
Materials and methods 
 
Cells and viruses 
 
The Madin-Darby bovine kidney (MDBK) cell line (ATCC CCL22) was maintained in Earle 
minimal essential medium (MEM) (Invitrogen, Merelbeke, Belgium) supplemented with 5% of heat-
inactivated foetal bovine serum (FBS) (BioWhittaker, Verviers, Belgium) and 2% penicillin (5,000 
Units/ml) streptomycin (5,000 µg/ml) (PS) (Invitrogen). The CvHV-1 virus Anlier strain and BoHV-1 
Lam 1.1 (Metzler et al., 1985), BoHV-1 K22 1.2a (Kendrick et al., 1958), BoHV-5 N569 (French, 
1962), BuHV-1 b6 (St George and Philpott, 1972), CpHV-1 Ba-1 (Buonavoglia et al., 1996), CvHV-
1 Banffshire 82 (Inglis et al., 1983), CvHV-2 Salla 82 (Ek-Kommonen et al., 1986), ElkHV-1 
(Deregt et al., 2000) virus strains were propagated on MDBK cells in MEM supplemented with 5% 
FBS. Viral stocks were produced by infection of confluent MDBK cells at a multiplicity of infection 
(MOI) of 0.1 in MEM supplemented with 2% PS and 5% FBS. When the cytopathic effect reached 
90%, culture medium was removed and clarified by centrifugation at 1,500 x g for 20 min. The 
supernatants were aliquoted, frozen at -80°C, and titrated by plaque assay on MDBK cells as 
previously described (Lemaire et al., 1999). 
 
Viral DNA extraction 
 
Viruses propagated on MDBK cells were clarified by centrifugation at 1,500 x g for 20 min. 
Supernatants were removed and further ultracentrifuged at 100,000 x g for 60 min. to pellet 
virions. Pellets were resuspended in TE buffer (10 mM TrisHCl pH 7.8, 1 mM EDTA) with 0.1% 
NP40, incubated 30 min at 37°C and ultracentrifuged 2 hours at 100,000 x g through a 30% (w/v) 
sucrose cushion. Pellets were resuspended in TE buffer with 0.5% sodium dodecylsulfate (SDS) and 
digested with proteinase K (700 µg/ml, Roche Diagnostic) for 2 h. at 56°C. Proteins were 
precipitated by the addition of half volume ammonium acetate (1.5 M, pH 7.5) and DNA was 
precipitated by addition of 2 volumes of ethanol. Viral DNA was extracted as previously described 
(Lemaire et al., 1999). 
Isolation and characterisation of a ruminant alphaherpesvirus in a free-ranging red deer 
 - 31 - 
Restriction enzyme analysis 
 
Viral DNA was submitted to BamHI and BstEII restriction endonucleases (New England 
Biolabs, England, United Kingdom). The digestion products were electrophoresed in a 0.7% Tris 
Acetate EDTA gel for 18 h at 40 V/cm and 500 mA. SmartLadder (10 kb; Eurogentec, Liège, 
Belgium) was used as molecular mass marker. 
 
Immunofluorescence staining 
 
An immunofluorescence assay was performed as described by Keuser and collaborators 
(2004) with minor modifications. Briefly, MDBK cells grown on glass coverslips were infected with 
the different viruses and incubated 48 h in MEM containing 5% FBS and 0.6% 
carboxymethylcellulose. The coverslips with individual plaques were fixed in PBS containing 2% 
(wt/vol) paraformaldehyde and incubated with undiluted hybridoma supernatant or 1,000-fold-
diluted ascitic fluid in PBS containing 5% FBS. As secondary antibodies, FITC-conjugated rabbit 
anti-mouse IgG (2 µg/ml; Dako) was used. Coverslips were mounted with a Prolong Antifade kit 
(Molecular Probes Europe BV, Leiden, The Netherlands). Pictures were captured with a charge-
coupled device Leica DC 300F camera (with Leica IM 50 V1.20 software) installed on an 
epifluorescence microscope. 
 
Sequencing and phylogenetic analysis 
 
Two different sets of primers were used in this study. The diagnostic PCR and the 
sequencing of a 443 bp region of glycoprotein B gene (UL27) was performed by applying the CR30 
(5'-TCGAARGCCGAGTACCTGCG-3'; sense; 5' end, position 56,051) and CR31 (5'-
CCAGTCCCAGGCRACCGTCAC-3'; antisense; 5' end, position 56,494) primer set (Ros and Belák, 
1999). To extend phylogenetic analyses between ruminant alphaherpesviruses and the viral isolate, 
another set of primers amplifying an estimated 624 bp region of glycoprotein E gene (US8) was 
designed: ALPHA/US8/914F (5’-CGARACSTGCATCTTYCACC-3’; sense; 5' end, position) and 
ALPHA/US8/1538R (5’-GGSTCGTTGSTYGGM-3’; antisense; 5' end, position). Fragments resulting 
from PCR were purified with QIAquick PCR Purification Kit (Quiagen, Venlo, The Netherlands) and 
cloned using the pGEM®-T Easy vector system (Promega, Leiden, The Nederlands). The sequencing 
was performed by the GIGA sequencing facility (GIGA, Liège, Belgium). Sequences were assembled 
and aligned by using the BioEdit Sequence Alignment Editor software (Hall, 1999). Phylogenetic 
analyses were performed, by distance methods, using the programs dnadist, neighbor and 
drawgram included in the PHYLIP package (Felsenstein, 1989). The reliability of the trees were 
assesed by resampling and analysing 1000 random data sets (bootstrapping) using Seqboot and 
consense software in the PHYLIP package. 
 
Nucleotide accession number 
 
The sequences reported in this paper have been deposited in the GenBank database 
under the accession numbers EF624466 to EF624479. The following previously GenBank published 
sequences were used in this study: BoHV-1 K22 UL27 [AF078725.1], BoHV-5 N569 UL27 
[AF078726.2], CvHV-1 Banffshire 82 UL27 [AF078729.2] and CvHV-2 Salla 82 UL27 [AF078727.2]. 
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Results 
 
Isolation and identification of a red deer alphaherpesvirus 
 
During the 2004 and 2005 hunting seasons, nasal and genital swabs were collected from 
free-living red deer in the South of Belgium. A viral isolate (050136) was obtained in MDBK cells 
inoculated with a nasal swab from a male fawn (Cervus elaphus) hunted in Anlier forest. The 
animal was in good shape and weighed 47 kg. The confirmation of the positive sample was 
performed by inoculation with the duplicate swab. The virus induced a cytopathic effect 
morphologically and temporally typical of a herpesvirus (Figure 1a). By PCR (Ros and Belák, 1999), 
a 443 bp region of glycoprotein B gene (UL27) was amplified (Figure 1b). Taken together, results 
suggested that the Anlier isolate belonged to the cluster of BoHV-1 related alphaherpesviruses. The 
analysis of the PCR product sequence showed that the Anlier isolate was close to BoHV-1 related 
ruminant alphaherpesviruses especially CvHV-1 (data not shown).  
 
               (a)                                                                       (b) 
 
 
 
 
 
 
 
 
 
Figure 1 – Isolation and identification of a red deer alphaherpesvirus. (a) Cytopathic effect of 
the Anlier isolate inoculated onto MDBK cells, overlaid with medium containing 0.6% carboxymethyl 
cellulose and photographed 72h later. (b) Molecular detection by PCR of the Anlier isolate DNA.  
 
Antigenic characterisation of the Anlier isolate within ruminant 
alphaherpesviruses 
 
In order to discriminate antigenically the Anlier isolate between bovine, caprine and cervid 
alphaherpesviruses, five selected monoclonal antibodies were tested by immunofluorescence assay 
on cells infected separately with the five related alphaherpesviruses: G14G11F5 for BoHV-1, 2915 
for BoHV-5, 2E5G5G1 for CpHV-1, 6C2 for CvHV-1 and 5G10 for CvHV-2. Monoclonal antibodies 
detected their specific viruses as demonstrated by Keuser and collaborators (2004), however, none 
of them reacted with the Anlier isolate. One can speculate that since CvHV-1 was also isolated from 
a red deer, CvHV-1 and the Anlier isolate might cross-react serologically. Therefore, other 
monoclonal antibodies were assessed to detect specifically the Anlier isolate. One monoclonal 
antibody, 6C3, identified the Anlier isolate. However, a weak reaction was also observed on CvHV-1 
or CvHV-2 infected cells (Figure 2).  
 
 
 
 
 
 
 
 
Figure 2 – Indirect immunofluorescence staining of MDBK cells infected with either BoHV-1, 
BoHV-5, CpHV-1, CvHV-1, CvHV-2, or the Anlier isolate. Cells were incubated until viral plaques 
were visible and were then treated as described in Materials and Methods. 6C3 is the primary antibody. 
Stainings were performed three times. Symbols: +, positive signal; -, negative signal; +/-, weak signal. 
BoHV-1 BoHV-5 CpHV-1 CvHV-1 CvHV-2 Isolate
- - - +/- +/- +
6C3
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Taken together, these results demonstrated that the Anlier isolate was antigenically 
distinct from BoHV-1, BoHV-5 and CpHV-1, but presumably possesses some common epitopes with 
CvHV-1 and CvHV-2. 
 
Genomic characterisation of a red deer alphaherpesvirus by comparison with 
ruminant alphaherpesviruses 
 
To avoid any misinterpretation due to antigenic cross reactions, Anlier isolate and 
ruminant alphaherpesviruses were submitted to restriction enzyme analysis by using two 
endonucleases, BamHI (Figure 3a) and BstEII (Figure 3b). The patterns were in accordance with 
the previously published patterns (Engels et al., 1987; Rimstad et al., 1992; Vanderplasschen et 
al., 1993) and clearly allowed a differentiation between each ruminant alphaherpesvirus as well as 
between BoHV-1 subtypes 1 and 2 (Figure 3). These data confirmed that the Anlier isolate was 
genomically distinct from the other related ruminant alphaherpesviruses. 
 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – BamHI (a) and BstEII (b) restriction endonuclease profiles of the Anlier isolate and 
ruminant alphaherpesviruses. 
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Phylogenetic relationship between a red deer alphaherpesvirus and ruminant 
alphaherpesviruses 
  
To further characterise the Anlier isolate, different regions of the genome were sequenced 
(Figure 4). Partial sequence data from UL27 encoding the glycoprotein B (gB) and US8 encoding 
the glycoprotein E (gE) were obtained for eight ruminant alphaherpesviruses including the two 
BoHV-1 subtypes and the Anlier isolate. These sequences represented two different degrees of 
conservation among ruminant alphaherpesviruses genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – PCR amplifications of selected parts of UL27 and US8 sequences of the Anlier 
isolate and ruminant alphaherpesviruses. 
  
The sequence lengths were 444 nucleotides for UL27 and varied between 597 and 609 
nucleotides for US8. By analysing multiple nucleotide sequences alignments in the US8 sequence, 
CvHV-1 and CvHV-2 differed from each other by 96 out of 609 bases, CvHV-1 and ElkHV-1 by 15 
out of 609 bases, ElkHV-1 and the Anlier isolate by 22 out of 609 bases, CvHV-2 and the Anlier 
isolate by 99 out of 609 bases, and CvHV-1 and the Anlier isolate by 16 out of 609 bases (data no 
shown).  
 
Tables 1 and 2 compare the percentage of nucleotide and amino acid sequence identity 
between each ruminant alphaherpesvirus.  
 
Phylogenetic analyses were also performed to assess the relationship between the Anlier 
isolate and other ruminant alphaherpesviruses (Figure 5). BoHV-5 and BuHV-1 clustered together 
and are the most closely related to BoHV-1 1.1 and BoHV-1 1.2. CpHV-1 is the most diverging 
ruminant alphaherpesvirus. CvHV-1 is more related to BoHV-1 than ElkHV-1 and CvHV-2 which is 
the most closely related to CpHV-1. The Anlier isolate clustered with CvHV-1 and the most closely 
related virus is ElkHV-1. The same topography was obtained for phylogenetic trees based on UL27 
(Figure 5a) and US8 nucleotide sequences (Figure 5b).  
 
Taken together, these data revealed high degrees of homology between each ruminant 
alphaherpesvirus, the highest being observed between CvHV-1 and the Anlier isolate 
demonstrating the identification of a new CvHV-1 strain. 
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Table 1 – UL27 nucleotide and amino acid sequence similarities between the Anlier isolate 
and ruminant alphaherpesviruses. 
  Nucleotide similarity 
 UL27 
BoHV-1 
Lam 
BoHV-1    
K22 
BoHV-5  
N569 
BuHV-1        
b6 
CpHV-1             
Ba-1 
CvHV-1 
Banf. 82 
CvHV-2 
Salla 82 
ElkHV-1 
CvHV-1 
Anlier 
SuHV-1 
Becker 
BoHV-1    
Lam  99 95.9 96.6 87.8 94.8 92.3 94.5 94.8 75.4 
BoHV-1    
K22 100  95.7 96.1 87.8 94.5 92.1 94.5 94.5 75.2 
BoHV-5  
N569 97.9 97.9  98.6 88.5 96.3 93.6 95.9 96.1 76.3 
BuHV-1             
b6 97.2 97.2 99.3  88.9 96.8 93.6 96.6 96.8 76.5 
CpHV-1           
Ba-1 88.5 88.5 88.5 87.8  88 88.7 88.2 87.8 75.6 
CvHV-1 
Banf. 82 94.5 94.5 95.2 95.9 87.8  95 99.3 99.3 76.5 
CvHV-2          
Salla 82 91.8 91.8 91.8 91.8 88.5 94.5  95.2 94.3 77.7 
ElkHV-1 94.5 94.5 94.5 94.5 88.5 98.6 95.9  98.8 75.9 
Isolate 94.5 94.5 95.2 95.2 86.4 98.6 93.2 97.2  75.9 
A
m
in
o
 a
c
id
 s
im
il
a
ri
ty
 
SuHV-1 
Becker 70.9 70.9 70.2 70.2 71.6 69.5 70.2 68.9 68.2  
 
 
Table 2 – US8 nucleotide and amino acid sequence similarities between the Anlier isolate 
and ruminant alphaherpesviruses. 
  Nucleotide similarity 
 US8 
BoHV-1 
Lam 
BoHV-1    
K22 
BoHV-5  
N569 
BuHV-1        
b6 
CpHV-1             
Ba-1 
CvHV-1 
Banf. 82 
CvHV-2 
Salla 82 
ElkHV-1 
CvHV-1 
Anlier 
SuHV-1 
Becker 
BoHV-1    
Lam  99.4 85.3 86.5 76.2 83.4 76.5 83.7 83.1 50.2 
BoHV-1    
K22 99  85 86.6 76.3 83.6 76.5 83.9 83.2 50 
BoHV-5  
N569 76.4 75.9  96.5 74.8 87.3 80.6  88.3 87 53.9 
BuHV-1             
b6 78.8 79.8 92.7  76.8 89 80.9 90 88.8 54 
CpHV-1           
Ba-1 59.7 60.1 59.3 61.2  77.8 76.3 78.6 77.8 50.2 
CvHV-1 
Banf. 82 69.8 70.8 76.4 79.8 60.2  82.6 97.5 97.3 53.2 
CvHV-2          
Salla 82 64.5 65 67.3 69.8 60.2 70.3  82.7 82.4 52.9 
ElkHV-1 69.8 70.8 77.8 81.2 61.2 94.2 70.8  96.2 53.9 
Isolate 70.3 71.2 76.4 80.2 57.8 95.1 69.8 92.3  52.4 
A
m
in
o
 a
c
id
 s
im
il
a
ri
ty
 
SuHV-1 
Becker 25 25 30.4 30.7 25.8 28.7 25.3 29.1 27.2  
 
 
Discussion 
 
The use of a consensus PCR detecting bovine, caprine, red deer and reindeer 
alphaherpesviruses (Ros and Belák, 1999) has allowed the detection and the identification of the 
CvHV-1 Anlier strain and its phylogenic position in the BoHV-1 related alphaherpesvirus cluster. No 
cross-reaction was observed when monoclonal antibodies specific of ruminant alphaherpesviruses 
were applied to cells infected with the Anlier strain. In contrast, the monoclonal antibody 6C3, 
described as being specific to CvHV-1 (Keuser et al., 2004), surprisingly detected more specifically 
the Anlier strain than CvHV-1. The weak reactivity observed with CvHV-2 could result from 
epitopes common with the Anlier strain. To further characterise the Anlier strain in comparison with 
ruminant alphaherpesviruses, restriction enzyme analysis were performed. Similarities in the 
BamHI and BstEII restriction patterns further support that the Anlier isolate is a new strain of 
CvHV-1.  
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Figure 5 – Phylogenetic relationships between the Anlier isolate and ruminant 
alphaherpesviruses. Trees were generated by using selected parts of UL27 (a) or US8 (b) nucleotide 
sequences, and were both rooted by using Suid herpesvirus 1 (SuHV-1) Becker strain gB sequence as an 
outgroup. The reliability of trees were assesed by resampling and analysing 1000 random data sets 
(bootstrapping) showed at branches. 
 
When analysing nucleotide and amino acid sequences similarities, the difference in the 
degree of conservation between UL27 and US8 sequences is demonstrated among BoHV-1 related 
ruminant alphaherpesviruses, confirming BoHV-5 previously obtained data (Delhon et al., 2003). 
Such difference in the level of conservation between UL27 and US8 sequences could influence the 
diagnosis of ruminant alphaherpesvirus infections by both BoHV-1 gB and gE blocking ELISAs. 
Indeed, experimentally BoHV-5 infected calves were shown to be positive in BoHV-1 gB blocking 
ELISA and negative in BoHV-1 gE blocking ELISA allowing the discrimination between BoHV-1 and 
BoHV-5 (Wellenberg et al., 2001). As the highest US8 sequences similarity is observed between 
BoHV-1 and BoHV-5, it can be hypothesised such methodology serologically discriminate between 
other heterologous infections, e.g. between BoHV-1 and CpHV-1 infection of goats (Thiry et al., 
2006b) or between BoHV-1 and CvHV-1 infection in red deer (Mollema et al., 2005). 
      
Phylogenetic analysis showed that the most closely related viruses to BoHV-1 1.1 and 
BoHV-1 1.2 are BoHV-5 and BuHV-1 followed by CvHV-1 and ElkHV-1 clustering together and 
further by CvHV-2 and CpHV-1. These results extend the knowledge on the genetic relatedness of 
BoHV-1 related ruminant alphaherpesviruses to BuHV-1 and ElkHV-1 (Deregt et al., 2005a; 2005b; 
Ros and Belák, 1999; De Carlo et al., 2004; Ros and Belák, 2002). Each ruminant alphaherpesvirus 
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is closely related to each other both for UL27 and US8 sequences similarities confirming the 
presence of a consistent group of ruminant alphaherpesviruses in the family Herpesviridae. 
Additionally, primers designed to partially amplify US8 bring a new tool in the detection of 
ruminant alphaherpesvirus infection. Furthermore, they could be used to differentiate wild type 
BoHV-1 from vaccinal gE-negative BoHV-1 (Schynts et al., 1999). 
  
Genetic analysis of the Anlier strain reveals clear differences with CvHV-1 reference strain 
(16 out of 609 bases for US8 and 3 out of 444 bases for UL27). However, nothing is known about 
the potential strain pathogenicity. Moreover, deeper investigations are necessary to assess if this 
red deer alphaherpesvirus is a new viral subtype. Experimental infection of red deer with CvHV-1 
lead to mild clinical signs, such as hyperthermia, nasal ulceration and conjunctivitis, and virus was 
reisolated from nasal and ocular swabs (Ronsholt et al., 1987; Reid et al., 1986). Natural infection 
of farmed red deer induced an ocular syndrome associated with various clinical manifestations 
(Inglis et al., 1983). Here, the Anlier strain was isolated from a nasal swab and the animal did not 
present any lesions. Moreover, no case of suspicious red deer death was noticed during 2004 and 
2005 hunting seasons although a high seroprevalence was observed (Grégoire and Linden, 
unpublished data). Based on these data, it can be postulated that Anlier strain as several other 
herpesviruses could induce subclinical respiratory infection. However, it can be also hypothesised 
that as other herpesviruses too, it may predispose the respiratory tract for secondary bacterial 
infections or has the capacity by itself to initiate other disease forms (Muylkens et al., 2007). In 
order to answer these questions, Anlier strain pathogenicity should be investigated by red deer 
experimental inoculation. 
  
Belgian CvHV-1 emergence might be explained by red deer translocation in Europe. The 
biogeographic history of European red deer is under human influence (Hartl et al., 2003; 
Niethammer et al., 1963). During the last one thousand years, there was an extensive trade of the 
species mainly with the aim to improve the hunted trophy quality (Hartl et al., 2003; Lowe and 
Gardiner, 1974). The existence of illegal translocation of animals by hunters was recently 
evidenced in Luxemburg. By using a multilocus genotyping, a red deer group was excluded from 
the autochthonous population (Frantz et al., 2006) suggesting the presence imported red deer 
from foreign countries. In the Walloon Region of Belgium, reintroduction of imported animals in 
wildlife is unclear due to a lack of documentation. An extinction of the species occurred in 1848 and 
red deer were most likely imported from eastern European countries. In this regard, genetic 
analysis showed that Scottish CvHV-1 Banffshire 82 strain is different from Belgian Anlier strain. 
Consequently, viral transmission to a Belgian red deer from a reintroduced Scottish farmed red 
deer can not be currently supported in absence of molecular epidemiology of the two strains.  
  
In contrast, the hypothesis of an endemic infection occurring in continental Europe has to 
be considered. A genetic cluster of red deer is distributed from Belgium, across Luxemburg, to 
Germany (Frantz et al., 2006). Similarly, the presence of genetic units over larger area has also 
been proven for the Engadin Valley population in eastern Switzerland (Kuehn et al., 2004) and in 
the Carpathian mountains in Romania (Feulner et al., 2004). It can be hypothesised that animals 
infected with Anlier strain belong to red deer genetic clusters described in the Czech Republic, 
Germany, and Hungary and spread the infection. This hypothesis is supported by the high BoHV-1 
seroprevalence observed in red deer in these countries (Kokles et al., 1988; Liebermann et al., 
1989; Muller et al., 1997; Pospisil et al., 1996). In Scotland, the wild red deer herds have produced 
the initial stocks for many deer farms (Hamilton, 1994) where the Scottish CvHV-1 Banffshire 82 
strain was isolated (Inglis et al., 1983). This strain was probably already established in the wild 
deer population in Great Britain. As most British populations are non-indigenous (Hartl et al., 2003; 
Niethammer et al., 1963), the virus could have been introduced a long time ago in the red deer 
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population in Great Britain from continental Europe and could have diverged from the original 
virus. The virus could have persisted in small populations because of latency (Ronsholt et al., 
1987) and the industrial deer farming facilitated the identification of the virus. However, additional 
experiments are requested to investigate if the Belgian Anlier strain could be the ancestor of the 
Scottish Banffshire 82 strain. 
 
 
Conclusions 
 
According to our knowledge, this is the first report on the isolation of a ruminant 
alphaherpesvirus from free-ranging red deer. The antigenic, genomic and genetic analysis 
demonstrated that the detected virus, termed CvHV-1 Anlier strain, is closely related to, but 
different from the CvHV-1 Banffshire 82 strain. This isolation and our knowledge of red deer 
population evolution in Europe allow the formulation of an interesting hypothesis on the origin of 
this virus in red deer knowing CvHV-1 Banffshire 82 strain had been isolated in farmed red deer in 
Scotland. Furthermore, our investigation brings the first comparative diagnosis of all known 
ruminant alphaherpesviruses related to BoHV-1 and especially a genetic definition of these viruses. 
 
 
Acknowledgements 
 
The authors wish to thank Bénédicte Mousset and Lorène Dams for their excellent 
technical assistance and Dr. D. Deregt for kindly providing ElkHV-1 strain. The authors are grateful 
to Dr. F. Meurens for the reading of the manuscript. This work was supported by the Walloon 
Region of Belgium. 
 
 
References 
 
Aguirre A.A., Hansen D.E., Starkey E.E., McLean R.G., Serologic survey of wild cervids for potential disease 
agents in selected national parks in the United States, Prev. Vet. Med. 21 (2005) 313–322. 
 
Buonavoglia C., Tempesta M., Cavalli A., Voigt V., Buonavoglia D., Conserva A., Corrente M., Reactivation of 
caprine herpesvirus 1 in latently infected goats, Comp. Immunol. Microbiol. Infect. Dis. 19 (1996) 275-281. 
 
De Carlo E., Re G.N., Letteriello R., Del Vecchio V., Giordanelli M.P., Magnino S., Fabbi M., Bazzocchi C., Bandi 
C., Galiero G., Molecular characterisation of a field strain of bubaline herpesvirus isolated from buffaloes 
(Bubalus bubalis) after pharmacological reactivation, Vet. Rec. 154 (2004) 171-174. 
 
Delhon G., Moraes M.P., Lu Z., Afonso C.L., Flores E.F., Weiblen R., Kutish G.F., Rock D.L., Genome of bovine 
herpesvirus 5, J. Virol. 77 (2003) 10339-10347. 
 
Deregt D., Jordan L.T., van Drunen Littel-van den Hurk S., Masri S.A., Tessaro S.V., Gilbert S.A., Antigenic and 
molecular characterization of a herpesvirus isolated from a North American elk, Am. J. Vet. Res. 61 (2000) 
1614-1618. 
 
Deregt D., Tessaro S.V., Gilbert S.A., Serological evidence of latency in cattle experimentally infected with elk 
herpesvirus, Vet. Rec. 156 (2005a) 610-611.  
 
Deregt D., Gilbert S.A., Campbell I., Burton K.M., Reid H.W., Hurk S.V., Penniket C., Baxi M.K., Phylogeny and 
antigenic relationships of three cervid herpesviruses, Virus Res. 114 (2005b) 140-148. 
 
Ek-Kommonen C., Veijalainen P., Rantala M., Neuvonen E., Neutralizing antibodies to bovine herpesvirus 1 in 
reindeer, Acta Vet. Scand. 23 (1982) 565-569. 
 
Ek-Kommonen C., Pelkonen S., Nettleton P.F., Isolation of a herpesvirus serologically related to bovine 
herpesvirus 1 from a reindeer (Rangifer tarandus), Acta Vet. Scand. 27 (1986) 299-301. 
 
Isolation and characterisation of a ruminant alphaherpesvirus in a free-ranging red deer 
 - 39 - 
Engels M., Loepfe E., Wild P., Schraner E., Wyler R., The genome of caprine herpesvirus 1: genome structure 
and relatedness to bovine herpesvirus 1, J. Gen. Virol. 68 (1987) 2019-2023. 
 
Felsenstein J., PHYLIP--Phylogeny Inference Package, (Version 3.2), Cladistics 5 (1989) 164-166. 
 
Feulner P.G., Bielfeldt W., Zachos F.E., Bradvarovic J., Eckert I., Hartl G.B., Mitochondrial DNA and 
microsatellite analyses of the genetic status of the presumed subspecies Cervus elaphus montanus (Carpathian 
red deer), Heredity 93 (2004) 299-306. 
 
Frantz A.C., Pourtois J.T., Heuertz M., Schley L., Flamand M.C., Krier A., Bertouille S., Chaumont F., Burke T., 
Genetic structure and assignment tests demonstrate illegal translocation of red deer (Cervus elaphus) into a 
continuous population, Mol. Ecol. 15 (2006) 3191-3203. 
 
French E.L., A specific virus encephalitis in calves: isolation and characterization of the causal agent, Aust. Vet. 
J. 38 (1962) 216-221. 
 
Hall T.A., BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 
95/98/NT, Nucl. Acids Symp. Ser. 41 (1999) 95-98. 
 
Hamilton W.J., The industry, in: Alexander T.L., Buxton D. (Ed.), Management and diseases of deer, The 
Veterinary Deer Society, London, 1994, pp. 7-13. 
 
Hartl G.B., Zachos F., Nadlinger K., Genetic diversity in European red deer (Cervus elaphus L.); anthropogenic 
influences on natural populations, C. R. Biologies 326 (2003) S37-S42. 
 
Inglis D.M., Bowie J.M., Allan M.J., Nettleton P.F., Ocular disease in red deer calves associated with a 
herpesvirus infection, Vet. Rec. 113 (1983) 182-183. 
 
Johnston L., Simmons G., McGavin M., A viral meningo-encephalitis in calves, Aust. Vet. J. 38 (1962) 207-215. 
 
Kendrick J.W., Gillespie J.H., Mc Entee K., Infectious pustular vulvovaginitis of cattle, Cornell Vet. 48 (1958) 
458-495. 
 
Keuser V., Schynts F., Detry B., Collard A., Robert B., Vanderplasschen A., Pastoret P.-P., Thiry E., Improved 
antigenic methods for differential diagnosis of bovine, caprine, and cervine alphaherpesviruses related to bovine 
herpesvirus 1, J. Clin. Microbiol. 42 (2004) 1228-1235. 
 
Kokles R., Dedek J., Loepelmann H., Serologische Untersuchungen auf Infektionen mit dem Virus der 
infektiösen bovinen Rhinotracheitis/infektiöse Vulvovaginitis und dem Parainfluenza-3-virus bei Rot-, Reh-, 
Dam- und Muffelwild, Monatsh. Veterinärmed. 43 (1988) 60-63. 
 
Kuehn R., Haller H., Schroeder W., Rottmann O., Genetic roots of the red deer (Cervus elaphus) population in 
Eastern Switzerland, J. Hered. 95 (2004) 136-143. 
 
Lemaire M., Schynts F., Meyer G., Thiry E., Antibody response to glycoprotein E after bovine herpesvirus type 1 
infection in passively immunised, glycoprotein E-negative calves, Vet. Rec. 144 (1999) 172-176. 
 
Liebermann H.D., Tabbaa J., Dedek H., Loepelmann H., Stubbe J., Selbitz H.J., Serologische Untersuchungen 
auf ausgewählte Virusinfektionen bei Wildwiederkäuern in der DDR, Monatsh. Veterinärmed. 44 (1989) 380-
382. 
 
Lillehaug A., Vikoren T., Larsen I.L., Akerstedt J., Tharaldsen J., Handeland K., Antibodies to ruminant alpha-
herpesviruses and pestiviruses in Norwegian cervids, J. Wildl. Dis. 39 (2003) 779-786. 
 
Lowe V.P.M., Gardiner A.S., A re-examination of the sub-species of Red deer (Cervus elaphus) with particular 
reference to the stocks in Britain, J. Zool. Lond. 174 (1974) 185-201. 
 
Lyaku J.R., Nettleton P.F., Mardsen H., A comparison of serological relationships among five ruminant 
alphaherpesviruses by ELISA, Arch. Virol. 124 (1992) 333-341. 
 
Martin W.B., Castrucci G., Frigeri F., Ferrari M., A serological comparison of some animal herpesviruses, Comp. 
Immunol. Microbiol. Infect. Dis. 13 (1990) 75-84. 
 
Metzler A.E., Schudel A.A., Engels M., Bovine herpesvirus 1: molecular and antigenic characteristics of variant 
viruses isolated from calves with neurological disease, Arch. Virol. 87 (1986) 205-217. 
 
Mollema L., Rijsewijk F.A.M., Nodelijk G., de Jong M.C.M., Quantification of the transmission of bovine 
herpesvirus 1 among red deer (Cervus elaphus) under experimental conditions, Vet. Microbiol. 111 (2005) 25-
34. 
 
Isolation and characterisation of a ruminant alphaherpesvirus in a free-ranging red deer 
 - 40 - 
Motha J., Jenner J., Serological relatedness of cervine herpesvirus-1 and bovine herpesvirus-1 and the 
prevalence of cervine herpesvirus-1 infection in farmed deer in New Zealand, New Z. Vet. J. 49 (2001) 162-
163. 
 
Muller T., Kramer M., Beier D., Untersuchungen zum Vorkommen von Antikorpern gegen ausgewahlte bovine 
und ovide Viruserkrankungen bei Reh-(Capreolus capreolus), Rot- (Cervus elaphus), Dam-(Dama dama) und 
Muffelwild (Ovis musimon) im Bundesland Brandenburg, Zeitschrift fur Jagdwissenschaft 43 (1997) 166-175. 
 
Muylkens B., Thiry J., Kirten P., Schynts F., Thiry E., Bovine herpesvirus 1 infection and infectious bovine 
rhinotracheitis, Vet. Res. 38 (2007) 181-209. 
 
Nettleton P.F., Sinclair J.A., Herring J.A., Inglis D.M., Fletcher T.J., Ross H.M., Bonniwell M.A., Prevalence of 
herpesvirus infection in British red deer and investigations of further disease outbreaks, Vet. Rec. 118 (1986) 
267-270. 
 
Nettleton P.F., Thiry E., Reid H.W., Pastoret P.-P., Herpesvirus infections in cervidae, Rev. Sci. Tech. Off. Int. 
Epiz. 7 (1988a) 977-988. 
 
Nettleton P.F., Ek-Kommonen C., Tanskanen R., Reid H.W., Sinclair J.A., Herring J.A., Studies in the 
epidemiology and pathogenesis of alphaherpesviruses from red deer (cervus elaphus) and reindeer (rangifer 
tarandus), The management and Health of Farmed deer (1988b) 143-147. 
 
Niethammer G., Die Einbürgerung von Säugetieren und Vögeln in Europa. Ergebnisse und Aussichten. Unter 
Mitarbeit von Niethammer J. und Szijj J., Paul Parey, 1963, Hamburg, Berlin. 
 
Nixon P., Edwards S., White H., Serological comparisons of antigenically related herpesviruses in cattle, red 
deer and goats, Vet. Res. Commun. 12 (1988) 355-362. 
 
Pospisil Z., Vyvlecka R., Cihal P., Lany P., Zendulkova D., Detection of herpesvirus serum antibodies in red deer 
(Cervus elaphus) imported into the Czech Republic, Vet. Med. 41 (1996) 279-282. 
 
Reid H.W., Nettleton P.F., Pow I., Sinclair J.A., Experimental infection of red deer (Cervus elaphus) and cattle 
with a herpesvirus isolated from red deer, Vet. Rec. 119 (1986) 156-158. 
 
Rimstad E., Krona R., Hyllseth B., Comparison of herpesviruses isolated from reindeer, goats, and cattle by 
restriction endonuclease analysis, Arch. Virol. 123 (1992) 389-397. 
 
Ronsholt L., Christensen L.S., Bitsch V., Latent herpesvirus infection in red deer: characterization of a specific 
deer herpesvirus including comparison of genomic restriction fragment patterns, Acta. Vet. Scand. 28 (1987) 
23-31. 
 
Ros C., Belak S., Studies of genetic relationships between bovine, caprine, cervine, and rangiferine 
alphaherpesviruses and improved molecular methods for virus detection and identification, J. Clin. Microbiol. 37 
(1999) 1247-1253. 
 
Ros C., Belak S., Characterization of the glycoprotein B gene from ruminant alphaherpesviruses, Virus Genes 24 
(2002) 99-105. 
 
Saito J.K., Gribble D.H., Berrios P.E., Knight H.D., Mc Kercher D.G., A new herpesvirus isolate from goats: 
Preliminary report, Am. J. Vet. Res. 35 (1974) 847-848. 
 
Schynts F., Baranowski E., Lemaire M., Thiry E., A specific PCR to differentiate between gE negative vaccine 
and wildtype bovine herpesvirus type 1 strains, Vet. Microbiol. 66 (1999) 187-195. 
 
St George T.D., Philpott M., Isolation of infectious bovine rhinotracheitis virus from the prepuce of water buffalo 
bulls in Australia, Aust. Vet. J. 48 (1972) 126. 
 
Thiry E., Vercouter M., Dubuisson J., Barrat J., Sepulchre C., Gerardy C., Meersschaert C., Collin B., Blancou J., 
Pastoret P.-P., Serological survey of herpesvirus infections in wild ruminants of France and Belgium, J. Wildl. 
Dis. 24 (1988) 268-273. 
 
Thiry J., Keuser  V., Muylkens B., Meurens F., Gogev S., Vanderplasschen A., Thiry E., Ruminant 
alphaherpesviruses related to bovine herpesvirus 1, Vet. Res. 37 (2006a) 169-190. 
 
Thiry J., Tempesta M., Camero M., Tarsitano E., Bellacicco A.L., Thiry E., Buonavoglia C., A live attenuated 
glycoprotein E negative bovine herpesvirus 1 vaccine induces a partial cross-protection against caprine 
herpesvirus 1 infection in goats, Vet. Microbiol. 113 (2006b) 303-308. 
 
Tisdall D.J., Rowe S.M., Isolation and characterisation of cervine herpesvirus-1 from red deer semen, New Z. 
Vet. J. 64 (2001) 111-114. 
 
Isolation and characterisation of a ruminant alphaherpesvirus in a free-ranging red deer 
 - 41 - 
Vanderplasschen A., Bublot M., Pastoret P.-P., Thiry E., Restriction maps of the DNA of cervid herpesvirus 1 and 
cervid herpesvirus 2, two viruses related to bovine herpesvirus 1, Arch. Virol. 128 (1993) 379-388. 
 
Wellenberg G.J., Mars M.H., van Oirschot J.T., Antibodies against bovine herpesvirus (BHV) 5 may be 
differentiated from antibodies against BHV1 in a BHV1 glycoprotein E blocking ELISA, Vet. Microbiol. 78 (2001) 
79-84. 
 
CHAPTER 
THREE 
Viral diversity 
  
 
 
 
 
 
 
 
 
 
 
 
 
Serological evidence of caprine herpesvirus 1 
infection in Mediterranean France 
 
  
Julien Thiry, Claude Saegerman, Christophe Chartier,                                    
Pascale Mercier, Véronique Keuser and Etienne Thiry 
 
Veterinary Microbiology (2007) doi:10.1016/j.vetmic.2007.10.009 
 
 
 
Caprine herpesvirus 1 (CpHV-1) is responsible of a systemic 
disease in kids and genital diseases inducing abortions in adult goats. In 
Europe, CpHV-1 is widespread in Mediterranean countries such as Greece, 
Italy and Spain. As France is geographically close to these countries, a 
survey was conducted to investigate the presence of CpHV-1 in goats in a 
Mediterranean department (Corse-du-Sud) and in continental departments 
(Dordogne and Vendée) of this country. Taking into account the close 
antigenic and genetic relationships between bovine herpesvirus 1 (BoHV-1) 
and CpHV-1, the serological detection was performed by using BoHV-1 
glycoproteins B (gB) and E (gE) blocking ELISAs. The analysis of 2,548 
serum samples in a BoHV-1 gB blocking ELISA revealed that a ruminant 
alphaherpesvirus infection related to BoHV-1 was widespread in Corse-du-
Sud whereas no positive animals was detected in Dordogne and Vendée. 
Furthermore, the specificity and the sensitivity of the BoHV-1 gB blocking 
ELISA to detect a BoHV-1 related infection in goats were evaluated. A 
subsequent analysis by a BoHV-1 gE blocking ELISA demonstrated that 
22.6% of gB-positive serum samples were also gE-positive. Cross-
seroneutralisation assays afforded the unambiguous identification of 
antibodies against CpHV-1 in gB-positive goats. The likely presence of 
CpHV-1 in Corse-du-Sud supported by a high seroprevalence (61.9%) in all 
investigated flocks extends the number of countries infected with CpHV-1. 
Moreover, the difference observed between Corse-du-Sud and Dordogne 
and Vendée suggests that CpHV-1 is more prevalent in Mediterranean 
countries or regions than in central and northern Europe. 
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Introduction 
 
Caprine herpesvirus 1 (CpHV-1) causes mainly a systemic infection in neonatal kids. 
Although most infections in adults are subclinical, CpHV-1 can provoke vulvovaginitis (Grewal and 
Wells, 1986), balanoposthitis (Tarigan et al., 1987), and abortion (Keuser et al., 2002). Although 
the economical impact of the infection has not been determined yet at the level of a country, it 
may be important in infected flocks because of abortions, returns to oestrus, and neonatal 
mortality (Thiry et al., 2007a). CpHV-1 was first isolated in 1975 in California from newborn kids 
showing enteritis (Saito et al., 1974). Five years later, it was recovered in the Bregaglia valley of 
Switzerland from kids affected with a similar disease (Mettler et al., 1979). The distribution of 
CpHV-1 infection has not been systematically studied in goats but has been worldwide identified 
(Thiry et al., 2007a) as in Europe (Buonavoglia et al., 1996; Keuser et al., 2004; Koptopoulos et 
al., 1988; Mettler et al., 1979; Muluneh and Liebermann, 1990), Australia (Grewal and Wells, 
1986), Canada (Chenier et al., 2004), New Zealand (Horner et al., 1982) and USA (Saito et al., 
1974). In many countries where goats play an economical role, a high prevalence is observed: 
more than 50% in Greece (Koptopoulos et al., 1988), between 30 and 60% in southern Italy 
(Guercio et al., 1998; Tempesta et al., 1994; Thiry et al., 2006c) and 21% in Spain (Keuser et al., 
2004; Thiry et al., 2006c). The CpHV-1 infection was identified neither in Belgium nor in France 
(Thiry et al., 2006c). Therefore, in Europe, although the first isolation was performed in 
Switzerland, CpHV-1 infection seems to be more prevalent in Mediterranean than in Northern 
European countries. 
 
On the basis of its antigenic and genetic properties, CpHV-1 belongs to a cluster of 
ruminant alphaherpesviruses closely related to bovine herpesvirus 1 (BoHV-1) (Thiry et al., 
2006a). BoHV-1 is responsible of diseases of major economic concern in many parts of the world 
and especially in Europe. The infection causes a variety of clinical diseases in cattle including 
infectious bovine rhinotracheitis (IBR) and infectious pustular vulvovaginitis (IPV) (Muylkens et al., 
2007). In order to detect and control IBR, specific molecular and serological diagnostic tests were 
developed. Currently, the serological diagnosis is based on the use of commercial BoHV-1 
glycoprotein B (gB) and glycoprotein E (gE) blocking enzyme-linked immunosorbent assays 
(ELISA) which are fast, inexpensive and simple methods for screening large numbers of test 
samples (Kramps et al., 2004). The existence of the consistent group of ruminant 
alphaherpesviruses closely related to BoHV-1 leads to a theoretical problem to distinguish 
serologically between these viruses (Thiry et al., 2006a). When they are analysed by ELISA or 
seroneutralisation, BoHV-1 and related ruminant alphaherpesviruses cross-react due to antigenic 
cross-relationships (Lyaku et al., 1992; Martin et al., 1990; Nixon et al., 1988). Thus, the use of a 
BoHV-1 gB blocking ELISA allows the identification of such a ruminant alphaherpesvirus infection 
but is not able to make a differentiation.  
 
The current study aims to investigate the epidemiological situation in France, a country 
which includes both Mediterranean and northern areas, in order to study if CpHV-1 prevalence is 
different in Mediterranean than in Northern Europe. Furthermore, the results of this survey were 
improved by the validation of the serological assay in order to detect a BoHV-1 related infection 
and especially a CpHV-1 infection in goats. The combination with a BoHV-1 gE blocking ELISA could 
lead to distinguish between CpHV-1 and BoHV-1 as demonstrated for bovine herpesvirus 5 (BoHV-
5) (Wellenberg et al., 2001). Cattle experimentally infected with BoHV-5 are detected seropositive 
by a BoHV-1 gB blocking ELISA and seronegative by a BoHV-1 gE blocking ELISA (Wellenberg et 
al., 2001). BoHV-5 being the alphaherpesvirus the most closely related to BoHV-1 (Ros et Belák, 
1999 ; 2002) and showing antigenic differences for gE (Kaashoek et al., 1995 ; Wellenberg et al., 
2001), it could be hypothesised that CpHV-1 gE has more pronounced antigenic differences and 
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may allow the differentiation from BoHV-1 by using BoHV-1 gB and gE blocking ELISA. As BoHV-1 
gB blocking ELISA is used as a screening tool to detect antibodies against a related BoHV-1 
infection, the validation of this test in goats was evaluated under field and experimental conditions. 
 
 
Materials and methods 
 
Flocks, animals and serums samples 
 
Field serum samples were collected in several French flocks in Corse-du-Sud (department 
2A), in Dordogne (department 24) and in Vendée (department 85). Goat flock size ranged from 7 
to 304 adult animals over than 6 months of age. All flocks were composed of dairy breeds and 
produced milk for dairies or for on-farm cheese making. The sampling size corresponded to the 
whole adult flock size. The experimental serum samples came from four Belgian goats intranasally 
inoculated with the CpHV-1 E/CH strain at a dose of 106 plaque forming units (PFU) per nostril 
(Keuser et al., 2002) and two Danish calves intranasally inoculated with the BoHV-1 Iowa strain at 
a dose of 5x107 PFU per nostril (Muylkens et al., 2006). Prior to inoculation, absence of antibodies 
against CpHV-1 in goats was confirmed by serum neutralisation assay (Keuser et al., 2002) and 
absence of antibodies against BoHV-1 in calves was confirmed by BoHV-1 gB blocking ELISA 
(Muylkens et al., 2006). 
 
Enzyme linked immunosorbent assay (ELISA) 
 
To detect antibodies in serum samples, a BoHV-1 gB blocking ELISA (SERELISATM IBR/IPV 
gB Ab Mono Blocking, Synbiotics Europe, Lyon, France) and a BoHV-1 gE blocking ELISA (Herdchek 
Anti-IBR gE, Idexx, Germany) were used following the instructions of the manufacturers. Serum 
samples were analysed in duplicate and the average was used to calculate the competition 
percentage. The cut off was fixed to 45% of competition. Serum samples identified as doubtful 
were analysed in a second round, when identified twice doubtful, serum samples were considered 
as positive. 
 
Serum neutralisation assay 
 
Serum samples were heated at 56°C for 30 min. Serial twofold dilutions of each serum 
sample were incubated at 37°C for 2 h. in the presence of 75 PFU of CpHV-1 Ba-1 strain 
(Buonavoglia et al., 1996) or 12 h. in the presence of 75 PFU of BoHV-1 Iowa strain (Miller and van 
der Maaten, 1984). Each virus-serum dilution was then dispensed into 96 wells microplates 
containing Madin Darby Bovine Kidney (MDBK, ATCC CCL-22) cells grown as previously described 
(Lemaire et al., 1999). Readings were made after incubation for 3 days at 37°C. The titres were 
expressed as the reciproqual of the highest dilution of serum sample inhibiting cytopathic effect. 
 
Statistical analysis 
 
Statistical analyses were carried out in STATA/SE 8 (StataCorp, 2003). 
 
Results 
 
Serums from flocks sampled in Corse-du-Sud (n=1,430), Dordogne (n=997) and Vendée 
(n=121) departments in France were tested in a BoHV-1 gB blocking ELISA. The apparent 
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prevalences are given in Table 1. In Corse-du-Sud, all flocks tested were seropositive. The within-
herd prevalence ranged from 38.7% to 73.7% with an individual prevalence of 57.9% (95% 
confident interval (CI): 55.3%-60.5%). In Dordogne and Vendée, serum samples were consistently 
negative.  
 
In regards to these data, the specificity and the sensitivity of the BoHV-1 gB blocking 
ELISA to detect a BoHV-1 related infection in goats were evaluated with a cut-off of 45% of 
competition. On the basis of 1,118 serum samples from Dordogne and Vendée, regions presumably 
free of BoHV-1 related virus infection in goats, the measured specificity was 100% (95% CI: 
99.67%-100%). The sensitivity of the ELISA was assessed by testing serum samples obtained from 
serial bleedings of four goats experimentally infected with CpHV-1 (n=31). All serum samples but 
two taken at day 7 post infection were detected positive. The measured sensitivity was 93.5% 
(95% CI: 78.6%-99.2%).  
 
The true prevalences were calculated for each region (Table 1) according the following 
equation: True Prevalence = (Apparent Prevalence + Specificity - 1) / (Sensitivity + Specificity - 1) 
(Toma et al., 2001). In Corse-du-Sud, the within-herd prevalence ranged from 41.36% to 78.86% 
with an individual prevalence of 61.93% (95% CI: 59.13%-64.68%). Dordogne and Vendée 
obviously kept their free status.  
 
 
Table 1 - Serological prevalence of CpHV-1 infection in Corse-du-Sud, Dordogne and Vendée. 
Department Flocks Animals a Apparent prevalence b True prevalence b, c 
Corse-du-Sud A 126 72.22 (63.54-79.83) 77.22 (67.93-85.37) 
 B 143 49.65 (41.19-58.13) 53.06 (44-62.13) 
 C 114 54.39 (44.79-63.74) 58.13 (47.85-68.14) 
 D 118 73.73 (64.83-81.40) 78.84 (69.31-87.05) 
 E 75 54.67 (42.75-66.21) 58.43 (45.67-70.78) 
 F 144 55.56 (47.05-63.83) 59.38 (50.27-68.24) 
 G 91 41.76 (31.50-52.57) 44.61 (33.63-56.18) 
 H 195 66.67 (59.58-73.24) 71.28 (63.69-78.31) 
 I 181 38.67 (31.54-46.18) 41.30 (33.67-49.34) 
 J 102 63.72 (53.61-73.02) 68.12 (57.30-78.08) 
 K 141 65.96 (57.51-73.72) 70.52 (61.47-78.82) 
 Total 1430 57.90 (55.29-60.48) 61.89 (59.09-64.65) 
Dordogne L 22 0 (0-12.7) 0 (0-13.50) 
 M 304 0 (0-0.99) 0 (0-0.96) 
 N 115 0 (0-2.57) 0 (0-2.65) 
 O 288 0 (0-0.99) 0 (0-0.96) 
 P 15 0 (0-18.1) 0 (0-19.28) 
 Q 56 0 (0-5.2) 0 (0-5.47) 
 R 7 0 (0-35) 0 (0-37.37) 
 S 82 0 (0-3.6) 0 (0-3.76) 
 T 51 0 (0-5.7) 0 (0-6.01) 
 U 30 0 (0-9.5) 0 (0-10.07) 
 V 27 0 (0-10.5) 0 (0-11.14) 
 Total 997 0 (0-0.30) 0 (0-0.22) 
Vendée W 121 0 (0-2.44) 0 (0-2.52) 
a Number of goats analysed in BoHV-1 gB blocking ELISA. 
b Seroprevalence expressed in percent with 95% confidence interval in brackets (exact binomial). 
c The true prevalence was measured according to a specificity of 100% and a sensitivity of 93.5%. 
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The distribution of the data obtained from the investigated goat population clearly 
illustrates that a BoHV-1 gB blocking ELISA significantly detects a BoHV-1 related infection in goats 
(Figure 1). The goat population in Corse-du-Sud presents a bimodal distribution (Figure 1a) 
contrarily to the non-infected population in Dordogne and Vendée (Figure 1b) and the experimental 
infected population (Figure 1c). 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Distribution of goat population in Corse-du-Sud (a), Dordogne and Vendée (b), and 
in experimental conditions (c), in regards to the percentage of inhibition from a BoHV-1 gB 
blocking ELISA. The experimental conditions are explained in the section materials and methods. 
 
A BoHV-1 gE blocking ELISA was applied on serum samples detected positive in the 
BoHV-1 gB blocking ELISA (gB-positive) to fully distinguish BoHV-1 from a related infection. The 
analysis revealed that 22.6% of gB-positive serum samples in Corse-du-Sud were positive in the 
BoHV-1 gE blocking ELISA (gE-positive) (Table 2).  
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Table 2 - Serological analysis in BoHV-1 gE blocking ELISA of serum 
samples detected positive in BoHV-1 gB blocking ELISA. 
Flocks Animals a gE-Positive gE-Doubtful 
A 91 15 4 
B 71 11 9 
C 62 14 7 
D 87 18 6 
E 41 7 4 
F 80 8 8 
G 38 7 0 
H 130 10 10 
I 70 11 9 
J 65 4 2 
K 93 14 9 
Total 828 119 68 
a Number of goats detected positive in BoHV-1 gB blocking ELISA. 
 
In this context, different categories of serum samples were tested by a serum 
neutralisation assay (Table 3). Cross-seroneutralisation assays showed that serums from CpHV-1 
experimentally infected goats neutralise CpHV-1 to a much greater extent than BoHV-1. Such one 
way cross-seroneutralisation was observed with gB-positive serum samples and affords evidences 
that the infection serologically detected in goats by the BoHV-1 gB blocking ELISA is a CpHV-1 
infection (Table 3). 
 
 
Discussion 
 
The serological diagnosis of ruminant alphaherpesviruses related to BoHV-1 is made 
difficult by their antigenic cross-relationships. The existence of cross-reactions in serological assays 
as seroneutralisation and the ability of these viruses to cross, at least in some instances, the 
species barrier raise theoretical issues for differential diagnosis (Thiry et al., 2006a). The currently 
available serological tests are almost unable to discriminate related ruminant alphaherpesviruses. 
The current study reports the serological evidence of CpHV-1 infection occurring in Corse-du-Sud, a 
Mediterranean French department situated in Corsica, by applying a BoHV-1 gB blocking ELISA 
which has been evaluated in experimental conditions for sensitivity and under field conditions for 
specifity to detect CpHV-1 in goat species. Cross-seroneutralisation assays confirmed that 
antibodies detected were directed against CpHV-1 and not against BoHV-1. 
  
The analysis of goat serum samples in a BoHV-1 gB blocking ELISA revealed that BoHV-1 
related infection did not occur in Dordogne and Vendée, or only occurred at a low prevalence, not 
detected by our survey. In contrast, a high seroprevalence was observed in Corse-du-Sud. The gB-
positive serum samples most likely come from animals infected with CpHV-1. Indeed, several 
studies showed that gB is relatively well conserved within related ruminant alphaherpesviruses 
(Ros and Belák, 2002; Thiry et al., 2007b). Thus, BoHV-1 gB may include epitopes which most of 
them are shared with CpHV-1; antibodies directed against CpHV-1 may cross react in an ELISA 
using BoHV-1 gB as antigen as demonstrated for BoHV-5 (Wellenberg et al., 2001). The analysis of 
serum samples from CpHV-1 experimentally infected goats in a BoHV-1 gB blocking ELISA 
demonstrated a good sensitivity. Furthermore, the serum neutralisation assay demonstrated that 
CpHV-1 was indeed neutralised with both field and experimental goat serum samples. 
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The use of a BoHV-1 gE blocking ELISA could lead to the discrimination between BoHV-1 
and other ruminant alphaherpesvirus infections as demonstrated for BoHV-5 (Wellenberg et al., 
2001). BoHV-5 is one of the ruminant alphaherpesviruses the most related to BoHV-1 whereas 
CpHV-1 seems to be the most distantly related to BoHV-1 (Ros and Belák, 1999; 2002). Recent 
partial sequencing of US8 gene encoding gE confirmed the genetic divergence within the cluster of 
BoHV-1 related ruminant alphaherpesviruses (Thiry et al., 2007b). At the same level, BoHV-5 
shows differences in the gE antigenicity (Kaashoek et al., 1995; Wellenberg et al., 2001). 
Therefore, serum samples from goats seropositive to BoHV-1 gB were expected to be negative in a 
BoHV-1 gE blocking ELISA. Surprisingly, 22.6% of gB-positive serum samples were also positive in 
BoHV-1 gE blocking ELISA. A first explanation would be that gE-positive goats could have been 
infected with BoHV-1. Nevertheless, natural infections of goats with BoHV-1 have been only 
seldomly reported (Tolari et al., 1990 ; Whetstone et Evermann, 1988), whereas goats have been 
Table 3 - Cross serum neutralisation assay of different categories of serum samples 
against BoHV-1 and CpHV-1. 
Neutralising antibody titre against 
Categories of serum samples 
CpHV-1 BoHV-1 
Goats experimentally infected with CpHV-1 1:32 1:8 
 1:64 1:8 
Calves experimentally infected with BoHV-1 <1:4 1:32 
 <1:4 1:32 
gB-negative/gE-negative a <1:4 <1:4 
 <1:4 <1:4 
gB-positive/gE-negative a 1:8 <1:4 
 1:16 <1:4 
 1:16 <1:4 
 1:32 1:4 
 1:32 1:8 
 1:64 1:4 
 1:64 1:8 
 1:64 1:16 
gB-positive/gE-doubtful a 1:4 <1:4 
 1:8 <1:4 
 1:8 <1:4 
 1:16 <1:4 
 1:16 1:4 
 1:16 1:4 
 1:32 <1:4 
 1:64 1:16 
 1:64 1:32 
 1:128 1:16 
gB-positive/gE-positive a 1:8 <1:4 
 1:8 <1:4 
 1:16 <1:4 
 1:16 1:4 
 1:32 <1:4 
 1:64 1:4 
 1:64 1:8 
 1:64 1:8 
 1:64 1:16 
 1:64 1:16 
a Serum samples detected negative, doubtful or positive in BoHV-1 gB and gE blocking ELISA. 
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successfully infected experimentally with BoHV-1 inducing a serologic response and establishment 
of a latent infection (Six et al., 2001). In Corsica, the direct contact between cattle and goats is 
incidental because flocks and herds are not mixed although sharing the same rangeland pastures in 
mountains and plains. Therefore, the transmission of BoHV-1 from cattle to goats would be only 
exceptional, such cross-infection being very rare, and a BoHV-1 infection in goats is not likely to 
occur. The very high seroprevalence observed in the current study strongly supports a large 
circulation of CpHV-1. Furthermore, the differentiation between BoHV-1 and CpHV-1 can be made 
taking profit of a one way cross-neutralisation (Engels et al., 1983). In the current study, serum 
samples neutralised CpHV-1 to a much greater extent than BoHV-1 and afforded the ultimate 
identification of a CpHV-1 infection. On the other hand, goat population in Corsica is almost 
exclusively composed by the local breed underlining the quasi-absence of introduction of animals 
from the continental France or from Italy for ages (Hugot and Bouche, 1999). The only and limited 
importations are from southern continental departments as Var or Bouches-du-Rhône in particular 
with Rove breed animals (Gauthier, personal communication). 
 
As a BoHV-1 infection is not a likely explanation, the detection of gE-positive and gE-
negative results could be explained by large differences in the antigenicity of gE epitopes as 
described for Pseudorabies virus (Jacobs and Kimman, 1994). Furthermore, BoHV-1 strains that do 
not express a particular gE-epitope in cell culture can induce antibodies that are detected in a 
BoHV-1 gE blocking ELISA (van Oirschot et al., 1999). In contrast, the gE-positivity observed could 
reflect the level of immunisation induced after a CpHV-1 infection. As demonstrated for a BoHV-1 
infection, a primary infection leads to a high production of antibody (Muylkens et al., 2007). 
Therefore, when a serum is found highly positive by both BoHV-1 gB and gE blocking ELISA, goats 
could be highly immunised after a recent CpHV-1 infection or reactivation. Contrarily, a lower 
antibody response could be the result of a previous infection leading to latent persistence. Indeed, 
latency is closely associated with long-term maintenance of BoHV-1 neutralising antibodies during 
two to three years after infection (Kaashoek et al., 1996). CpHV-1 could follow the same pattern of 
evolution and latently infected goats could have lower antibody levels associated with gB-positive 
and gE-negative results. 
 
BoHV-1 marker vaccines made of a mutant with a deletion in one of the non-essential 
genes have been developed to be used in eradication campaigns of IBR initiated in several 
European countries. The commonest used vaccines are either attenuated or killed viruses carrying 
a deletion in the gene encoding the glycoprotein E (Bosch et al., 1996; Kaashoek et al., 1994). The 
control of the infection relies on the use of BoHV-1 gB and gE blocking ELISA in order to 
differentiate infected and gE-negative vaccinated animals (European Food Safety Authority, 2005). 
In the context of the IBR certification in France, some cattle have been identified seropositive to 
BoHV-1 from herds qualified as free of IBR. An attempted explanation would be the cross-infection 
of cattle with a related ruminant alphaherpesvirus as for example CpHV-1 (Thiry et al., 2006b). 
The obtained results do not support this hypothesis. Indeed, CpHV-1 infection is absent in 
continental France or the seroprevalence is at least very low. Nevertheless, the current sampling is 
restricted to Dordogne and Vendée, and therefore cannot rule out the presence of CpHV-1 infection 
in other French regions especially in the Mediterranean part of the country as CpHV-1 infection has 
been identified in Corsica in the current study.   
 
As demonstrated for BoHV-1 (Kaashoek et al., 1996), CpHV-1-specific humoral response 
is an indicator of a CpHV-1 infection that has taken place. In addition, specific antibody titres could 
persist in goats for many years, detection of latently infected animals and flocks by serological 
tests is therefore reliable and of great diagnostic relevance. Moreover, a gB-positive/gE-negative 
result could not be attributed to a BoHV-5 cross-infection because BoHV-5 infection has never been 
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described in Europe so far. In regards to the specificity and the sensitivity measured, a BoHV-1 gB 
blocking ELISA is a useful tool to detect CpHV-1 infection in a flock. A negative result in BoHV-1 gE 
blocking ELISA could differentiate BoHV-1 from CpHV-1 infection in goats. In the case of a positive 
result, a cross-seroneutralisation assay will identify the infection. A continuous monitoring of the 
epidemiology of ruminant infection with CpHV-1 is essential in European countries involved in IBR 
control and eradication in order to identify potential BoHV-1 related virus reservoirs which could be 
implicated in IBR misdiagnosis. 
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Taking into account the close antigenic relationship between 
bovine herpesvirus 1 (BoHV-1) and caprine herpesvirus 1 (CpHV-1), a live 
attenuated glycoprotein E (gE) negative BoHV-1 vaccine was assessed in 
goats with the aim to protect against CpHV-1 infection. Vaccine safety was 
evaluated by intranasal inoculation of two groups of goats with either a gE-
negative BoHV-1 vaccine or a virulent BoHV-1. The length of viral excretion 
and the peak viral titre were reduced with the gE-negative vaccine. To 
assess the efficacy, two goats were inoculated intranasally twice two weeks 
apart with a gE-negative BoHV-1 vaccine. Four weeks later, immunised and 
control goats were challenged with CpHV-1. A two log10 reduction in the 
peak viral titre was observed and the challenge virus excretion lasted two 
days more in immunised than in control goats. These data indicate the 
safety and the partial efficacy of a live attenuated gE-negative BoHV-1 
vaccine intranasally administrated in goats. 
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Introduction 
 
Among the subfamily Alphaherpesvirinae, bovine herpesvirus 1 (BoHV-1) is a major 
pathogen of cattle responsible of infectious bovine rhinotracheitis (IBR). This disease is of major 
economic concern in Europe and this situation led to the development of BoHV-1 marker vaccines 
based on the deletion in the glycoprotein E (gE) gene. Such gE-negative vaccines either attenuated 
or inactivated have proven their safety and efficacy in the target bovine species (van Oirschot et 
al., 1996). They can reduce severity of disease, virus shedding, and virus circulation in a 
population (van Oirschot et al., 1996).  
 
Several ruminant alphaherpesviruses, and among other caprine herpesvirus 1 (CpHV-1) 
are antigenically and genetically closely related to BoHV-1. The existence of antigenic cross-
reactions between these viruses and their ability to cross the species barrier raise theoretical 
problems for the differential diagnosis and the detection of any other virus reservoir, both in 
regions and countries where BoHV-1 infection has been eradicated and in those where the control 
of IBR is currently or will be undertaken (Thiry et al., 2001). 
 
CpHV-1 is responsible of severe economic losses in Mediterranean countries. In kids, 
CpHV-1 is responsible of a systemic disease characterised by high morbidity and mortality, and 
ulcerative and necrotic lesions throughout the enteric tract (Mettler et al., 1979). In adult goats, 
infections of the reproductive tract as vulvovaginitis, balanoposthitis or spontaneous abortion are 
observed (Williams et al., 1997; Uzal et al., 2004). A classical inactivated vaccine has been 
developed. It shows a high immunogenicity and confers a good clinical protection (Tempesta et al., 
2001). However, this vaccine has very little chance to be marketed because the veterinary 
pharmaceutical industry has only poor interest in the development of vaccines for minor species 
like goats.  
 
Taking into account the issue of ruminant alphaherpesvirus diagnosis, the economical 
constraints of the veterinary pharmaceutical industry and the well-being of animals, we 
hypothesised that the intranasal use of an already licensed live attenuated gE-negative BoHV-1 
vaccine could be an alternative tool to protect goats against CpHV-1 infection. Therefore, we 
decided to assess the safety and the efficacy of a live attenuated gE-negative BoHV-1 vaccine in 
goats, firstly by comparison with a virulent BoHV-1 and, secondly by immunisation followed by a 
CpHV-1 challenge. 
 
 
Materials and methods 
 
Animals 
 
Nine goats, approximately 4-5 years of age, were used. All goats were originated from 
two CpHV-1 seronegative Italian flocks. Prior to inoculation, absence of antibodies against BoHV-1 
and CpHV-1 was confirmed by serum neutralisation assay. 
 
Cells and viruses 
 
The Madin-Darby bovine kidney (MDBK) cell line (ATCC CCL22) was maintained as 
previously described (Tempesta et al., 2001). The BoHV-1 virus Ciney strain, characterised as 
highly virulent (Lemaire et al., 1999), the challenge CpHV-1 virus Ba-1 strain (Buonavoglia et al., 
1996) and the BoHV-1 virus Los Angeles strain (Madin et al., 1956) used for serum neutralisation 
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assays were produced and titrated as described by Tempesta et al. (2001). The gE-negative BoHV-
1 vaccine virus used for immunisation is the commercial vaccine Bayovac® IBR-marker vivum 
(Bayer, Italy). 
 
Experimental design 
 
Safety assessment 
 
Six goats were randomly allocated into two groups of three goats. These groups were 
inoculated intranasally in the form of aerosol and received 2 ml per nostril of virulent BoHV-1 Ciney 
at a dose of 104.8 TCID50 or 2 ml per nostril of vaccine gE-negative BoHV-1 at a dose of 10
4.8 
TCID50. Goats were clinically examined and rectal temperatures were measured daily for 21 days. 
Nasal and vaginal swabs were collected daily for 21 days. Blood samples were collected daily for 21 
days for virological findings and weekly during the whole experiment at days 0, 7, 14, 21, 28, 35, 
42 and 49 for serology.  
 
Efficacy assessment 
 
Two goats were inoculated intranasally in the form of aerosol twice two weeks apart and 
received 2 ml per nostril of vaccine gE-negative BoHV-1 at a dose of 104.8 TCID50. One goat was 
kept uninoculated as negative control. On day 28, all goats were challenged by the intranasal route 
with 107 TCID50 of CpHV-1 Ba-1 strain. Goats were clinically examined daily from day -1 (before 
first immunisation) up to day 7, from day 13 (before second immunisation) up to day 21, and from 
day 27 (before the challenge) up to day 42. Rectal temperatures and nasal and vaginal swabs were 
collected with the same time schedule. Blood samples were collected with the same time schedule 
for virological findings and weekly during the whole experiment at days 0, 7, 14, 21, 28, 35, 42 
and 49 for serology. 
 
Virus isolation, polymerase chain reaction and serum neutralisation assays 
 
The virus isolation was performed as described by Tempesta et al. (2001). Buffy coats 
were separated from blood by centrifugation in presence of lympholyte (Cedarlane, Canada). 
Sample preparation and polymerase chain reaction (PCR) were performed as previously described 
with minor modifications (Vilcek et al., 1993; Tempesta et al., 1999). Serum neutralisation assays 
were performed as described by Tempesta et al. (2001). The titre of each serum was expressed as 
the highest serum dilution which neutralised the virus. 
 
 
Results 
 
Safety assessment 
 
Clinical examination 
 
The infection with the virulent BoHV-1 Ciney or the gE-negative BoHV-1 vaccine did not 
induce any undesirable local or systemic reaction. Goats inoculated with the gE-negative BoHV-1 
did not show any clinical sign of disease. The mean rectal temperature was normal. On the 
opposite, hyperthermia was noticed in the group inoculated with the BoHV-1 Ciney (Figure 1). 
Clinical signs as diarrhoea or vaginal hyperaemia were also observed in this group. 
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Figure 1 – Mean rectal temperatures after intranasal infection. Goats were inoculated at day 0 
with the virulent Ciney or the gE-negative vaccine BoHV-1 strain. 
 
Virus isolation and detection of viral DNA by PCR 
 
Goats infected with the gE-negative BoHV-1 vaccine excreted approximately 2 to 4 log10 
less viruses than those infected with the virulent BoHV-1 Ciney. The length of the virus excretion 
was 12 days shorter for animals infected with the vaccine virus (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Mean titres of BoHV-1 in nasal swabs after intranasal infection. Goats were 
inoculated at day 0 with the virulent Ciney or the gE-negative vaccine BoHV-1 strain. Titres are 
expressed as log10 tissue culture infectious dose 50 (TCID50) per 1 ml of nasal secretions. 
 
The virus was also detected by PCR in nasal swabs from each goat. Buffy coat samples 
were consistently negative for animals inoculated with the gE-negative BoHV-1. On the opposite, 
virus was recovered from days 5 up to 9 in buffy coats from goats inoculated with the BoHV-1 
Ciney. In vaginal swabs, virus was not isolated by cell culture and not detected by PCR in both 
groups. 
 
Immune responses 
 
The BoHV-1 neutralising antibody titres of goats inoculated with the virulent BoHV-1 
Ciney were below 1:2 at days 0 and 7. At day 14, titres increased to 1:2 and, at days 21, 28, 35, 
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42 and 49, to 1:4 and 1:8. BoHV-1 neutralising antibodies were not detected in goats inoculated 
with the gE-negative BoHV-1 vaccine. 
 
Efficacy assessment 
 
Clinical examination 
 
After challenge of both immunised and control goats with CpHV-1 Ba-1, goats expressed 
only very few clinical signs, especially hyperthermia was noticed in each goat and lasted an 
average of ten days (data not shown). 
 
Virus isolation and detection of viral DNA by PCR 
 
Following the first immunisation (day 0) with the gE-negative BoHV-1 vaccine, virus was 
isolated by cell culture and detected by PCR in nasal swabs. The peak viral titre was 104.8 TCID50 
per 1 ml of nasal secretions. Virus was not recovered from vaginal swabs and buffy coats. After the 
second immunisation (day 14), all samples were consistently negative (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Mean titres of BoHV-1 in nasal swabs after intranasal immunisation. Goats were 
immunised intranasally twice two weeks apart (days 0 and 14) with the gE-negative BoHV-1 vaccine 
strain. Titres are expressed as log10 tissue culture infectious dose 50 (TCID50) per 1 ml of nasal 
secretions. 
 
Two weeks later (day 28), control and immunised goats were challenged with the CpHV-1 
Ba-1. A two log10 reduction in the peak viral titre was observed in nasal swabs from immunised 
goats. Virus excretion lasted 2 days more in immunised animals than in the control goat (Figure 4). 
The virus was isolated in cell culture and detected by PCR in buffy coats (days 3 to 5 post 
challenge), nasal and vaginal swabs from control and immunised goats. 
 
Immune responses 
 
After the first (day 0) and the second immunisations (day 14) with the gE-negative BoHV-
1 vaccine, the BoHV-1 neutralising antibody titres of goats were below 1:2. During days post-
challenge (day 28), every goat seroconverted. A sharp increase in titres was observed in all 
immunised goats: 1:4 at day 35, 1:32 and 1:64 at days 42 and 49. The non immunised control 
goat showed a similar increase in BoHV-1 neutralising antibodies: 1:4 at day 35, 1:64 at days 42 
and 49. 
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Figure 4 – Mean titres of CpHV-1 in nasal swabs after intranasal challenge (day 0) with the 
Ba-1 CpHV-1 strain. Goats were previously immunised intranasally twice two weeks apart with the gE-
negative BoHV-1 vaccine strain. A non immunised control goat was inoculated at the same time. Titres 
are expressed as log10 tissue culture infectious dose 50 (TCID50) per 1 ml of nasal secretions. 
 
  
Discussion  
 
The safety of a gE-negative BoHV-1 vaccine was assessed in goats by comparison with a 
virulent BoHV-1. Absence of adverse effects and local or systemic clinical signs suggested that the 
use of gE-negative BoHV-1 vaccine was safe in goats. On the opposite, animals inoculated with a 
virulent BoHV-1 showed an increase of the length of virus excretion and developed mild clinical 
signs. The susceptibility of goats to BoHV-1 is in accordance with previously described results (Six 
et al., 2001) and goat would be suggested as a less expensive animal model to study the in vivo 
properties of BoHV-1 infection.  
 
In addition, the efficacy of a gE-negative BoHV-1 vaccine was assessed in goats by an 
immunisation experiment followed by a CpHV-1 challenge. After challenge, the reduction of the 
peak viral titre suggests that a gE-negative BoHV-1 vaccine could induce a cross-protection against 
CpHV-1 infection. However, the challenge virus excretion lasted two days more in immunised than 
in control goats indicating that the gE-negative BoHV-1 vaccine did not afford a sufficient 
protection. These results must be confirmed in a next experiment involving a higher number of 
animals. Both in safety and efficacy assessments, BoHV-1 neutralising antibody titres suggest a 
weak humoral immune response. It could be explained by a weak replication of BoHV-1 in goats. 
The development of a goat specific interferon-gamma assay could afford more information on the 
acquired cell-mediated immunity to gE-negative BoHV-1 immunisation and CpHV-1 infection. 
 
Besides prevention of CpHV-1 induced disease, control of CpHV-1 infection by vaccination 
would be helpful in countries involved in BoHV-1 eradication in cattle while possessing a significant 
population of goats. Indeed, such vaccination could reduce the circulation of CpHV-1 in goats. In 
consequence, goats would be less infected by an alphaherpesvirus close to BoHV-1 and therefore 
less involved in BoHV-1 misdiagnosis due to CpHV-1 infection. Another issue linked to the use of 
gE-negative virus vaccine would be its hypothetical latent infection in goats. BoHV-1 can indeed 
establish latency in this species, but with a poor reactivation success rate (Engels et al., 1992; Six 
et al., 2001). Moreover, gE-negative BoHV-1 are also less effective in reactivation and reexcretion 
(Mars et al., 2000; Lemaire et al., 2001). The risk of reactivation and reexcretion of a gE-negative 
BoHV-1 in goats is therefore very low.  
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In conclusion, the obtained data, although limited, clearly demonstrated the safety of the 
intranasal use of a gE-negative marker vaccine in goats. However, the efficacy assessment showed 
that a live attenuated gE-negative BoHV-1 vaccine can afford only a partial cross-protection against 
CpHV-1 infection in goats. 
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Caprine herpesvirus 1 (CpHV-1), responsible of various clinical 
manifestations in goats, is antigenically and genetically closely related to 
bovine herpesvirus 1 (BoHV-1). On the basis of these common properties, a 
live attenuated glycoprotein E (gE) negative BoHV-1 vaccine was assessed 
in goats by an intranasal immunisation twice three weeks apart followed by 
a subsequent CpHV-1 intravaginal challenge which is the natural route of 
infection in goats. To analyse the safety and the efficacy of this marker 
vaccine, two groups of goats served as controls: one was immunised with a 
virulent CpHV-1 and one was kept uninoculated until the challenge. The 
vaccine did not induce any undesirable local or systemic reaction and goats 
did not excrete gE-negative BoHV-1. After challenge, a significant reduction 
in disease severity was observed in immunised goats. Moreover, goats 
immunised with either gE-negative BoHV-1 or CpHV-1 exhibited a 
significant reduction in the length and the peak of viral excretion. 
Antibodies neutralising both BoHV-1 and CpHV-1 were raised in immunised 
goats. These data show that the intranasal application of a live attenuated 
gE-negative BoHV-1 vaccine is able to afford a clinical protection and a 
reduction of virus excretion in goats challenged by a CpHV-1 genital 
infection. 
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Introduction 
 
The subfamily Alphaherpesvirinae includes a cluster of closely related ruminant viruses 
with bovine herpesvirus 1 (BoHV-1) as prototype (Thiry et al., 2006a). BoHV-1, a major cattle 
pathogen, is typically responsible of infectious bovine rhinotracheitis (IBR) causing severe 
economic losses in livestock (Muylkens et al., 2007). Since its isolation, several conventional 
vaccines have been developed. These vaccines usually prevented clinical signs and reduced the 
amount of excreted viruses. However, there was still a need for improvements in order to use them 
in control and/or eradication programmes (van Oirschot et al., 1996). Therefore, BoHV-1 marker 
vaccines comprising attenuated or killed mutants with a deletion in one of the non-essential genes 
(gE) were developed and eradication campaigns were initiated in many European countries. They 
have proven their safety and efficacy in the target bovine species since they are efficacious at 
reducing disease severity, virus shedding, and circulation in a population (Mars et al., 2000; 2001).  
 
Caprine herpesvirus 1 (CpHV-1) is associated with two different syndromes in goats, a 
lethal systemic disease in kids (Saito et al., 1974; Van der Lugt and Randles, 1993)  and a genital 
disease leading to balanoposthitis (Tarigan et al., 1987), vulvovaginitis (Grewal and Wells, 1986) 
and abortion (Keuser et al., 2002) in adults. These clinical signs and the virus presence in nasal, 
ocular, rectal and vaginal samples suggest both the venereal transmission as the principal virus 
entry route and infection persistence within herds (Tempesta et al., 1998; 1999a). The genital 
tropism of CpHV-1 was confirmed by the detection of viral DNA in sacral ganglia of latently infected 
goats (Tempesta et al., 1999b). According to serological investigations, the infection occurs 
worldwide with highest prevalences observed in Mediterranean countries (Kao et al., 1985; Keuser 
et al., 2004; Koptopoulos et al., 1988; Muluneh et al., 1990; Plebani et al., 1983; Thiry et al., 
2006c). However, the economical losses due to CpHV-1 infection are probably underestimated. To 
date, a classical inactivated vaccine has been developed (Tempesta et al., 2001; Camero et al., 
2007), however, it can not be licensed since the market of veterinary medicinal products for minor 
species, like goats, is not economically profitable. Consequently, the control of this infection still 
relies on hygienic prophylactic measures (Thiry et al., 2006a).  
 
BoHV-1 and CpHV-1 are antigenically and genetically closely related (Thiry et al., 2006a). 
This relationship was originally demonstrated by serological assays (Kao et al., 1985; Berrios et al., 
1975; Mettler et al., 1979; Ackermann et al., 1986) and lately by phylogenetic analysis (Ros and 
Belak, 1999; 2002; Ros et al., 1999). These viruses are able to some extent to cross the species 
barrier and establish infection in heterologous animal species (Pirak et al., 1983; Engels et al., 
1992). Experimental reactivation of latent infection of BoHV-1 in goats was successfully performed 
(Six et al., 2001). Moreover, it has been recently demonstrated that a live attenuated gE-negative 
BoHV-1 vaccine was partially able to protect goats against nasal CpHV-1 infection (Thiry et al., 
2006b).  
 
In the following study, it is hypothesised that an intranasal administration (of a bovine 
vaccine) could afford a protection against the clinical genital infection. Indeed, for many years, the 
upper respiratory mucosa has been proven to be suitable for vaccine delivery. The recent advances 
in the study of the mucosal immune system strengthen this mode of administration as being a very 
effective route for vaccination for both peripheral and mucosal immunity (Davis, 2001). In human, 
nasal mucosa can serve as an efficient site for the induction of specific IgA and IgG responses in 
vaginal secretions (Bergquist et al., 1997; Johansson et al., 2001). The goat genital tract might 
employ similar homing mechanisms as those of the upper respiratory tract and therefore could 
receive primed immune cells from the nasopharynx-associated lymphoid tissue (NALT) (Brandtzaeg 
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et al., 1999). Therefore, it was decided to investigate gE-negative BoHV-1 intranasal route of 
vaccination in goats with the aim to protect this species against CpHV-1 genital infection. 
 
 
Materials and methods 
 
Cells and viruses 
 
The Madin-Darby bovine kidney (MDBK) cell line (ATCC CCL22) was maintained in 
Dulbecco-Minimal Essential Medium (D-MEM) supplemented with 10% of foetal bovine serum 
(FBS). The challenge CpHV-1 Ba-1 strain (Buonavoglia et al., 1996) was produced by infection of 
MDBK cells in D-MEM supplemented with 10% of FBS. At 72 h after infection, culture medium was 
removed and clarified by centrifugation at 1,500 x g for 20 min. Supernatants were divided into 
aliquots, frozen at -80°C and titrated by tissue culture infectious dose 50 (TCID50) method on 
MDBK cells. The gE-negative BoHV-1 vaccine virus strain used for immunisation is the commercial 
vaccine Rispoval® IBR-marker vivum (Pfizer Animal Health). The BoHV-1 Iowa (Miller and van der 
Maaten, 1984) and the CpHV-1 Ba-1 strains were used for serum neutralisation assays. 
 
Experimental design 
 
Nine dairy Alpine, Ionica, Maltese and Saanen crossbred goats, approximately 4-5 years 
of age, were used. All goats were originated from a CpHV-1 seronegative flock in Italy. Prior to 
inoculation, absence of antibodies against BoHV-1 and CpHV-1 was confirmed by serum 
neutralisation assay. The goats were randomly divided in three groups of three goats. Each group 
was separated in different airspaces. Two groups were inoculated intranasally by aerosolization 
twice three weeks apart as follows: group 1 served as positive control and received 2 ml per nostril 
of virulent CpHV-1 Ba-1 at a dose of 105.25 TCID50/50µl, and group 2 received 2 ml per nostril of 
gE-negative BoHV-1 vaccine at a dose of 104.25 TCID50/50µl. Group 3 served as negative control 
and was kept uninoculated before challenge. On day 42, all goats were challenged by the 
intravaginal route with 4 ml of virulent CpHV-1 Ba-1 (106.25 TCID50/50µl). All precautions were 
taken to avoid viral spread. Clothes and boots were changed before entering any stable. For 
handling, new gloves were used between groups. Clinical monitoring and all sampling procedures 
were carried out in a blind manner.  
 
Goats were clinically examined daily from day -1 (before infection) up to day 21 following 
the challenge and rectal temperatures were also measured up to day 16 post-challenge. Clinical 
observations were carried out at approximately the same time everyday and by the same scientist 
throughout the study. Clinical monitoring included the following clinical signs: apathy, anorexia, 
vaginal haemorrhage, vaginal discharge, pain, hyperemia of vulva and vagina, oedema of vulva 
and vagina, number of lesions in vulva and vagina. A clinical score from 0 to 2 was given for each 
clinical parameter except temperature. Scores quantifying the oedema of vulva and vagina were 
multiplied by 2. Scores quantifying the number of lesions in vulva and vagina were multiplied by 3.  
 
Blood samples for serology were collected from the jugular vein of animals weekly during 
the whole experiment at days 0, 7, 14, 21, 28, 35, 42, 49, 56 and 63 after the primary 
immunisation. Serums obtained after centrifugation were stored at -20°C until analysis. 
Heparinised blood samples for buffy coat extraction, nasal and vaginal swabs were collected daily 
up to day 14 after first immunisation, up to day 14 after second immunisation, and during 14 days 
post-challenge, using one swab per animal, swabbing deeply into each nostril or vagina. 
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Viral characterisation 
 
Samples were immersed in 1 ml of D-MEM and centrifuged at 5,000 x g for 5 min. The 
supernatant was then treated with a 10% antibiotics mixture (5,000 UI/ml penicillin, 2,500 µg/ml 
streptomycin, 10 µg/ml amphotericin) for 30 min at room temperature and titrated by the TCID50 
method on MDBK cells cultured in 96-well microtitre plates. The excess of samples was stored 
frozen at -80°C. Cells were examined daily for cytopathic effect (CPE). The virus titre was 
expressed as TCID50 per 50 µl of secretion. Buffy coats were separated from blood by 
centrifugation in presence of lympholyte (Cedarlane, Canada). Sample preparation and polymerase 
chain reaction (PCR) were performed as previously described with minor modifications (Tempesta 
et al., 1999a; Vilcek, 1993). Viral DNA were prepared from supernatants of MDBK cell cultures 
infected with viruses isolated on days 1 and 4 after challenge (Keuser et al., 2004). Two µg of DNA 
were submitted to BstEII restriction analysis (New England Biolabs) and DNA fragments were 
separated in a 0.7% Tris Acetate EDTA gel for 22 h at 30 V/cm and 500 mA. 
 
Serological analysis 
 
Serial twofold dilutions of each serum were mixed with either 100 TICD50 of BoHV-1 Iowa 
strain or 100 TICD50 of CpHV-1 Ba-1 strain in 96-well microtitre plates. The plates were held for 90 
min at room temperature and 20,000 MDBK cells were then added to each well. Analysis was done 
after three days of incubation at 37°C in presence of 5% CO2. The titre of each serum was 
expressed as the highest serum dilution which neutralised the virus in 50% of the wells (Lemaire et 
al., 2001). The BoHV-1 gE blocking ELISA (Herdchek Anti-IBR gE, Idexx, Germany) was used 
following the manufacturer instructions. Serums were analysed in duplicate. 
 
Statistical analysis 
 
Statistical comparisons in the clinical, virological and serological data were performed in 
the form of mixed models for repeated measurements by SAS procedure (procedure MIXED) (Littell 
et al., 1998). 
 
 
Results 
 
Clinical and viral responses after intranasal immunisation 
 
Goats intranasally inoculated with virulent CpHV-1 or gE-negative BoHV-1 vaccine kept a 
good general state of health. No signs of severe disease as anorexia, apathy, oedema or lesions 
were observed. The gE-negative BoHV-1 immunisation did not induce any undesirable local or 
systemic reaction and goats did not show any clinical sign of disease. On the opposite, goats 
inoculated with CpHV-1 expressed mild clinical signs as hyperemia and nasal discharge. Based on 
the mean rectal temperature, the statistical analysis revealed significant differences between 
groups (p<0.005). From day 3 after immunisation, the mean temperatures of CpHV-1 inoculated 
goats were higher than the temperature of gE-negative BoHV-1 immunised goats (p<0.001) (data 
not shown). 
 
Following the first immunisation (day 0), only CpHV-1 was excreted by goats (Figure 1). 
CpHV-1 was isolated in cell culture and was detected by PCR in nasal swabs but was not recovered 
from vaginal swabs and buffy coats. The peak viral titre was 106.6 TCID50 per 50 µl of nasal 
secretions. After the second immunisation (day 21), both samples from gE-negative BoHV-1 and 
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from CpHV-1 infected goats were consistently negative by isolation in cell culture and detection by 
PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Mean titres of BoHV-1 or CpHV-1 in nasal swabs recorded after intranasal 
immunisation. Goats were immunised intranasally with either live attenuated gE-negative BoHV-1 
vaccine or virulent CpHV-1 Ba-1. Titres are expressed as log10 TCID50 per 50 µl of nasal secretions. 
 
Viral excretion after CpHV-1 intravaginal challenge 
 
Three weeks after the second immunisation, control and immunised goats were 
intravaginally challenged with the virulent CpHV-1 Ba-1 strain (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Mean titres of CpHV-1 in vaginal swabs recorded after CpHV-1 Ba-1 intravaginal 
challenge. Goats were previously immunised intranasally with either live attenuated gE-negative BoHV-
1 vaccine or virulent CpHV-1 Ba-1. The control group was not inoculated with any preparation. Titres are 
expressed as log10 TCID50 per 50 µl of vaginal secretions. 
 
The mean CpHV-1 titres in vaginal swabs were significantly different (p<0.0001) between 
groups immunised with either gE-negative BoHV-1 vaccine or virulent CpHV-1 and the non-
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immunised group. The lowest excretion titres were obtained in the CpHV-1 immunised group 
compared to gE-negative BoHV-1 immunised or non-immunised groups (p<0.0001). The 
immunisation with gE-negative BoHV-1 vaccine decreased the mean challenge virus excretion 
titres: 1.42 log on day 2, 1.75 log on day 3, 1.5 log on day 6, 1.66 log on day 7, 2.75 on day 8, 
except on days 4, 5 and 9 after challenge where the mean excretion titres, although not 
significantly different, were lower than the mean excretion titres obtained on the same day in non-
immunised goats. Furthermore, the gE-negative BoHV-1 vaccine shortened the challenge strain 
shedding. While no viral shedding was detected on day 12 in non-immunised group, goats from the 
gE-negative BoHV-1 immunised group excreted the challenge CpHV-1 during a significantly shorter 
time period. The shortest virus shedding, up to day 1 after challenge, was detected in the CpHV-1 
immunised group (Figure 2). 
 
On days 1 and 4 after challenge, viruses from one goat in each group were further 
propagated individually and characterised using restriction enzyme analysis. The BstEII profiles 
confirmed that viruses excreted after challenge by goats immunised with gE-negative BoHV-1 
vaccine were CpHV-1 challenge Ba-1 strain (data not shown). 
 
Clinical protection against CpHV-1 intravaginal challenge 
 
Groups intranasally immunised with either virulent CpHV-1 or gE-negative BoHV-1 
vaccines were protected against the clinical form of the genital CpHV-1 infection (Figure 3). 
Consequently, the clinical score of each group was significantly lower (p<0.0001) than in the non-
immunised group. The statistical analysis revealed no significant difference between the gE-
negative BoHV-1 immunised and the CpHV-1 immunised groups (p=0.06) except at days 5 and 6 
after challenge. At these days, goats immunised with gE-negative BoHV-1 vaccine showed mild 
oedema or vulva hyperemia.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 –Mean clinical scores recorded after CpHV-1 Ba-1 intravaginal challenge. Goats were 
previously immunised intranasally with either live attenuated gE-negative BoHV-1 vaccine or virulent 
CpHV-1 Ba-1. The control group was not inoculated with any preparation. 
 
The mean rectal temperature of immunised groups was significantly lower (p<0.0001) 
than those of the non-immunised group except at the challenge peak (days 3 and 5 after 
challenge). Additionally, the group inoculated with virulent CpHV-1 exhibited a significant lower 
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temperature (p<0.0001) than the gE-negative BoHV-1 vaccine immunised group. Overall, goats 
did not show any sign of hyperthermia (data not shown). 
 
Immune responses after immunisation and challenge 
 
In goats immunised with either virulent CpHV-1 or gE-negative BoHV-1 vaccine, CpHV-1 
neutralising antibodies were observed from day 14 after the first immunisation (Figure 4). No 
significant difference between groups was noticed. After the second immunisation, a sharp increase 
in CpHV-1 neutralising antibody titres was observed in the CpHV-1 immunised group. In contrast, 
goats immunised with gE-negative BoHV-1 did not show any boost of the primary immune 
response (Figure 4). Following the CpHV-1 intravaginal challenge, the mean CpHV-1 neutralising 
antibody titres were significantly different (p<0.0001) between groups immunised with gE-negative 
BoHV-1 or CpHV-1 and the non-immunised group. Interestingly, goats immunised with gE-negative 
BoHV-1 vaccine showed an increase in CpHV-1 neutralising antibodies, but their neutralising titres 
were much lower than that of CpHV-1 immunised goats (Figure 4). Neutralising antibody titres 
were lower against BoHV-1 than CpHV-1 in all groups (data not shown). Moreover, all animals 
remained negative with the BoHV-1 gE blocking ELISA. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4 – Evolution of CpHV-1 neutralising antibody titres in goats intranasally immunised on 
day 0 with either live attenuated gE-negative BoHV-1 vaccine or virulent CpHV-1 Ba-1. The 
control group was not inoculated with any preparation. Goats were intravaginally challenged with 
virulent CpHV-1 Ba-1 on day 42. Neutralising titres are expressed as the initial dilution of serum that 
neutralised 50% of wells, calculated using the Spearman-Kärber method. 
 
 
Discussion  
 
Taking advantage of the susceptibility of goats to BoHV-1 (Thiry et al., 2006b), the 
efficacy of a live attenuated gE-negative BoHV-1 vaccine was assessed in goats after two intranasal 
administrations followed by a subsequent CpHV-1 intravaginal challenge. The intranasal use of a 
gE-negative BoHV-1 vaccine enabled a cross-protection against CpHV-1 genital infection which is 
the natural route of infection in goats. As observed in human, nasal mucosa can serve as an 
efficient site for the induction of a specific protective response in the genital tract. It is likely a 
consequence of the induction of specific IgA and IgG responses in vaginal secretions. The presence 
of specific antibody secreting cells (ASCs) in the genital tract have been demonstrated after nasal 
vaccination in mice (Eriksson et al., 1998; Johansson et al., 1998). In another study, it has been 
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shown that T lymphocyte homing to the genital mucosa requires the interaction of integrins αLβ2 
and α4β1 with endothelial intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 
(VCAM-1), respectively (Perry et al., 1998; Johansson et al., 1999). Since both nasal and genital 
mucosa express VCAM-1, this adressin could be involved in the homing of specific ASCs to the 
genital tract. Moreover, chemokine like CC chemokine ligand 28, which is expressed in both 
tissues, could interact with the chemokine receptor 10 expressed on nasal ASCs and be involved 
too in the homing of specific ASCs to the genital area (Johansen et al., 2005; Meurens et al., 
2007). Although the underlying mechanism was not investigated in this study, it can be speculated 
that such pathways could be involved in the current protection. 
 
Following the first immunisation, the safety of the gE-negative BoHV-1 vaccine in goats 
was evidenced by the absence of side effects and local or systemic reactions. Interestingly, goats 
did not excrete gE-negative BoHV-1 although a low level of BoHV-1 excretion was observed 
previously (Thiry et al., 2006b). A weaker replication of gE-negative BoHV-1 could account for this 
result. Nevertheless, the presence of neutralising antibodies against BoHV-1 after the first and 
second immunisations suggests the replication of gE-negative BoHV-1 in goats. It can be 
hypothesised that the first immunisation induced a strong mucosal immunity leading to the 
neutralisation of newly replicated viruses after the second immunisation. The absence of detection 
of anti-gE antibodies is consistent with the absence of gE in the bovine vaccine and shows that the 
antigenicity of gE is different in BoHV-1 and CpHV-1.  
 
Another issue to consider is the possible establishment of gE-negative BoHV-1 in a latent 
state in vaccinated goats. Indeed, BoHV-1 is able to establish latency in goats but with a poor 
reactivation success rate (Engels et al., 1992; Six et al., 2001). However, gE-negative BoHV-1 is 
less effective in reactivation and reexcretion than wild type viruses in calves (Mars et al., 2000; 
Lemaire et al., 2001). Therefore, the risk of reactivation and reexcretion of a gE-negative BoHV-1 
in goats is low. Otherwise, the vaccination could also lead to the emergence of new recombinant 
viruses. Indeed, despite the fact that in the subfamily Alphaherpesvirinae, viruses of different 
species show very few sequence similarities to allow homologous recombination, several 
interspecific recombinants were isolated in vitro (Thiry et al., 2005). Natural recombinants between 
equid herpesviruses 1 and 4 were, for example, recently identified (Pagamjav et al., 2005). 
Therefore, the question of recombinants rising from cross-infection of CpHV-1 infected goats with 
BoHV-1 needs to be considered. Among the cluster of ruminant alphaherpesviruses related to 
BoHV-1, only two recombinant viruses between BoHV-1 and BoHV-5 were isolated, and any 
recombinant between BoHV-1 and less closely related CpHV-1 and CvHV-2 was detected in vitro 
(Meurens et al., 2004). Consequently, in regards of these data and especially the low level of 
excretion, the vaccination described here is likely to be completely safe. 
 
The reduction of the clinical score was considered as the most relevant parameter 
showing the efficacy of nasal immunisation against CpHV-1. Goats immunised intranasally with gE-
negative BoHV-1 vaccine were clinically protected. Moreover, the difference between goats 
immunised with either gE-negative BoHV-1 or CpHV-1 was not statistically significant. The gE-
negative BoHV-1 vaccine was not only effective in preventing development of genital disease upon 
challenge, but also in significantly reducing the magnitude and the duration of challenge CpHV-1 
excretion. A high protection against clinical signs was also observed after immunisation by 
intranasal infection with CpHV-1. However, in natural conditions, the same kind of protection is not 
likely to be reached because the main route of transmission is venereal instead of respiratory 
(Tempesta et al., 1998; 1999a). The current CpHV-1 vaginal challenge used in this assay was even 
more severe than in previous experiments (Tempesta et al., 2000; 2002) and this result brings a 
good validation of the current study. The significant differences observed between immunised and 
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non-immunised groups have been obtained with a relatively low number of animals, therefore 
despite a lower power of the statistical test. These data allowed the identification of a strong effect 
of vaccination with the live attenuated gE-negative BoHV-1 vaccine (Howell, 1997). Moreover, 
nasal vaccination is an interesting alternative for inducing specific antibody responses in female 
genital tract, both for convenience and because the outcome of vaginal vaccination might be 
dependent on the time point in the oestral cycle for vaccine administration (Johansson et al., 
2001).       
 
Concerning infection control, such vaccination could bring several advantages. Indeed, 
the existence of antigenic cross-reactions between ruminant alphaherpesviruses related to BoHV-1 
and their ability to cross the species barrier raise theoretical problems for the differential diagnosis 
and the detection of any other virus reservoir, both in regions and countries where BoHV-1 
infection has been eradicated and in those where the control of IBR is currently or will be 
undertaken (Muylkens et al., 2007). The use of such vaccination could reduce the circulation of 
CpHV-1 in goats which would be therefore less involved in BoHV-1 misdiagnosis due to infection 
with a closely related alphaherpesvirus. Moreover, the development of new vaccines in order to 
protect minor species against infection causing economical and management problems meets a 
poor interest from the pharmaceutical industry. In this context, a classical inactivated vaccine 
inducing a good protection against CpHV-1 infection in goats was developed but was not licensed 
(Tempesta et al., 2001; Camero et al., 2007). Consequently, it was required to investigate the 
capacity of an already licensed bovine vaccine to induce a cross-protection against a related virus 
infection in goats according to the principle of the cascade. The European Union has recently 
pointed out the requirements of medicinal veterinary products for minor uses and minor species, as 
goats for example (Committee for Veterinary Medicinal Products, 2004). The results obtained in 
this study clearly show that a bovine vaccine can be safely and efficiently used in goats. 
 
 
Conclusion  
 
Regarding the issue of ruminant alphaherpesvirus diagnosis, the economical constraints of 
the veterinary pharmaceutical industry and the well-being of animals, this study brings an 
expected tool for the CpHV-1 induced disease prevention. Indeed, the intranasal administration of 
a live attenuated gE-negative BoHV-1 vaccine protects goats clinically and virologically against 
CpHV-1 genital infection which is the natural route of infection in goats. In addition, the current 
study emphasises the interest of studying intranasal vaccination approaches against genitally 
transmitted infections through the mucosal immune system. 
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Ruminant herpesviruses have been widely described because they are causative agents of 
diseases of economic importance (Engels and Ackermann, 1996; Schwyzer and Ackermann, 1996; 
Thiry et al., 2006b). Illustrating the spectacular evolutionary success of the family Herpesviridae 
(Davison, 2002), several ruminant herpesviruses are able to infect heterologous species leading to 
various clinical signs or subclinical infections. For example, sheep is susceptible to BoHV-1 but the 
infection is asymptomatic (Whetstone and Evermann, 1988). In contrast, the development of a 
severe illness can occur as for example Aujeszky’s disease, a fatal meningoencephalitis in cattle 
caused by suid herpesvirus 1, a pig alphaherpesvirus (Wittmann, 1989). In the same way, equine 
herpesvirus 1 causes nervous and ocular syndromes in alpacas and llamas in South America 
(Rebhun et al., 1988). The determination of the spectrum of herpesvirus susceptible species is 
made more difficult by the existence of viruses closely related as, for example, the cluster of 
ruminant alphaherpesviruses related to BoHV-1. 
 
In order to characterise the relationship existing between BoHV-1 and its related viruses, 
phylogenetic analyses were performed by sequencing a selected part of UL27 encoding 
glycoprotein B and US8 encoding glycoprotein E. The choice of these genes was determined by 
their degree of divergence observed when comparing BoHV-1 and BoHV-5 genomes (Delhon et al., 
2003). The obtained data confirm the genetic relatedness of the members of this cluster. BoHV-5 
and BuHV-1 are the most closely related viruses to BoHV-1, followed by CvHV-1 and ElkHV-1 
clustering together and with CvHV-2 and CpHV-1. The exact knowledge of the evolutionary 
relationships among these viruses request complete genome sequencing but this analysis is 
complicated by the large size of herpesvirus genome. Another possibility would be to compare 
different regions distributed along the genome of each virus as demonstrated by the study of the 
BoHV-4 evolution history (Dewals et al., 2006). Such analysis could bring interesting data about 
events that occurred in the past between herpesviruses and their ruminant hosts. Although 
humans certainly play an important role with the extensive trade of ruminants, this question has to 
be raised when knowing that BoHV-1 is worldwide distributed (Muylkens et al., 2007), BoHV-5 is 
mainly distributed in South America (Meyer et al., 2007), but has been isolated in Australia and 
USA; BuHV-1 was isolated in Australia (Bulach and Studdert, 1990) and its presence is 
demonstrated in Italy (De Carlo et al., 2004) and highly suspected in Argentina (Romera, personal 
communication); CpHV-1, CvHV-1 and CvHV-2 are present in Europe (Thiry et al., 2006c; Inglis et 
al., 1983. Ek-kommonen et al., 1986) and ElkHV-1 was recovered from a North American elk in 
Canada (Deregt et al., 2000).   
 
The present work gives a contribution to the knowledge of the natural history of the 
cluster of ruminant alphaherpesviruses related to BoHV-1. The first isolation of CvHV-1 in a free-
ranging red deer linked to the knowledge of the evolution of red deer populations in Europe allowed 
an interesting hypothesis about the origin of this virus. The genetic analysis showed that the virus 
isolated in Anlier was different from the virus isolated in Scotland. Moreover, in absence of clinical 
signs observed in the hunted fawn sampled, it is difficult to confirm the presence of a new viral 
subtype because nothing is known about the pathogenicity. The data suggest the existence of a 
new strain of CvHV-1 which is named Anlier. In regards of the observed prevalence and the 
presence of red deer over large area, this virus could be responsible of an endemic infection 
spreading in Europe. Indeed, the prevalence of a BoHV-1 related alphaherpesvirus infection in red 
deer ranged between 5.4 to 71% in Czech Republic (Pospisil et al., 1996), Germany (Muller et al., 
1997) and Hungary (Kalman and Egyed, 2005) as well as 28.9% in Belgium (Grégoire and Linden, 
unpublished data). Moreover, the same genetic cluster of red deer is present through Central and 
Western Europe (Feulner et al., 2004; Frantz et al., 2004; Kuehn et al., 2004). This explanation of 
the emergence of CvHV-1 Anlier in Belgium is more likely than the result of an illegal translocation 
of a Scottish farmed red deer in wildlife. However, molecular epidemiologic study of several isolates 
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of the two strains is required to firmly assess if the Belgian CvHV-1 Anlier strain could be the 
ancestor of the Scottish CvHV-1 Banffshire 82 strain. This goal will be difficult to achieve due to the 
need to search for viral infections in wildlife.   
 
Until now, no severe epidemic resulting from herpesvirus infections was identified in wild 
fauna. Nevertheless, several free ranging ruminants are susceptible to these viruses which are 
presumably responsible for sporadic diseases. Such infections have low clinical consequences but 
their epidemiologic role is important. The infection of free ranging animals contributes to maintain 
viruses in a specific region and within a population that could become a virus reservoir for domestic 
ruminants. The current development of breeding of ruminants taken from wild fauna has to take 
into account these infections. Indeed, the increase of farmed animal density allows the emergence 
of epidemic diseases whereas they should be sporadic in natural conditions and go unnoticed. 
Moreover, the proximity with domestic animals enhances the risk of transmission of these viruses 
to recently introduced animals. Thus, it should not be true to reduce the impact of herpesvirus 
infections in free ranging ruminants to a simple circulation of viruses in a wild population resulting 
from a transmission by domestic animals. In the same way, the situation observed in domestic 
ruminants can not be transferred to free ranging ruminants. When viruses are antigenically and 
genetically closely related, serological misdiagnosis can occur because the context leads to 
conclude that the wild species is infected by a virus specific of a domestic species.           
 
The best example of this misinterpretation is the situation observed in Finland in 1982. An 
epidemiological survey in the Finnish reindeer population showed that 23% of animals were 
seropositive to BoHV-1, while all cattle were seronegative (Ek-Kommonen et al., 1982). These data 
strongly suggested a BoHV-1 infection of reindeer with an absence of transmission to cattle due to 
an apparent lack of contact between the two ruminant species. This hypothesis was rapidly 
rejected. From a BoHV-1 seropositive reindeer, a new virus was isolated and further characterised 
as CvHV-2. This infection provided a likely explanation of the presence of anti-CvHV-2 antibodies 
cross-reacting with BoHV-1 in reindeer (Ek-Kommonen et al., 1986). In spite of this epidemiologic 
situation in reindeer, the Finnish cattle population maintained an IBR free status.  
 
Another example revealing the importance of clarifying the cause of potential serological 
cross-relationships with BoHV-1 is the difficulty encountered by the French veterinary authorities to 
differentiate true and false BoHV-1 positive cattle in the framework of an IBR herd certification. In 
France, a herd gets label “A” after repeated serological investigations leading to a so-called “IBR-
free status”. However, cattle purchased from these herds are sporadically identified as seropositive 
to BoHV-1 (Petit, 2002; Thiry et al., 2007a). Among other hypotheses, one explanation of this 
“false” seropositivity would be the infection with a BoHV-1 related virus that has crossed the 
species barrier.  
 
As demonstrated in the first study, BoHV-5 is the most closely related virus to BoHV-1. 
However, BoHV-5 was never identified in Europe, except once in Hungary (Bartha et al., 1969). 
ElkHV-1 has been only identified in Canada (Deregt et al., 2000). In Europe, these two viruses 
cannot therefore contribute to IBR misdiagnosis, contrarily to the other four ruminant 
alphaherpesviruses. In regards to the low number of buffalo livestock in France, the hypothesis of 
BuHV-1 infection of cattle could be rejected. The transmission of CvHV-1 in cattle would be only 
exceptional due to the weak susceptibility of cattle to CvHV-1 (Ronsholt et al., 1987) and the 
seldom epidemiologic situation where bovine and red deer could meet each other. In the same 
way, it was demonstrated that BoHV1 will probably not survive longer than a few decades (several 
times the mean deer lifetime) in red deer populations (Mollema et al., 2005). As reindeer are not 
present in France, CvHV-2 infection can be also excluded. Interestingly, the Finnish situation 
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demonstrated that the presence of infected reindeer did not present a risk factor of BoHV-1 
seropositive cattle. Consequently, the only virus that could be responsible of IBR misdiagnosis in 
France is CpHV-1 because goats and cattle can be in close contact in some field situations.  
 
The results obtained in the second study did not support this hypothesis. Indeed, CpHV-1 
infection is either absent or at a very low prevalence in continental France. The current sampling is 
restricted to Dordogne and Vendée, but a previous seroepidemiologic study also failed to identify 
seropositive goats in mainland France (Thiry et al., 2006d). Contrarily, a very high seroprevalence 
of CpHV-1 was measured in the Corse-du-Sud department. In Corsica, the contact between cattle 
and goats is very limited because flocks and herds are not mixed although they share the same 
rangeland pastures in mountains and plains. Therefore, the transmission of CpHV-1 from goats to 
cattle would be only exceptional, such cross-infection being very rare, and a BoHV-1 infection in 
goats is not likely to occur.  
 
The use of a BoHV-1 gB blocking ELISA to investigate the epidemiologic situation of 
CpHV-1 in France was motivated by the presence of anti-gB antibodies at high titres, their early 
onset and persistence after infection in cattle (Kramps et al., 1994) but primarily because gene 
encoding gB is one of the most conserved within the cluster of ruminant alphaherpesviruses related 
to BoHV-1 as demonstrated in the first study. The statistical analysis measured a specificity of 
100% and a sensitivity of 93.5%. These results are similar than those obtained by the inter-
laboratory comparison tests revealing a specificity of 99% and a sensitivity of 96% for the 
detection of antibodies against BoHV-1 (Kramps et al., 2004). The only minor point that can be 
discussed is the sensitivity assessment resulting from serial bleeding of CpHV-1 infected goats. It 
would be useful to measure it from naturally CpHV-1 infected goats or at least one bleeding of 
several experimentally CpHV-1 infected goats. However, the cross serum neutralisation showed 
that all gB-positive serum samples neutralised to a greater extent CpHV-1 than BoHV-1. Therefore, 
the BoHV-1 gB blocking ELISA can be validated for the detection of CpHV-1 infected goats in flocks.  
 
The BoHV-1 gB blocking ELISA was shown to be the most sensitive test to detect 
antibodies against BoHV-1 followed by indirect ELISA and serum neutralisation assay in contrast 
with BoHV-1 gE blocking ELISA showing a lower analytical sensitivity (de Wit et al., 1998; Beer et 
al., 2003; Kramps et al., 2004). The differentiation expected between BoHV-1 and CpHV-1 
immunisation was not observed when using the BoHV-1 gE blocking ELISA. 22.6% of gB and 
CpHV-1 positive goat serum samples did react in the BoHV-1 gE blocking ELISA. Several 
hypotheses are suggested to explain the gE-positive results. First, the level of immunisation 
induced after CpHV-1 infection or the long-term maintenance of lower antibody titres after latent 
establishment could be an explanation (Kaashoek et al., 1996). Another phenomenon could be a 
steric hindrance due to antibody binding to neighbouring epitopes on gE preventing the interaction 
with the specific antibody, as demonstrated for the attenuated strain not expressing a particular 
gE-epitope (van Oirschot et al., 1999). Differences in the antigenicity of gE or either in vitro and in 
vivo gE expression has also to be taken into account (Wellenberg et al., 2001). Contrarily, the 
incidental occurrence of weak false-positive reactions when testing serum samples that have not 
been frozen or heat-inactivated before the assay (Beer et al., 2003; Isa et al., 2003) has to be 
rejected. In the current study, all serum samples were frozen, thawed and incubated 30 min. at 
56°C, therefore, the diagnostic sensitivity was not affected and the results obtained were relevant. 
In regards to those, it is interesting to discuss the method described by Wellenberg and 
collaborators (2001) able to differentiate anti-BoHV-5 from anti-BoHV-1 antibodies. They obtained 
weak positive reactions in the BoHV-1 gE blocking ELISA with experimental BoHV-5 calves serum 
samples. Here, the analysis of serum samples from experimentally CpHV-1 infected goats always 
leaded to gE-negative results (Keuser and Thiry, unpublished results) in contrast to field serum 
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samples. It would be therefore of interest to analyse BoHV-5 positive field serum samples in order 
to see if a clear differentiation can be made.    
 
The present work also afforded data about differential and comparative diagnosis of each 
ruminant alphaherpesvirus related to BoHV-1. Thus, the detection and the identification of the 
CvHV-1 Anlier strain demonstrated the speed and the efficiency of the consensus PCR developed by 
Ros and Belák (1999) and confirmed it as a useful diagnostic tool to detect bovine, caprine, red 
deer and reindeer alphaherpesviruses from field samples. The primer set designed to partly amplify 
US8 can also be used to detect the related viruses but would be more appropriate for monitoring 
the spread of live marker vaccine and the gE genotype of viral field isolate (Schynts et al., 1999) 
as well as the differentiation between these latter and wildtype BoHV-1. Another diagnostic method 
applied was the immunofluorescence assay developed by Keuser and collaborators (2004a). 
Attempted reactions between viruses and their specific monoclonal antibody were observed but no 
reaction was detected with CvHV-1 Anlier. Believing that epitopes of the two CvHV-1 strains could 
be different, the monoclonal antibody 6C3, which is different from the CvHV-1 monoclonal antibody 
6C2, was assessed. By ELISA and flow cytometry, 6C2 detected specifically CvHV-1 but not CvHV-
2. Identical results were obtained by ELISA for 6C3 but not by flow cytometry whereas 6C3 
detected only weakly CvHV-1 (Keuser et al., 2004a). Following this reasoning, the antigenic 
differentiation of the two CvHV-1 strains was enabled. The first comparison of restriction patterns 
of all ruminant alphaherpesviruses was also performed and demonstrated that these related 
viruses can be clearly differentiated from each other at a genomic level.    
 
Diagnosis and vaccination are complementary tools of control of infectious diseases. Thus, 
in the context of IBR control and eradication, some European countries have applied a strategy 
named “Differentiation of Infected from Vaccinated Animals” (Vannier et al., 2007). BoHV-1 marker 
vaccines carrying a deletion of the gE gene were developed to prevent BoHV-1 infection. The use of 
these vaccines together with a serological detection of gE-specific antibodies in a BoHV-1 gE 
blocking ELISA allows the discrimination between infected and vaccinated animals (Muylkens et al., 
2007). Such scheme was developed because IBR is a widespread disease with severe economic 
impact in the European cattle industry. Contrarily to BoHV-1, CpHV-1 infection is not responsible 
for important issues of commercial interest which could justify a specific vaccine development. 
However, the serological evidence of CpHV-1 in France extended its geographic distribution in 
Mediterranean Europe and therefore CpHV-1 appears to be the most relevant ruminant 
alphaherpesvirus infection besides BoHV-1. Taking into account the close antigenic and genetic 
relationships between BoHV-1 and CpHV-1, a live attenuated gE-negative BoHV-1 vaccine was 
assessed in order to protect goats against CpHV-1 infection. The choice of this live vaccine was 
based on previous studies showing its efficacy and safety in cattle. Indeed, the live attenuated gE-
negative vaccine induced immunity within a few days after vaccination (Kaashoek and van 
Oirschot, 1996). Moreover, the immunity conferred by the live vaccine is large and includes 
humoral, cell-mediated and mucosal immune responses. 
 
The virulence of gE-negative BoHV-1 had not been determined in goats although natural 
BoHV-1 infection in goats was already reported (Tolari et al., 1990; Whetstone and Evermann, 
1988) and was successfully reproduced in experimental conditions (Six et al., 2001). The current 
safety assessment demonstrated the absence of adverse effects and local or systemic reactions. 
The difference of excretion between goats inoculated with either virulent BoHV-1 or gE-negative 
BoHV-1 vaccine was similar to that was described in cattle (Lemaire et al., 2000). Interestingly, 
viral excretion by nasal routes in goats suggested a similar pathogenesis of BoHV-1 infection as in 
cattle. Consequently, goats could be proposed as an alternative model to study virus host 
interactions. Unfortunately, the immune response seems to be different in the heterologous species 
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in regards to the weak level of serological reaction observed and therefore could not be analysed 
with this model. Moreover, the susceptibility of goats to a gE-negative BoHV-1 showed that gE is 
not an important component involved in the outcome of BoHV-1 infection in the heterologous host 
contrarily that was demonstrated for gC (Engels et al., 1992). This reasoning could be extended to 
gI because associated with gE in a functional complex allowing the cell-to-cell spread (Tyborowska 
et al., 2000; Baranowski et al., 1996). Together, these data demonstrated the utility to vaccinate 
goats with a live attenuated BoHV-1 gE-negative firstly to protect against CpHV-1 infection and 
secondly to avoid serological misdiagnosis in the rare cases where goats can be cross-infected with 
BoHV-1.  
 
The experimental challenge design of the efficacy assessment was similar to those having 
demonstrated a protection against intranasal CpHV-1 infection by a classical inactivated vaccine 
(Tempesta et al., 2001). In the preliminary experiment, when goats were immunised twice two 
weeks a part with the live attenuated gE-negative BoHV-1 vaccine, only a partial cross-protection 
was afforded against CpHV-1 intranasal challenge. Such nasal infection is rarely reported in natural 
conditions. The genital mucosa is the principal entry route as demonstrated by the isolation of 
CpHV-1 DNA in sacral ganglia of latently infected goats (Tempesta et al., 1999b). Therefore, the 
best method to assess the efficacy of the gE-negative BoHV-1 vaccine was to induce a CpHV-1 
intravaginal challenge which was even more severe in the present work than in previous studies 
(Tempesta et al., 2000; 2001; 2002). The most relevant parameter observed was the reduction of 
the clinical score. Associated with the absence of gE-negative BoHV-1 shedding after immunisation 
and a significant reduction of challenge virus excretion, the intranasal inoculation of a live 
attenuated gE-negative BoHV-1 vaccine appeared to be completely safe and induces both clinical 
and partial virological protection against CpHV-1 genital infection.  
 
Several studies have investigated the mucosal delivery of vaccines to protect the genital 
tract against sexually transmitted infectious diseases. The rationale for such studies is based 
mainly on the concept of a common mucosal immune system (Mestecky et al., 1994). Intranasal 
immunisation has been commonly used as a mean of mucosal vaccine delivery to provide immune 
protection to local and distal mucosal surfaces. It is an interesting alternative both for convenience 
and because the outcome of vaginal vaccination might be dependent on the time point in the 
oestral cycle for vaccine administration (Johansson et al., 2001). In human, the best known genital 
herpesvirus is human herpesvirus 2 (HHV-2) which shares the same peripheral pathogenesis and 
induces similar lesions than CpHV-1 in goats. Different degrees of protection against genital HHV-2 
challenge has been demonstrated after intranasal immunisation with adenovirus vectors expressing 
HHV-2 gB (Gallichan and Rosenthal, 1998), live attenuated HHV-2 strains (Parr and Parr, 1999), or 
plasmid DNA encoding HHV-2 gB (Kuklin et al., 1997). To date no treatment is available to prevent 
the disease induced by HHV-2. CpHV-1 infection of goats could be a useful model to assess vaccine 
prototypes against HHV-2 infection as already done for the development of antiviral therapy 
(Tempesta et al., 2007a). 
 
The mechanism inducing the genital protection observed after intranasal immunisation 
was investigated in mice following genital HHV-2 challenge. In vaginal secretions of immunised 
mice, neutralising antibodies are mainly IgG that is different than in upper respiratory tract where 
protective antibodies are secretory IgA. The importance of these latter for protective immunity in 
the upper respiratory tract led to the hypothesis that a strong IgA response is needed to raise an 
optimal immune protection in the female genital tract. Thus, it was demonstrated that the 
intranasal immunisation, more than immunisation at any other IgA inductive site, has the potential 
to induce better protection against genital infections because of its ability to induce IgA responses 
there (Parr and Parr, 1994; 1997; Murphy et al., 1999). Recently, an inactivated CpHV-1 vaccine in 
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association with the heat-labile enterotoxin of Escherichia coli LTK63 has been demonstrated to 
induce a strong protection against CpHV-1 genital infection. In this experiment, virus-specific 
mucosal IgA showed a progressive increasing level starting from the first immunisation to reach a 
peak after the second immunisation, with a booster post-challenge (Tempesta et al., 2007b). In 
regard to this result, the likely explanation of the genital protection observed in the current study 
would be a consequence of the induction of a specific IgA response in goat vaginal secretions.  
 
The key of the vaccination described in third and fourth studies was the antigenic and 
genetic relationship between BoHV-1 and CpHV-1. Such heterologous vaccination through the 
species barrier with an already licensed vaccine meets the “cascade” principle and the concept of 
“minor use - minor species” recently pointed out by the working party of immunological products of 
the European agency for the evaluation of medicinal products (Committee for Veterinary Medicinal 
Products, 2004). A minor species includes a wide range of animals other than cattle, horses, pigs, 
chickens, turkeys, dogs and cats which are classified as major species. Despite its importance in 
agriculture, goat is considered as a “minor species” and drugs to treat it are included in the 
category of “minor use” drugs. There are few approved drugs available for “minor use”, but efforts 
to increase their number are being pursued on two fronts: through new legislation and through 
research partnerships. The protection of goats against CpHV-1 described in the present work 
illustrates these objectives. Nevertheless, the treatment of minor species is of an important animal 
health concern. However, the biosafety issue of such vaccination has to be assessed. As for 
example, the massive use of a live attenuated gE-negative BoHV-1 vaccine raises the question of 
the risk of recombination between the vaccinal strain, wild type BoHV-1 strains and related viruses. 
About cross-infection of goats with BoHV-1, the risk of recombination between BoHV-1 and CpHV-1 
appears limited because no recombinant virus was detected in vitro between these two viruses 
(Meurens, 2004). The major requirements of the European Pharmacopoeia for registration of 
vaccines, a significant reduction of clinical signs and virus shedding, is met and the live attenuated 
gE-negative BoHV-1 vaccine could be used in goats illustrating the concept “minor use - minor 
species”. 
 
In conclusion, this work contributed to the knowledge of ruminant alphaherpesviruses 
related to BoHV-1. Further molecular studies should investigate the ruminant alphaherpesvirus 
history and evolution. The isolation of CvHV-1 in a free ranging red deer and the serological 
detection of CpHV-1 in goats demonstrated that each BoHV-1 related virus is closely associated 
with its specific host. However, a continuous attention has to be paid because ruminant hosts are 
still potential reservoirs of BoHV-1. In this context, the distribution of ruminant alphaherpesviruses 
in Europe has to be studied in more details especially in wild ruminant populations. The use of 
BoHV-1 gB blocking ELISA should be currently the best serological tool to detect such infections as 
for example CvHV-2 in reindeer and BuHV-1 in buffaloes. Nevertheless, it is still of interest to study 
the antigenic relationship in this viral cluster in order to develop a serological method able to 
clearly discriminate ruminant alphaherpesvirus infections.  
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Introduction 
 
Herpesviruses have mainly co-evolved with their hosts for millions of years. 
Consequently, different related host species may have been infected by various genetically related 
herpesviruses. Illustrating this concept, several ruminant alphaherpesviruses have been shown to 
form a cluster of viruses closely related to bovine herpesvirus 1 (BoHV-1). This latter virus, 
prototype of this cluster, is a major pathogen in cattle associated with various clinical 
manifestations including infectious bovine rhinotracheitis (IBR) and infectious pustular 
vulvovaginitis (IPV). IBR is a disease of major economic concern in many parts of the world and 
especially in Europe, both in European countries where this viral infection has been eradicated and 
in those where the control of IBR is currently or will be undertaken. The massive use of vaccination 
allowed the reduction of the number of clinical IBR cases. 
 
However, the existence of alphaherpesviruses closely related to BoHV-1 has to be taken 
into account in IBR control. The following viruses can be distinguished: bovine herpesvirus 5 
(BoHV-5) responsible for severe meningo-encephalitis in calves, bubaline herpesvirus 1 (BuHV-1) 
inducing a subclinical genital infection in water buffalo (Bubalus bubalis), caprine herpesvirus 1 
(CpHV-1) causing systemic disease in young kids and abortion in adult goats, cervid herpesvirus 1 
(CvHV-1) responsible of severe ocular syndrome in red deer (Cervus elaphus), cervid herpesvirus 2 
(CvHV-2) and elk herpesvirus 1 (ElkHV-1), which induce a subclinical genital infection respectively 
in  reindeer (Rangifer tarandus) and elk (Cervus canadensis). Ruminant alphaherpesviruses related 
to BoHV-1 are antigenically and genetically closely related to each other. Their common biological 
properties allow heterologous infection and therefore the crossing of the species barrier. Thus, 
experimental cross-infection studies show that BoHV-1 is able to infect buffalo, goats, red deer, 
reindeer and sheep. Inversely, bovines are susceptible to BoHV-5, CpHV-1, CvHV-1 and CvHV-2. 
 
Consequently, the main objective of the present work is dedicated to afford a better 
knowledge of the interaction between alphaherpesviruses and their ruminant hosts. To meet the 
objective, two approaches have been developed: the study of the viral diversity aiming to extend 
both epidemiological and virological data about ruminant alphaherpesviruses related to BoHV-1 and 
the study of the heterologous protection aiming to protect a minor ruminant species against 
infections with BoHV-1 related alphaherpesviruses. 
 
 
Results 
 
Illustrating the issues associated to the distribution of ruminant alphaherpesviruses 
related to BoHV-1, an original situation has been described in Belgium. In 2001 and 2002, 28.9% 
of red deer have been detected seropositive to BoHV-1. In absence of contact between cattle and 
red deer, it has been suggested that a virus related to BoHV-1 was spreading in the Belgian red 
deer population. Nasal and genital swabs have been collected in hunted red deer and have been 
inoculated onto bovine kidney cells in order to isolate the viral agent responsible of the 
seropositivity of Belgian red deer. A viral isolate was detected from nasal sample of a male fawn 
hunted in the Anlier forest. The analysis of a 443 bp sequence of glycoprotein B demonstrated that 
the viral isolate was related to ruminant alphaherpesviruses and especially CvHV-1. This red deer 
alphaherpesvirus was then characterised by comparison with the other ruminant 
alphaherpesviruses. The viral isolate was antigenically distinct from the other related viruses 
although it presumably possesses some common epitopes with CvHV-1 and CvHV-2 because a 
weak reaction was detected in immunofluorescence. The analysis of BamHI and BstEII restriction 
profiles showed ruminant alphaherpesviruses and especially the viral isolate can be distinguished 
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by their genomic profile. A phylogenetic analysis of these related viruses has been also undertaken. 
Partial sequence data from UL27 encoding the glycoprotein B (gB) and US8 encoding the 
glycoprotein E (gE) have been sequenced. This analysis has confirmed that the viral isolate and 
related viruses constituted a consistent cluster within the subfamily of alphaherpesviruses. BoHV-5 
and BuHV-1 clustered together and are the most closely related to BoHV-1 1.1, BoHV-1 1.2. CpHV-
1 is the most diverging ruminant alphaherpesvirus. CvHV-1 is more related to BoHV-1 than ElkHV-
1 and CvHV-2 which is the most closely related to CpHV-1. The Anlier isolate clustered with CvHV-1 
and the most closely related virus is ElkHV-1. The viral isolate is indeed a different CvHV-1 strain 
than the CvHV-1 Banffshire 82 strain. Taken together, these data report the first isolation of a 
ruminant alphaherpesvirus in wild fauna, which has been named CvHV-1 Anlier.  
 
This isolation demonstrates that a ruminant can be identified as positive to BoHV-1 while 
it is infected with another alphaherpesvirus. In France, cattle purchased from herds so-called “IBR-
free status” are sporadically identified as seropositive to BoHV-1. Among other hypotheses, the 
likely explanation for this “false” seropositivity would be a cross-infection with a related 
alphaherpesvirus. The most “plausible” virus leading to such diagnosis misinterpretation is CpHV-1 
infecting goat. In this context, an epidemiologic study has been performed in order to determine if 
a CpHV-1 infection was present in France. The analysis of 2,548 serums in BoHV-1 gB blocking 
ELISA revealed that a ruminant alphaherpesvirus infection was spreading in Corse-du-Sud while no 
goat was detected positive in Dordogne and Vendée. Taking into account the results obtained in 
Dordogne and Vendée, a specificity of 100% has been measured for the BoHV-1 gB blocking ELISA. 
By testing serums from goats experimentally infected with CpHV-1, the sensibility has been 
calculated to 93.5%. The analysis in BoHV-1 gE blocking ELISA showed that 22.6% of gB-
seropositive serums were also gE-seropositive. The BoHV-1 gE blocking ELISA was therefore not 
able to differentiate between BoHV-1 and CpHV-1 infections. However, the analysis of serums in 
cross seroneutralisation has strongly identified antibodies against CpHV-1 in gB-positive serums. 
The presence of CpHV-1 in Corse-du-Sud associated to high prevalence (61.9%) in all analysed 
flocks extends the number of countries infected with CpHV-1. Moreover, the difference observed 
between Corse-du-Sud and Dordogne and Vendée suggests that CpHV-1 is more prevalent in 
Mediterranean regions or countries than in Central or northern Europe. 
 
CpHV-1 therefore appears as the BoHV-1 related virus which has the highest economic 
concern in Europe. Goat is a species defined as minor and the veterinary medicine industry has no 
commercial interest toward vaccine development protecting this species against CpHV-1. As BoHV-
1 and CpHV-1 are antigenically and genetically related, a live attenuated BoHV-1 vaccine carrying a 
deletion in the gene encoding gE could protect goats against CpHV-1 infection. The vaccine safety 
has been assessed by intranasal inoculation of either BoHV-1 virulent strain or gE deleted BoHV-1 
vaccine in two groups of two goats. The length of viral excretion and the peak viral titre have been 
decreased in the immunised group. In order to assess the vaccine efficacy, a group of goats was 
immunised twice two weeks a part with the vaccine while a control group was kept uninoculated. 
Four weeks later, immunised and control goats have been intranasally challenged with CpHV-1. A 
decrease of the peak viral titre was observed in immunised goats. However, the viral excretion 
lengthened two days more than in control group. It is concluded that this live attenuated gE-
negative BoHV-1 vaccine induces a partial cross-protection against a CpHV-1 nasal infection in 
goats.   
 
In regards to the results obtained in this preliminary experiment, the vaccine has been 
assessed against a CpHV-1 genital infection which is the natural route of infection in goats. To 
reach this goal, a group of goats was immunised twice three weeks a part with the gE-negative 
BoHV-1 vaccine followed by a subsequent CpHV-1 intravaginal challenge. To analyse the safety and 
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the efficacy of this marker vaccine, two groups of goats served as controls: one was immunised 
with a virulent CpHV-1 and one was kept uninoculated until the challenge. The vaccine did not 
induce any undesirable local or systemic reaction and goats did not excrete gE-negative BoHV-1. 
After challenge, a significant reduction in disease severity was observed in immunised goats. 
Moreover, goats immunised with either gE-negative BoHV-1 or CpHV-1 exhibited a significant 
reduction in the length and the peak of viral excretion. Antibodies neutralising both BoHV-1 and 
CpHV-1 were raised in immunised goats. These data show that the intranasal application of a live 
attenuated gE-negative BoHV-1 vaccine is able to afford a clinical protection and a reduction of 
virus excretion in goats challenged by a CpHV-1 genital infection.  
 
 
Conclusions 
 
This study has been performed in order to afford a better knowledge of the interaction 
between alphaherpesviruses and their ruminant hosts. The antigenic, genetic and genomic 
relationships existing between BoHV-1 and ruminant alphaherpesviruses have been analysed. It 
has been demonstrated that these viruses constitute a strong cluster within the subfamily of 
alphaherpesviruses. The exact knowledge of the evolutionary relationships among these viruses 
request complete genome sequencing but this analysis is complicated by the large size of 
herpesvirus genome. Another possibility would be to compare different regions distributed along 
the genome of each virus as demonstrated by the study of the BoHV-4 history evolution (Dewals et 
al., 2006). Such analysis could bring interesting data about recombination and transmission events 
that occurred in the past between herpesviruses and their ruminant species. Nevertheless, the 
present work gives a contribution to the knowledge of the natural history of the cluster of ruminant 
alphaherpesviruses related to BoHV-1. Thus, the first isolation of CvHV-1 in a free-ranging red deer 
linked to the knowledge of the evolution of red deer populations in Europe allowed an interesting 
hypothesis about the origin of this virus. In regards of the observed prevalence and the presence of 
red deer over large area, this virus could be responsible of an endemic infection spreading in 
Europe. This virus may have been introduced after European red deer importation to constitute the 
initial stocks of Scottish farms. Consequently, CvHV-1 Anlier strain could be the ancestor of the 
Scottish CvHV-1 Banffshire 82 strain. However, molecular epidemiologic study of several isolates of 
the two strains is required to firmly assess this hypothesis. 
 
This isolation has demonstrated that misinterpretation of the serologic status of ruminant 
can be observed; the Belgian red deer was not infected with BoHV-1 but with its own herpesvirus. 
These difficulties of interpretation are encountered in France in bovines free of IBR and detected 
later as positive in serology. As BoHV-5 and ElkHV-1 have not been identified in Europe, that there 
is a very few number of buffalo farms in France, and that CvHV-1 and CvHV-2 transmission to 
bovine would be exceptional, the only virus that could be responsible of misdiagnosis in France is 
CpHV-1. Indeed, goats and cattle can be in close contact in some field situations. The results 
obtained in the second study did not support this hypothesis. Indeed, CpHV-1 infection is either 
absent or at a very low prevalence in continental France. Contrarily, a very high seroprevalence of 
CpHV-1 was measured in the Corse-du-Sud department. In Corsica, the contact between cattle and 
goats is very limited because flocks and herds are not mixed. Therefore, the transmission of CpHV-
1 from goats to cattle would be only exceptional, such cross-infection being very rare, and a BoHV-
1 infection in goats is not likely to occur. As the current sampling is restricted to Dordogne and 
Vendée, a particular attention to CpHV-1 has to be paid in continental France and especially in the 
Mediterranean region. Such monitoring can be performed with the BoHV-1 gB blocking ELISA which 
has been validated in the current study.  
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The CpHV-1 infection is therefore extended to the entire Mediterranean region and 
appears to be the most relevant ruminant alphaherpesvirus infection besides BoHV-1. In this 
context, it is necessary to protect goats to reduce the CpHV-1 circulation in the caprine population 
and economic concerns caused by this infection. The preliminary assessment of the live attenuated 
BoHV-1 vaccine carrying a deletion in the gene encoding gE has shown that goats could respond to 
such vaccination. As goat is completely susceptible to BoHV-1, this species could also be used as 
an experimental model to study the in vivo BoHV-1 properties. A partial efficacy against CpHV-1 
nasal infection has been observed. Moreover, the gE-negative BoHV-1 vaccine has been assessed 
against CpHV-1 genital infection which is the natural route of infection in goats. The intranasal use 
of a gE-negative BoHV-1 vaccine enabled a clinical protection and a significant reduction of the 
viral excretion in goats infected genitally with CpHV-1. These results demonstrate that nasal 
mucosa can serve as an efficient site for the induction of a specific protective response in the 
genital tract. In humans, several mechanisms are proposed to explain such immune induction 
involving antibody secreting cells and leading to specific IgA and IgG responses. Such mechanisms 
could be involved in the observed response in vaccinated goats but were not analysed in the 
current study. The biosafety of such cross protection induced with BoHV-1 vaccine against CpHV-1 
has also to be considered. Indeed, viruses can be established in a latent state. In bovine, 
experiments have shown that gE-negative viruses are less reactivated and reexcreted than wild 
viruses. Consequently, the risk of reactivation and reexcretion in goats is therefore very low. 
Otherwise, the emergence of recombinant viruses between CpHV-1 and BoHV-1 after cross 
infection in goats has to be discussed. Among the cluster of ruminant alphaherpesviruses related to 
BoHV-1, only two recombinant viruses between BoHV-1 and BoHV-5 were isolated, and no 
recombinant between BoHV-1 and less closely related CpHV-1 was detected in vitro. Consequently, 
the cross vaccination described here is likely to be completely safe. Moreover, the use of already 
licensed vaccine is interesting knowing that the development of new vaccines to protect minor 
species is of a weak interest for the pharmaceutical industry.  
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Introduction 
 
Les herpèsvirus ont principalement co-évolué avec leurs hôtes depuis des millions 
d’années. Par conséquent, différentes espèces hôtes apparentées ont pu être infectées avec des 
herpèsvirus génétiquement apparentés. Illustrant ce concept, il a été démontré que plusieurs 
alphaherpèsvirus de ruminants forment un groupe de virus proches de l’herpèsvirus bovin 1 
(BoHV-1). Ce dernier virus, prototype du groupe, est un pathogène majeur du bétail associé à 
différentes manifestations cliniques comprenant la rhinotrachéite infectieuse bovine (IBR) et la 
vulvovaginite infectieuse pustuleuse (IPV). L’IBR est une maladie à répercussion économique 
mondiale et plus spécialement en Europe, dont plusieurs états membres ont éradiqué cette 
infection virale ou entrepris un programme de contrôle de l’IBR. L’utilisation massive de la 
vaccination a permis une réduction significative du nombre de cas cliniques d’IBR. 
 
Cependant, l’existence d’alphaherpèsvirus étroitement apparentés au BoHV-1 doit être 
prise en considération dans les programmes de contrôle de l’IBR. On distingue l’herpèsvirus bovin 5 
(BoHV-5) responsable de méningo-encéphalites mortelles chez le veau, l’herpèsvirus du buffle 
(BuHV-1) qui induit une infection génitale subclinique chez le buffle d’eau (Bubalus bubalis), 
l’herpèsvirus caprin 1 (CpHV-1) causant une maladie généralisée chez le chevreau et des affections 
génitales chez la chèvre, l’herpèsvirus du cerf (CvHV-1) responsable d’une grave maladie oculaire 
chez le cerf (Cervus elaphus), les herpèsvirus du renne (CvHV-2) et du wapiti (ElkHV-1), qui 
induisent une infection génitale subclinique respectivement chez le renne (Rangifer tarandus) et 
chez le wapiti (Cervus canadensis). Les alphaherpèsvirus de ruminants apparentés au BoHV-1 sont 
antigéniquement et génétiquement proches entre eux. Leurs propriétés biologiques communes leur 
permet d’infecter des espèces hétérologues et donc de traverser la barrière d’espèce. Ainsi, des 
expériences d’infections croisées ont montré que le BoHV-1 était capable d’infecter le buffle, la 
chèvre, le cerf et le renne, ainsi que le mouton. Inversement, les bovins sont sensibles aux BoHV-
5, CpHV-1, CvHV-1 et CvHV-2. 
 
 Par conséquent, l’objectif principal de ce travail est d’apporter une meilleure 
connaissance de l’interaction entre les alphaherpèsvirus et leurs hôtes ruminants. Afin d’atteindre 
cet objectif, deux approches ont été développées : l’étude de la diversité virale ayant pour but 
d’étendre les données épidémiologiques et virologiques concernant les alphaherpèsvirus de 
ruminants apparentés au BoHV-1, et l’étude de la vaccination hétérologue ayant pour but de 
protéger les espèces de ruminants considérées comme mineures contre l’infection par les 
alphaherpèsvirus apparentés au BoHV-1. 
 
 
Résultats 
 
Illustrant la problématique liée à la distribution des alphaherpèsvirus de ruminants 
apparentés au BoHV-1, une situation originale a été décrite en Belgique. En 2001 et 2002, 28,9% 
de cerfs ont été détectés séropositifs envers le BoHV-1. En l’absence de contact entre le bétail et 
les cerfs, il a été suggéré qu’un virus apparenté au BoHV-1 circulait dans la population belge de 
cerfs. Des écouvillons nasaux et génitaux ont été prélevés sur des cerfs tués sur chasse et ont été 
inoculés à des cellules rénales bovines afin d’isoler l’agent viral responsable de la séropositivité des 
cerfs belges. Un isolat viral a été détecté à partir du prélèvement nasal d’un faon male tué dans la 
forêt d’Anlier. L’analyse d’une séquence de 443 pb de la glycoprotéine B a montré que l’isolat viral 
était apparenté au groupe des alphaherpèsvirus de ruminants et plus spécialement au CvHV-1. Cet 
alphaherpèsvirus de cerf fut alors caractérisé par rapport aux autres alphaherpèsvirus de 
ruminants. L’isolat viral était différent des autres virus apparentés au niveau antigénique bien qu’il 
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possède certainement des épitopes en commun avec le CvHV-1 et le CvHV-2 car une faible réaction 
est détectée en immunofluorescence. L’analyse des profils de restriction par BamHI et BstEII a 
montré que les alphaherpèsvirus de ruminants et plus spécialement l’isolat viral pouvaient être 
différenciés par leurs profils génomiques. Une analyse phylogénétique des différents virus a 
également été entreprise. A cette fin, une région du gène UL27 codant la glycoprotéine B (gB) et 
une région du gène US8 codant la glycoprotéine E (gE) ont été séquencées. Cette analyse a 
confirmé que l’isolat viral et les virus apparentés formaient un groupe consistant au sein de la 
sous-famille des alphaherpèsvirus. Le BoHV-5 et le BuHV-1 se groupent ensemble et sont les virus 
les plus proches des sous-types 1 et 2 du BoHV-1. Le CpHV-1 est le virus le plus divergent au sein 
des alphaherpèsvirus de ruminants. Le CvHV-1 est plus apparenté au BoHV-1 que l’ElkHV-1 et le 
CvHV-2, ce dernier étant le plus proche du CpHV-1. L’isolat viral forme un groupe avec le CvHV-1 
et est en fait une souche de CvHV-1 différente de la souche de référence CvHV-1 Banffshire 82. 
L’ensemble de ces résultats décrit le premier isolement d’un alphaherpèsvirus de ruminant en 
faune sauvage, qui a été dénommé CvHV-1 Anlier.         
   
Cet isolement démontre qu’un ruminant peut être identifié comme positif envers le BoHV-
1 alors qu’il est infecté par un autre alphaherpèsvirus. En France, certains bovins issus d’élevages 
possédant une appellation « indemnes d’IBR » sont sporadiquement révélés positifs à l’achat. Une 
explication de cette fausse séropositivité serait une infection croisée avec un alphaherpèsvirus 
apparenté. Le virus le plus plausible causant ce type d’erreur de diagnostic est le CpHV-1 infectant 
la chèvre. Dans ce cadre, une enquête épidémiologique a été réalisée pour déterminer si une 
infection à CpHV-1 était présente en France. L’analyse de 2548 sérums par un ELISA de blocage 
BoHV-1 gB a révélé qu’une infection à alphaherpèsvirus de ruminant circulait en Corse-du-Sud 
alors qu’aucune chèvre n’était détectée positive en Dordogne et en Vendée. Sur base des résultats 
obtenus en Dordogne et Vendée, une spécificité de 100% a été mesurée pour l’ELISA de blocage 
BoHV-1 gB. En testant des sérums de chèvres expérimentalement infectées avec le CpHV-1, la 
sensibilité du test a été calculée à 93,5%. L’analyse par un ELISA de blocage BoHV-1 gE a montré 
que 22,6% des sérums gB-positifs étaient également gE-positifs. L’ELISA gE n’était donc pas 
capable de différencier les infections à BoHV-1 et à CpHV-1. Cependant, une analyse de ces sérums 
par séroneutralisation croisée a formellement identifié la présence d’anticorps dirigés contre le 
CpHV-1 dans les sérums positifs envers gB. La présence du CpHV-1 en Corse-du-Sud, supportée 
par une prévalence élevée (61,9%) dans toutes les chèvreries analysées, étend le nombre de pays 
infectés par le CpHV-1. De plus, la différence observée entre la Corse-du-Sud et la Dordogne et la 
Vendée suggère que le CpHV-1 est plus prévalent dans les régions ou pays méditerranéens qu’en 
Europe centrale ou du nord. 
 
Le CpHV-1 apparaît donc comme le virus apparenté au BoHV-1 qui a la plus grande 
importance épidémiologique en Europe. La chèvre est une espèce qualifiée de mineure et l’industrie 
du médicament vétérinaire ne montre pas d’intérêt à développer un vaccin protégeant cette espèce 
contre le CpHV-1. Comme le BoHV-1 et le CpHV-1 sont antigéniquement et génétiquement 
apparentés, un vaccin vivant atténué porteur d’une délétion dans le gène codant la gE du BoHV-1 
pourrait protéger la chèvre contre l’infection à CpHV-1. L’innocuité du vaccin a été évaluée par 
l’inoculation intranasale d’une souche sauvage de BoHV-1 ou du vaccin BoHV-1 délété de la gE 
dans deux groupes de chèvres. La durée d’excrétion virale et le pic du titre viral ont été réduits 
dans le groupe vacciné. Afin d’évaluer l’efficacité du vaccin, un groupe de chèvres a été immunisé à 
deux semaines d’intervalle avec le vaccin alors qu’un groupe, servant de contrôle, n’a pas été 
inoculé. Quatre semaines plus tard, les chèvres immunisées et contrôles ont été soumis à une 
infection nasale par le CpHV-1. Une diminution du pic du titre viral de l’ordre de deux log10 a été 
observée chez les chèvres immunisées. Cependant, l’excrétion virale a duré deux jours de plus 
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qu’au sein du groupe contrôle. Il en ressort donc que ce vaccin vivant délété de la gE du BoHV-1 
induit une protection croisée partielle contre l’infection nasale de la chèvre par le CpHV-1.  
 
Sur base des résultats issus de cette expérience préliminaire, le vaccin a été testé contre 
une infection génitale par le CpHV-1, qui est la voie naturelle d’infection chez la chèvre. A cette fin, 
un groupe de chèvres a été immunisé deux fois à trois semaines d’intervalle avec le vaccin BoHV-1 
gE-négatif suivi par une épreuve virulente avec le CpHV-1 inoculé par voie intravaginale. Pour 
analyser l’innocuité et l’efficacité du vaccin, deux groupes de chèvres ont servi de contrôle: un 
groupe immunisé par voie intranasale avec le CpHV-1 et un groupe non inoculé jusqu’à l’épreuve 
virulente. Le vaccin n’a pas induit de réactions locale ou généralisée indésirables et les chèvres 
n’ont pas excrété le virus vaccinal BoHV-1 gE-négatif. Après l’épreuve virulente, une diminution 
significative des signes cliniques a été observée chez les chèvres vaccinées. De plus, les chèvres 
immunisées avec le vaccin ou le CpHV-1 ont montré une diminution de la durée et du pic 
d’excrétion virale. Des anticorps neutralisant à la fois le BoHV-1 et le CpHV-1 ont également été 
détectés. L’ensemble de ces résultats montre que l’application intranasale de ce vaccin vivant 
atténué délété de la gE du BoHV-1 apporte une protection clinique et une diminution de l’excrétion 
virale chez les chèvres infectées par le CpHV-1 par la voie génitale.  
 
          
Conclusions 
 
Ce travail a été réalisé afin d’obtenir une meilleure connaissance des interactions entre les 
alphaherpèsvirus et leurs hôtes ruminants. Les relations antigéniques, génétiques et génomiques 
existant entre le BoHV-1 et les alphaherpèsvirus de ruminants ont été analysées. Il a été démontré 
notamment que ces virus formaient un groupe consistant au sein de la sous-famille des 
alphaherpèsvirus. La relation évolutive exacte entre ces virus apparentés requiert certainement un 
séquençage complet du génome. Cette analyse est compliquée à mettre en œuvre car les 
herpèsvirus possèdent un génome de grande taille. Cependant, la comparaison de différentes 
régions au niveau du génome pourrait être envisagée et permettrait d’obtenir des informations 
intéressantes concernant les événements de recombinaison et de transmission qui se sont produits 
entre ces virus. Toutefois, les données obtenues ont permis de contribuer à la connaissance de 
l’histoire naturelle de ce groupe d’alphaherpèsvirus de ruminants. Ainsi, le premier isolement de 
CvHV-1 chez un cerf sauvage associé à la connaissance de l’évolution des populations de cerfs en 
Europe permet d’émettre une hypothèse intéressante à propos de l’origine de ce virus. En effet, en 
tenant compte des prévalences observées dans les pays de l’Est et la présence de cerfs sur de 
grandes étendues en Europe, le CvHV-1 Anlier pourrait être responsable d’une infection endémique 
circulant de l’Europe de l’Est vers l’Europe occidentale. Ce virus aurait pu être introduit après 
importation de cerfs européens afin de constituer les stocks initiaux dans les fermes écossaises. 
Par conséquent, le CvHV-1 Anlier pourrait être l’ancêtre du CvHV-1 Banffshire 82 isolé en Ecosse. 
Cependant, une étude d’épidémiologie moléculaire de plusieurs isolats est requise pour confirmer 
cette hypothèse.  
 
Cet isolement a montré que des erreurs d’interprétation quant au statut sérologique des 
ruminants peuvent survenir, le cerf belge n’était pas infecté par le BoHV-1 mais bien par son 
herpèsvirus spécifique. Ces difficultés d’interprétation sont reproduites en France chez des bovins 
certifiés indemnes d’IBR et détectés par la suite positifs en sérologie. Etant donné que le BoHV-5 et 
l’ElkHV-1 n’ont pas été identifiés en Europe, que les fermes de buffles sensibles au BuHV-1 sont 
extrêmement rares en France, et que la transmission du CvHV-1 ou du CvHV-2 chez le bovin serait 
exceptionnelle, le seul virus apparenté au BoHV-1 pouvant être responsable d’erreur de diagnostic 
est le CpHV-1, principalement dû au fait que les chèvres et le bétail pourraient être en contact sur 
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le terrain. Les résultats obtenus lors de l’analyse séroépidémiologique de l’infection à CpHV-1 en 
France ne supportent pas cette hypothèse. En effet, l’infection à CpHV-1 soit n’est pas présente, 
soit est présente à une très faible prévalence en France continentale. Par contre, des prévalences 
élevées ont été mesurées en Corse-du-Sud. Cependant, en Corse, le contact entre les chèvres et 
les bovins apparaît très limité car les élevages ne sont pas mélangés. La transmission du CpHV-1 
au bovin serait très certainement exceptionnelle. Etant donné que l’échantillonnage présent était 
restreint à la Dordogne et la Vendée, il faut rester vigilant vis à vis de cette infection en France 
continentale et plus spécialement dans la région méditerranéenne, le CpHV-1 ayant été identifié en 
Corse. Ce monitoring peut être réalisé à l’aide de l’ELISA de blocage BoHV-1 gB qui a été validé 
pour la détection du CpHV-1 lors de cette étude. 
 
      L’infection du CpHV-1 est donc étendue à l’ensemble de la région méditerranéenne et 
apparaît être l’infection à alphaherpèsvirus de ruminants épidémiologiquement la plus importante à 
côté du BoHV-1. Dans ce contexte, il est nécessaire de protéger les chèvres afin de limiter la 
circulation du CpHV-1 au sein de la population caprine et les répercussions économiques 
provoquées par cette infection. L’évaluation préliminaire du vaccin vivant atténué porteur d’une 
délétion dans le gène codant la gE a montré que la chèvre était réceptive à ce type de vaccination. 
Etant donné que la chèvre est complètement sensible au BoHV-1, cette espèce pourrait être 
utilisée comme modèle expérimental de moindre coût pour l’étude des propriétés in vivo du BoHV-
1. Une efficacité partielle contre l’infection nasale par le CpHV-1 a été observée. De plus, le vaccin 
BoHV-1 gE-négatif a été évalué contre l’infection génitale par le CpHV-1 qui est la voie naturelle 
d’infection chez la chèvre. L’administration intranasale de ce vaccin vivant atténué a induit une 
protection clinique et une diminution significative de l’excrétion virale chez les chèvres infectées 
par voie génitale avec le CpHV-1. Ceci montre que la muqueuse nasale peut être un site efficace 
pour l’induction d’une réponse protectrice spécifique dans le tractus génital. Chez l’homme, 
plusieurs mécanismes sont proposés pour expliquer cette induction d’immunité impliquant des 
cellules sécrétrices d’anticorps spécifiques et conduisant à des réponses IgA et IgG. Ces 
mécanismes pourraient intervenir dans la réponse observée chez les chèvres vaccinées mais n’ont 
pas été investigué lors de ce travail. La protection croisée induite par un vaccin BoHV-1 contre une 
infection par le CpHV-1 pose aussi des questions de biosécurité. Il faut considérer un éventuel 
établissement du virus sous forme latente. Des expériences chez les bovins ont montré que les 
virus BoHV-1 gE-négatif sont moins réactivés et réexcrétés que les virus BoHV-1 sauvages. Par 
conséquent, le risque de réactivation et de réexcrétion chez la chèvre doit être très faible. La 
question de l’émergence de recombinants entre le CpHV-1 et le BoHV-1 après infection croisée 
chez la chèvre doit également être posée. Des expériences de co-infection entre les différents 
alphaherpèsvirus de ruminants ont permis l’isolement in vitro de recombinants entre le BoHV-1 et 
le BoHV-5 mais aucun recombinants entre le BoHV-1 et le CpHV-1 n’ont été détectés. Cette 
vaccination croisée apparaît donc être complètement sûre. De plus, l’utilisation d’un vaccin déjà 
commercialisé est intéressante sachant que le développement de nouveaux vaccins pour protéger 
les espèces mineures est de faible intérêt pour l’industrie pharmaceutique. 
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Introduzione 
 
I virus erpetici si sono per la maggior parte co-evoluti con i loro ospiti nell’arco di milioni 
di anni. Di conseguenza, specie ospiti correlate possono essere infettate da diversi herpesvirus 
geneticamente correlati. E’ stato osservato che diversi alphaherpesvirus dei ruminanti hanno 
formato un gruppo di virus strettamente correlati a bovine herpesvirus 1 (BoHV-1). Quest’ultimo, 
che rappresenta il virus prototipo di questo gruppo, è uno dei patogeni più importanti del bovino, 
associato a diverse manifestazioni cliniche tra cui la rinotracheite infettiva bovina (IBR),  e la 
vulvovaginite pustolosa infettiva (IPV). L’IBR è una malattia economicamente molto importante in 
diverse parti del mondo e soprattutto in Europa sia in quei paesi dove l’infezione è stata eradicata 
sia in quelli in cui sono in corso o stanno per essere intrapresi piani di controllo. Il massiccio uso 
delle vaccinazioni ha permesso di ridurre il numero dei casi clinici di IBR. 
 
Tuttavia, nell’ottica del controllo dell’IBR deve essere tenuta in conto l’esistenza di 
alphaherpesvirus strettamente correlati a BoHV-1. Sono da prendere in considerazione bovine 
herpesvirus 5 (BoHV-5), responsabile di meningoencefalite nei vitelli, bubaline herpesvirus 1 
(BuHV-1) che causa un’infezione genitale a decorso subclinico nel bufalo d’acqua (Bubalus bubalis), 
caprine herpesvirus 1 (CpHV-1) che causa un’infezione sistemica nei capretti ed aborto nelle capre 
adulte, cervid herpesvirus 1 (CvHV-1) responsabile di una grave sindrome oculare nel cervo 
(Cervus elaphus), cervid herpesvirus 2 (CvHV-2) ed elk herpesvirus 1 (ElkHV-1) che inducono 
un’infezione genitale a decorso subclinico rispettivamente  nella renna (Rangifer tarandus) e 
nell’alce (Cervus canadensis). Gli alphaherpesvirus dei ruminanti correlati a BoHV-1 sono 
antigenicamente e geneticamente correlati tra loro. Le proprietà biologiche che li accomunano 
permettono loro di infettare specie eterologhe e quindi di  superare le barriere di specie. In tal 
senso, studi sperimentali di infezione crociata hanno dimostrato che BoHV-1 è in grado di infettare 
i bufali. All’inverso i bovini sono recettivi all’infezione da BoHV-5, CpHV-1, CvHV-1 and CvHV-2. 
 
Di conseguenza, l’obiettivo principale del presente lavoro è quello di dare un contributo 
per una più approfondita conoscenza dell’interazione tra gli alphavirus e i loro ospiti ruminanti. 
Sono stati utilizzati due approcci: lo studio della diversità dei virus allo scopo di fornire ulteriori dati 
virologici ed epidemiologici riguardo gli alphaherpesvirus dei ruminanti correlati a BoHV-1 e lo 
studio della protezione eterologa al fine di proteggere le specie ruminanti minori nei confronti delle 
infezioni da herpesvirus correlati a BoHV-1. 
 
 
Risultati 
 
Una situazione particolare è stata descritta in Belgio che può illustrare le problematiche 
associate alla distribuzione degli alphaherpesvirus dei ruminanti correlati a BoHV-1. Nel 2001 e 
2002, il 28.9% dei cervi è risultato sierologicamente positivo nei confronti di BoHV-1. In 
considerazione della mancanza di contatto tra bovini e cervi è stato ipotizzato che un virus 
correlato a BoHV-1 stesse diffondendo nella popolazione cervina del Belgio. Tamponi nasali e 
genitali prelevati da cervi cacciati sono stati inoculati in colture di cellule renali di bovino al fine di 
isolare il virus responsabile della sieropositività dei cervi belgi. Un virus è stato isolato da un 
campione nasale di un daino maschio cacciato nella foresta di Anlier. L’analisi di una sequenza di 
442 bp della glicoproteina B ha dimostrato che il virus isolato era correlato agli alphaherpesvirus 
dei ruminanti, soprattutto a CvHV-1. L’herpesvirus del cervo è stato poi caratterizzato sulla base 
del confronto con gli altri herpesvirus dei ruminanti. Il virus era antigenicamente distinto dagli altri 
virus correlati benché presumibilmente condividesse alcuni epitopi con CvHV-1 e CvHV-2 come 
evidenziato da una debole reattività al test di immunofluorescenza. L’analisi di restrizione con gli 
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enzimi BamHI e BstEII ha permesso la differenziazione dei diversi alphaherpesvirus dei ruminanti, 
soprattutto del virus isolato, sulla base dei loro profili genomici. E’ stata effettuata l’analisi 
filogenetica di questi virus correlati. In quest’ottica sono stati parzialmente sequenziati il segmento 
UL27 che codifica la glicoproteina B (gB)  e il segmento US8 che codifica la glicoproteina E (gE). 
Tale analisi ha confermato che sia il virus isolato che i virus correlati costituiscono un gruppo 
omogeneo all’interno della sottofamiglia degli alphaherpesvirus. BoHV-5 and BuHV-1 fanno parte 
dello stesso gruppo e sono gli alphaherpesvirus maggiormente correlati a BoHV-1 1.1 e BoHV-1 
1.2. CpHV-1 è l’alphaherpesvirus dei ruminanti che maggiormente si discosta. CvHV-1 è più 
correlato a BoHV-1 rispetto a ElkHV-1 e CvHV-2 che è il virus più strettamente correlato a CpHV-1. 
L’isolato di Anlier è raggruppato con CvHV-1 ed il virus più strettamente correlato è ElKHV-1. Il 
virus isolato è un ceppo CvHV-1 diverso dal ceppo CvHV-1 Banffshire 82. Nell’insieme, questi dati 
descrivono il primo isolamento di un alphaherpesvirus dei ruminanti nella fauna selvatica, 
denominato poi ceppo Anlier di CvHV-1.  
 
Questo isolamento dimostra che un bovino può essere identificato come postivo nei 
confronti di BoHV-1 mentre in realtà è infetto con un altro alphaherpesvirus. In Francia, bovini 
acquistati da allevamenti denominati “indenni da IBR” sono sporadicamente identificati come 
sieropositivi nei confronti di BoHV-1. Tra le varie ipotesi che possono essere formulate, la 
spiegazione più probabile per questa “falsa” sieropositività potrebbe essere un’ infezione crociata 
con un alphaherpesvirus correlato. Il virus maggiormente imputato di queste erronee 
interpretazioni diagnostiche è CpHV-1 che infetta le capre. In questo contesto è stato effettuato 
uno studio epidemiologico per valutare se in Francia è presente l’infezione da CpHV-1. L’analisi di 
2,548 sieri mediante un test gB blocking Elisa per BoHV-1 ha rivelato che un’infezione da  
alphaherpesvirus dei ruminanti si stava diffondendo nella Corsica del Sud mentre era 
completamente assente in Dordogne e Vendée. Tenendo conto dei risultati ottenuti in Dordogne e 
Vendée il test BoHV-1 gB blocking ELISA ha dimostrato una specificità del 100%. La sensibilità è 
stata calcolata del 93.5% quando sono stati testati i sieri di capre sperimentalmente infettate con 
CpHV-1. Il test BoHV-1 gE blocking Elisa ha dimostrato che il 22.6% dei sieri gB positivi era anche 
gE positivi. Il test BoHV-1 gE blocking ELISA non è stato in grado, quindi, di differenziare le 
infezioni da CpHV-1 e BoHV-1. Tuttavia, l’analisi dei sieri mediante il test di sieroneutralizzazione 
crociata ha chiaramente identificato gli anticorpi indotti da CpHV-1 nei sieri gB positivi. La presenza 
di CpHV-1 nella Corsica del Sud, insieme all’alta sieroprevalenza riscontrata (61.9%) in tutte le 
capre analizzate allunga la lista dei paesi in cui è presente l’infezione da CpHV-1. In più, la 
differenza evidenziata tra la Corsica del Sud e la Dordogne e la Vendée suggerisce che CpHV-1 ha 
una prevalenza maggiore nelle regioni o nei paesi che si affacciano sul Mediterraneo piuttosto che 
nell’Europa Centrale o del Nord. 
 
CpHV-1 quindi sembra essere il virus correlato a BoHV-1 con il maggiore impatto 
economico in Europa. Le capre sono considerate una specie minore e l’industria farmaceutica 
veterinaria è scarsamente interessata allo sviluppo di vaccini per la profilassi dell’infezione da 
CpHV-1. Dal momento che BoHV-1 e CpHV-1 sono geneticamente e antigenicamente correlati, è 
ipotizzabile che un vaccino attenuato costituito da un ceppo di BoHV-1 deleto per il gene 
codificante la gE potrebbe indurre protezione delle capre nei confronti dell’infezione da CpHV-1. La 
sicurezza del vaccino è stata accertata tramite inoculazione intranasale di due gruppi di due capre, 
con un ceppo di BoHV-1 virulento e un vaccino BoHV-1 deleto per la gE. Nel gruppo di animali 
immunizzati è stata osservata la diminuzione sia della durata dell’escrezione virale che del picco del 
titolo virale escreto. Al fine di verificare l’efficacia del vaccino, un gruppo di capre è stato 
immunizzato con il vaccino due volte a distanza di due settimane mentre un gruppo è stato tenuto 
come controllo e non vaccinato. Quattro settimane dopo, sia il gruppo immunizzato che quello di 
controllo sono stati infettati per via intranasale con CpHV-1. Nelle capre immunizzate è stata 
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osservata una diminuzione di due log10 del picco del titolo virale escreto. Tuttavia, l’escrezione 
virale è durata due giorni in più rispetto al gruppo di controllo. In conclusione il vaccino attenuato 
contenente BoHV-1 gE negativo induce una parziale protezione crociata nei confronti dell’infezione 
nasale da CpHV-1.   
 
 Facendo riferimento ai risultati ottenuti in questo esperimento preliminare, il vaccino è 
stato valutato nei confronti dell’infezione genitale da CpHV-1 che rappresenta la via naturale 
d’infezione nelle capre. A tale scopo, un gruppo di capre è stato immunizzato due volte a tre 
settimane di distanza con un vaccino attenuato contenente BoHV-1 deleto per la gE, e 
successivamente è stato infettato per via genitale con CpHV-1. Al fine di analizzare la sicurezza e 
l’efficacia di questo vaccino marker, due gruppi di capre sono stati utilizzati come controllo: un 
gruppo è stato immunizzato con ceppo virulento di CpHV-1 e l’altro non è stato inoculato fino al 
momento del challenge. Il vaccino non ha indotto alcun effetto avverso né locale né generale e le 
capre non hanno eliminato BoHV-1 gE negativo. Dopo il challenge, nelle capre immunizzate è stata 
osservata una diminuzione della gravità della malattia. Inoltre sia le capre immunizzate con BoHV-
1 gE negativo che quelle immunizzate con CpHV-1 hanno avuto una significativa riduzione della 
durata dell’escrezione virale e del piccolo del titolo virale eliminato. Le capre immunizzate hanno 
prodotto anticorpi neutralizzanti nei confronti di BoHV-1 e CpHV-1. Questi dati dimostrano che la 
somministrazione intranasale del vaccino attenuato con BoHV-1 gE negativo è in grado di offrire 
protezione clinica e riduzione dell’escrezione del virus nelle capre infettate con CpHV-1 per via 
genitale. 
 
 
Conclusioni 
 
Questo studio è stato condotto con lo scopo di contribuire ad una migliore conoscenza 
dell’interazione tra gli alphaherpesvirus e i loro ospiti ruminanti. Sono state analizzate le relazioni 
antigeniche, genetiche e genomiche esistenti tra BoHV-1 e gli alphaherpesvirus dei ruminanti. E’ 
stato dimostrato che questi virus costituiscono un gruppo molto forte all’interno della sottofamiglia 
degli alphaherpesvirus. La perfetta conoscenza delle relazioni evolutive esistenti tra questi virus 
richiede il sequenziamento completo del genoma ma questa analisi è complicata dalla grandezza 
del genoma degli herpesvirus. Un’altra possibilità potrebbe essere offerta dal confronto di differenti 
regioni distribuite nel genoma di ciascun virus come dimostrato dallo studio dell’evoluzione di 
BoHV-4. Tale analisi potrebbe fornire  dati interessanti riguardo i fenomeni di ricombinazione  e di 
trasmissione che sono accaduti nel passato tra gli herpesvirus e i loro ospiti ruminanti. 
Ciononostante, il presente lavoro offre un contributo alla conoscenza della storia naturale del 
gruppo di alphaherpesvirus dei ruminanti correlati a BoHV-1. Così, il primo isolamento di CvHV-1 in 
un cervo selvatico, unito alla conoscenza dell’evoluzione della popolazione cervina in Europa, ha 
permesso di formulare un’interessante ipotesi circa l’origine di questo virus. In considerazione della 
prevalenza osservata e della presenza dei cervi su una vasta area, questo virus potrebbe essere 
responsabile di un’infezione endemica che si sta diffondendo n Europa. Questo virus potrebbe 
essere stato introdotto in seguito all’importazione di cervi in Europa per costituire il primo nucleo di 
animali nelle fattorie scozzesi. Di conseguenza, il ceppo Anlier di CvHV-1 potrebbe rappresentare il 
progenitore del ceppo scozzese Banffshire 82 di CvHV-1. Tuttavia, è necessario uno studio 
epidemiologico molecolare di diversi isolati dei due ceppi per confermare definitivamente questa 
ipotesi. 
 
Questo isolamento ha dimostrato che può esistere una confusione riguardo lo stato 
sierologico dei ruminanti; il cervo belga non era infetto con BoHV-1 ma con il suo proprio omologo 
herpesvirus. Tali difficoltà di interpretazione si sono verificate in Francia in bovini indenni da IBR 
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riscontrati successivamente sierologicamente positivi. Dal momento che BoHV-5 e ElkHV-1 non 
sono stati identificati in Europa, che in Francia è presente un numero molto baso di allevamenti di 
bufali e che la trasmissione di CvHV-1 e CvHV-2 al bovino dovrebbe essere eccezionale, l’unico 
virus che potrebbe essere responsabile della confusione diagnostica in Francia è CpHV-1 poiché 
capre e bovini possono essere a stretto contatto in alcune situazioni di campo. I risultati ottenuti 
nel secondo studio non supportano questa ipotesi. Invero, l’infezione da CpHV-1 è assente o a 
prevalenza molto bassa nella Francia continentale. Al contrario, una sieroprevalenza molto alta di 
infezione da CpHV-1 è stata riscontrata nella Corsica del Sud. In Corsica, il contatto tra bovini e 
capre è molto limitato perché capre e bovini non sono allevati in promiscuità. Quindi, la 
trasmissione di CpHV-1 da capre a bovini dovrebbe essere eccezionale essendo l’infezione crociata 
molto rara e l’infezione da BoHV-1 nelle capre difficile da osservare. Poiché il campionamento è 
stato ristretto ai compartimenti della Dordogne e della Vendée, è auspicabile che lo studio 
epidemiologico su CpHV-1 sia esteso alla Francia continentale e soprattutto alla regione 
mediterranea. Tale monitoraggio potrebbe essere condotto con il test BoHV-1 gB blocking ELISA 
che è stato validato nel presente lavoro. 
 
L’infezione da CpHV-1 si è quindi estesa a tutta la regione mediterranea e sembra essere 
l‘infezione da alphaherpesvirus dei ruminanti più importante dopo quella da BoHV-1. In questo 
contesto è necessario proteggere le capre per ridurre la circolazione di CpHV-1 nella popolazione 
caprina e l’impatto economico dell’infezione. La valutazione preliminare del vaccino vivo attenuato 
costituito da BoHV-1 gE negativo, ha dimostrato che le capre sono “recettive” a tale vaccinazione. 
Poiché le capre sono totalmente sensibili a BoHV-1, questa specie potrebbe essere utilizzata come 
un modello sperimentale per studiare le caratteristiche di BoHV-1 in vivo. E’ stata osservata una 
parziale efficacia del vaccino nei confronti dell’infezione nasale da CpHV-1. Inoltre, il vaccino BoHV-
1 gE negativo è stato valutato nei confronti dell’infezione genitale da CpHV-1 che è la via naturale 
d’infezione nelle capre. L’uso della via intranasale per la somministrazione di un vaccino BoHV-1 gE 
negativo, ha determinato la protezione clinica e una significativa riduzione dell’escrezione virale 
nelle capre infettate per via genitale con CpHV-1. Questi risultati dimostrano che la mucosa nasale 
può rappresentare un sito efficiente per l’induzione di una risposta immune specifica nel tratto 
genitale. Nell’uomo, diversi meccanismi sono stati proposti per spiegare tale induzione immunitaria 
che coinvolge le cellule secernenti anticorpi e che conduce ad una risposta specifica rappresentata 
dalla produzione di IgA e IgG. Tali meccanismi potrebbero essere coinvolti nella risposta che è 
stata osservata nelle capre vaccinate ma non sono stati analizzanti nel presente lavoro. Deve 
essere presa in considerazione la biosicurezza di tale protezione crociata indotta con un vaccino 
costituito da BoHV-1 nei confronti di CpHV-1. Invero, i virus possono stabilire delle infezioni latenti. 
Gli esperimenti hanno dimostrato che nei bovini i virus gE negativi sono riattivabili meno facilmente 
ed escreti in misura minore rispetto ai virus selvaggi. Di conseguenza, il rischio di riattivazione e 
re-escrezione nelle capre è molto basso. In caso contrario, dovrebbe essere discussa anche 
l’insorgenza di virus ricombinanti tra CpHV-1 e BoHV-1 dopo infezione crociata. Tra i gruppi di 
alphaherpesvirus dei ruminanti correlati a BoHV-1, solo due virus ricombinanti tra BoHV-1 e BoHV-
5 sono stati isolati e nessun ricombinante  tra BoHV-1 e il virus meno strettamente  correlato 
CpHV-1 è stato svelato in vitro. Di conseguenza la vaccinazione crociata, qui descritta è 
verosimilmente sicura. Inoltre l’uso di un vaccino già registrato è interessante dal punto di vista 
commerciale in considerazione dello scarsa propensione delle industrie farmaceutiche a sviluppare 
nuovi vaccini per proteggere le specie minori.  
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